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Here I describe a new function of Focal Adhesion Kinase (FAK) in driving anti-
tumour immune evasion.  The kinase activity of FAK in squamous cancer cells 
drives the recruitment of regulatory T-cells (Tregs) by transcriptionally regulating 
chemokine/cytokine and ligand-receptor networks, including the transcription of 
CCL5 and TGFβ, which are required for enhanced Treg recruitment. In turn, these 
changes inhibit antigen-primed cytotoxic CD8+ T-cell activity in the tumour 
microenvironment, permitting survival and growth of FAK-expressing tumours.  I 
show that immune evasion requires FAK’s catalytic activity, and a small molecule 
FAK kinase inhibitor, VS-4718, which is currently in clinical development, drives 
depletion of Tregs and permits CD8+ T-cell-mediated tumour clearance.  It is 
therefore likely that FAK inhibitors may trigger immune-mediated tumour 







Cancer is a disease where cells of the body become damaged, grow uncontrollably 
and form tumours. Like many diseases, the body’s immune system has evolved to 
recognise and destroy infected or damaged cells. After a cell becomes damaged, the 
immune system is turned on and destroys the damaged cell, allowing healthy cells to 
take its place. However, after the immune system has done this, it must be turned off 
to stop healthy cell coming under attack. Specialized regulatory cells called Tregs 
help to turn off the active immune system, allowing the damaged cells to be quickly 
recognised and destroyed without this ‘autoimmune response’ damaging healthy 
tissues. So why does this not happen in cancer? Tumours can hijack Tregs in order to 
turn off the immune response prematurely, before it can destroy the whole tumour. 
This allows the tumour to escape the immune response, and the tumour continues to 
grow without attack from the immune system.  
Recent work has begun to try and ‘re-activate’ the immune system in cancer. Here, 
drugs aimed at the immune cells themselves, turn the immune response ‘back on’, 
causing the tumour to become under attack from the immune cells once more. This 
approach can have some drastic side effects however, as activating the immune 
response in this way can lead to autoimmune disease, and so treatment with these 
drugs becomes a balancing act; by activating the immune system to kill the cancer by 
stopping the ability to turn itself off, treatment with these drugs hopes to destroy the 
tumour before the autoimmune response damages healthy tissue. Not only this, but 
the tumour still has the ability to hijack the regulatory Tregs, and so these types of 
treatments can be ineffective at destroying the tumour but still carry the risk of 
seriously damaging healthy tissue.   
I have discovered a way to target the tumours ability to hijack the regulatory Tregs, 
making the tumour visible to the immune system. Using drugs to target a protein that 
is found in tumour cells called Focal Adhesion Kinase (FAK), these compound stop 
the tumour from using Tregs to hide from the immune response, allowing the 
immune cells to destroy the tumour. Drugs aimed at FAK have very few side effects 
and are much safer to use. I have also shown that this not only leads to the 
destruction of tumours by the immune system in a number of different types of 
 
 3 
cancer, but that this could make other drugs aimed at the immune cells safer and 
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Cancer is a multifactorial disease in which cells uncontrollably proliferate, invade 
and destroy surrounding tissue.  It is one of the leading causes of morbidity and 
mortality worldwide, with approximately 14 million new cases and 8.2 million 
cancer related deaths in 20121. DNA damage-induced mutations can give rise to 
cancer initiating oncogenes that drive the transformation of a single normal cell into 
a cancer cell, which in turn proliferate and grow into a tumour.  A number of factors 
contribute to the onset of transformation, the most prevalent being exposure to 
carcinogens including: 1) chemical carcinogens such as tobacco and asbestos, 2) 
physical carcinogens such as exposure to UV and ionizing radiation and 3) biological 
carcinogens including infection from parasites, bacteria or viruses such as HPV-16. 
The majority of cells damaged in this way undergo programmed cell death, however, 
a very small contingent of cells may progress to form a tumour. These initiating 
factors may interact with predisposing genetic, age-related, environmental, dietary, 
and exercise-related factors to determine a person’s susceptibility to cancer 
development. For example, a number of high-risk heritable mutations are linked to 
increased genetic susceptibility. Mutations in the BRCA1/2 genes are known to 
predispose women to an 80% and 55% chance of developing breast and ovarian 
cancer respectively by the time they are 90 years old. Mutations in the APC gene 
lead to the autosomal dominant familial adenomatous polyposis (FAP) syndrome, 
greatly increasing the risk of bowel cancer.  This complex relationship between 
genetic predisposition and exposure to a vast array of carcinogens is one of the 
reasons why cancer is such a heterogeneous disease and remains difficult to treat.  
Following the initiating event, cancer cells must acquire a number of distinct 
capabilities necessary to promote tumour growth, progression and survival as 
proposed in the seminal review by Hanahan and Weinberg2,3 (Figure 1.1).  These 
include genome instability and mutation, sustaining proliferative signals, avoiding 
immune destruction and activating invasion and metastatic progression, all of which 
a tumour must acquire to survive. The progression and development of a tumour 
compares to and even exceeds the complexity of that of a developing healthy organ. 
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The archetypal view of cancer development and tumour progression is focussed on a 
mass of transformed cells proliferating unhindered to produce a solid primary 
tumour. This mass contains a heterogeneous population of transformed cells from 
different clonal origins, each potentially harbouring distinct mutational differences. 
However, cancer is not merely an autonomous mass of mutant cells. Rather, a large 
body of work has identified that tumours contain a complex milieu of immune and 
stromal cells, sequestered by the tumour to help promote survival and progression. 
The requirements of a tumour are not sustainable by the surrounding tissue alone, 
and thus developing tumours establish a new, more permissive niche in order to 
survive, known as the tumour microenvironment. Which cells are recruited to the 
tumour microenvironment and whether they aid or hinder the development and 
progression of a tumour is the primary focus of this chapter. I will also discuss how 
the tumour influences, subverts or evades these responses. 
 
  
Figure 1.1 I The Hallmarks of Cancer. Outline of the ten Hallmarks of cancer (the original six 
(Hanahan and Weinberg, 2000) and four emerging hallmarks (Hanahan & Weinberg 2011)). 
Hanahan and Weinberg propose that cancers must acquire most if not all of these capabilities in 
order to grow, survive and progress. Adapted from Hallmarks of cancer: the next generation. 




2 The tumour and its surrounding microenvironment 
 
In response to the unrestrained proliferation of transformed cells, and in an attempt to 
re-establish tissue homeostasis, the surrounding stroma generates an acute 
inflammatory response leading to an imbalance of immune and stromal cells4,5. 
Manipulation of this microenvironment therefore becomes imperative to tumour 
survival. Pioneering studies, in part lead by the Dvorak lab, have made the collective 
conclusion that stromal involvement in tumorigenesis resembles that of acute 
inflammatory responses such as wound healing6-9. Classical players in wound healing 
(immune cells, endothelial cells and fibroblasts) that typically coordinate to resolve 
damage after a wound, instead react paradoxically and promote tumour survival5, 
identifying cancer as ‘a wound that never heals’10. Further work has established that 
the surrounding microenvironment not only aids tumour survival, but also the 
induction, selection and expansion of neoplastic cells for malignant progression11,12. 
When you consider all the required ‘hallmarks’ of cancer, seven noticeably involve 
contributions by immune and stromal cells of the tumour microenvironment13. How 
these cells contribute to these traits is discussed below. 
 
2.1 Immune cells and their functions in cancer  
The mammalian immune system is comprised of a repertoire of different cell 
populations and mediators that co-operate to instill protection against pathogens, 
whilst simultaneously maintaining tolerance against self-antigen14 (Figure 2.1). The 
immune system is composed of two distinct compartments – adaptive and innate – 
differentiated by time of activation and antigen specificity15.  Cells of the innate 
compartment, namely macrophages, mast cells, neutrophils, natural killer (NK) cells 
and dendritic cells (DCs) are first responders to sites of injury. Macrophages, mast 
cells and DCs serve as sentinel cells, residing in tissues and monitoring their 
environment for changes in tissue homeostasis. After homeostasis is perturbed, either 
by injury, infection or transformation, macrophages and mast cells secrete a number 
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of soluble factors that induce the mobilization and infiltration of other immune cells 
(leukocytes) to the site. These factors include cytokines, chemokines, reactive 
oxygen species (ROSs), matrix metalloproteinase (MMPs) and other extracellular 
matrix (ECM) remodeling enzymes15.  This process is known as inflammation, and 
serves to mediate tissue repair mechanisms, kill any potential pathogens and 
readdress tissue homeostasis. DCs and macrophages act as antigen presenting cells 
(APCs), taking up foreign antigen and migrating to the lymph nodes in order to 
present their antigens to the adaptive immune response leading to its activation.  
  
Figure 2.1 I Leukocyte Hierarchy within the innate and adaptive arms of the 
immune response. left panel Most cells of the innate immune response are derived form a 
shared myeloid progenitor cell and are therefore referred to collectively as myeloid cells. From 
this progenitor cell is derived the CFU-G and CFU-M from which granulocytes and monocytes are 
derived respectively. right panel All cells of the adaptive immune response are derived from the 
lymphoid progenitor cell and are referred to as lymphocytes. CFU-G = granulocytic colony 
forming unit; CFU-M = monocytic colony forming unit; MDSC = myeloid-derived suppressor cell; 




The adaptive immune compartment contains T lymphocytes, namely cytotoxic CD8+ 
T-cells and CD4+ T-cells, and B lymphocytes. The primary function of these cells is 
to identify and specifically destroy pathogen-infected cells or damaged cells as 
efficiently as possible, but also play roles in the host defense against pathogens such 
ass extracellular bacteria. However, these cells firstly require activation by direct 
interactions with mature APCs14,15. Each individual B and T lymphocyte are 
antigenically committed to a specific unique antigen15, which if presented to them 
leads to the rapid clonal expansion of that T- or B-cell in order to attain the number 
of cells required to achieve an effective immune response. This delay is why the 
adaptive immune response is slower than the innate at responding to inflammation. 
Upon expansion and activation this compartment is highly sophisticated and efficient 
at destroying infected or damaged cells. This ability requires very stringent 
regulation however, as hyper-activated adaptive responses can lead to damage to 
adjacent tissues and autoimmune disease. A specialized regulatory CD4+ T-cell 
called Tregs helps to suppress the activated adaptive response. How this occurs will 
be discussed in detail below (2.1.3).  
The heightened and activated innate and adaptive immune responses are stopped by 
the resolution of inflammation. It was initially believed that inflammation was 
resolved by a passive catabolic mechanism and with the removal of the initial 
pro-inflammatory mediators the inflammation would simply ‘burn itself out’16. 
However with the discovery of anti-inflammatory agents such as IL-10 and 
adenosine, and with the discovery of the anti-inflammatory roles of nitric oxide (NO) 
in the regulation of inflammatory myeloid cell apoptosis17, it is now believed that 
inflammation is resolved through active mechanisms16,18. Key mediators of the 
resolution phase include anti-inflammatory cytokines such as IL-10, inhibitors of 
pattern recognition receptors, prostaglandins, resolvins and lipoxins16. The exact 
mechanisms by which resolution occurs, and how and when the resolution phase is 
initiated is still to be determined. However, what is clear is that the resolution of 
inflammation precedes the final stages of tissue repair, and leads to the return to 
tissue homeostasis. In normal physiological conditions, inflammation is resolved 
 
 18 
shortly after tissue repair or pathogenic destruction. This is not the case in cancer, 
where inflammation is either not resolved, or is left unresolved long enough to aid 
tumour development.  
Virchow was the first to identify a link between chronic inflammation and cancer in 
186319, but since then three key lines of evidence have linked aberrant chronic 
inflammation to cancer development. Firstly, 16.1% of the global incidence of cancer 
can be attributed to inflammation-inducing infectious organisms20, notably 
Helicobacter pylori in gastric cancer21, human papilloma virus (HPV) in cervical and 
head and neck cancers22,23, and hepatitis B and C in hepatocellular carcinoma24. 
Secondly, chronic inflammatory diseases such as inflammatory bowel disease 
(IBD)25, chronic pancreatitis26 and pelvic inflammatory disease27 increase the risk of 
developing colorectal carcinoma, pancreatic cancer and ovarian cancer 
respectively28.  Finally, treatment with non-steroidal anti-inflammatory drugs 
(NSAIDs) have shown to decrease the onset of cancer; prolonged intake of aspirin is 
associated with reduction in the incidence of colorectal cancer29; treatment with 
tolfenamic acid saw reduced incidence of pancreatic, esophageal and lung cancers30; 
treatment with COX2 inhibitor NSAID Celecoxib has been approved as an 
adjunctive therapy for the reduction of polyps in FAP. The type of inflammatory 
response associated with increased cancer risk is often referred to as ‘smoldering 
inflammation’, due to its low grade and lack of overt clinical concequences31,32. 
Growing evidence that inflammation is in fact the root cause of many cancers has 
lead to pro-tumorigenic inflammation to be included as a hallmark of cancer3,32 
With growing interest in the contribution of inflammation in cancer development, 
work turned to the identification of leukocytes within the tumour microenvironment 
itself. Populations from both arms of the immune response have since been found in 
or adjacent to neoplastic tissue. Work has shown that these immune cells contribute 
to tumorigenicity in four ways; to facilitate cellular transformation, to prevent or 
regulate tumour outgrowth, to modulate tumour immunogenicity and to aid 
progression of tumour development and malignant conversion33,34. Whether a 
specific immune population will contribute to each of these functions is determined 
by the inflammatory state of the tumour, the stage of tumour development, the other 
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immune populations involved and the repertoire of tumour-associated antigens 
(TAAs) presented by APCs or expressed on tumour cells33. Thus immune cells may 
act in both a pro-tumorigenic and anti-tumorigenic capacity. Here I discuss the 
specific functions of immune cells within the tumour microenvironment, focusing on 
macrophages and DCs from the innate compartment, T-cells from the adaptive 
compartment, and the immunosuppressive cells that regulate these responses, 
myeloid-derived suppressor cells (MDSCs) and Tregs. 
 
2.1.1 Macrophages: mediators of tissue repair to promote tumour 
survival 
  
Macrophages (CD45+ CD11b+ F4/80+ cells) are critical components of the tumour 
immune milieu. Two major subtypes of macrophages exist in the tumour 
microenvironment, resident macrophages and inflammatory macrophages35. It is 
worth identifying at this point that the work within this thesis discusses mouse 
macrophages and not human, and although both mouse and human macrophages do 
have a number of similarities, they are also distinct within the markers used to 
identify them, and in some cases within their mechanism of action36. As discussed 
above, resident macrophages act as sentinel cells within tissues and contribute to the 
initiation of inflammation. Inflammatory macrophages are recruited from the 
peripheral lymphoid tissues or are differentiated from Ly6C+ inflammatory 
monocytes at the site of inflammation. Macrophages are highly plastic cells that can 
exist in two polar differentiated states, M1 (classical) macrophages and M2 
(alternative) macrophages37. M1 macrophages are a anti-tumorigenic, highly 
phagocytic, pro-inflammatory population activated by lipopolysaccharide (LPS) or 
INF-γ and characterised by the expression of ‘M1 genes’ such as Nos2, IL12b and 
Ciita37-41.  M2 macrophages show high expression of ‘M2 marker genes’ such as 
MMR, Tie2, Arg1 and Retnla, and display pro–tumorigenic functions; they reduce 
inflammation and promote mechanisms of wound-healing such the activation of 
fibroblasts and angiogenesis37-41. Both M1 and M2 macrophages are polar 
differentiated populations that exist in constant state of flux determined by the 
surrounding microenvironment, resulting in intra-tumoural macrophages with aspects 
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from both M1 and M2 phenotypes (hence the term ‘macrophage polarization’).  The 
factors that mediate macrophage polarization remain unclear. However, M1 and M2 
phenotypes are akin to TH1 and TH2 T-cell mediated inflammatory responses, 
requiring IFN-γ and IL-4 respectively.  STAT signalling appears to direct a number 
of M1 and M2 differentiation specific genes, such as Stat1, an essential mediator of 
M1 polarization in the presence of IFN-γ, and Stat6, which is required for M2 
polarization in response to IL-4and IL-1339.   
Macrophages are an abundant population of leukocytes in solid tumours35 and Ly6C+ 
macrophages appear phenotypically distinct in the tumour microenvironment from 
resident macrophages. The role of resident macrophages in cancer is unclear, but the 
roles of inflammatory macrophages have been better characterised in work 
investigating CCR2+ tumour associated macrophages (TAMs).  A large proportion of 
intra-tumoural inflammatory macrophages are CCR2+ TAMs, and increased 
infiltration or the upregulation of TAM-associated gene signatures correlates with 
poor prognosis in many human cancers31,35,38,42,43. TAMs have many functions within 
the tumour microenvironment and at the distant metastatic site, and have been shown 
to regulate both tumorigenesis and the progression of the primary tumour. 
 
2.1.1.1 Macrophages regulate inflammation that drives tumorigenesis 
Macrophages and other myeloid cells induce inflammation at sites of injury, but 
macrophages are central to the ‘smouldering inflammatory response’ seen in 
cancer44. The inflammatory state of myeloid cells is controlled by NFκB and Stat3 
mediated signalling which act in direct opposition to each other45. NFκB is a central 
signal transducer downstream of toll-like receptor (TLR) activation, which results in 
the expression of inflammatory mediating cytokines such as IL-12 and TNF-α31,46,47. 
The transcription factor Stat3 functions to suppress the inflammatory response, and 
acts as the major target of the immunosuppressive cytokine IL-1031,46. Myeloid 
specific ablation of Stat3 or NFκB signalling components induces or suppresses 
chronic inflammation respectively and has been shown to effect tumour initiation. 
Ablation of myeloid Stat3 induced inflammation in the colon results in chronic 
colitis and invasive colonic adenocarcinoma. Myeloid specific inhibition of NFκB 
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signalling by the ablation of IκB kinase α (IKKα) reduces inflammation and tumour 
progression in mouse models of intestinal cancer48.  
After the initial genotoxic-transforming event, macrophages are recruited to the 
tissue and adopt a M1 phenotype to induce an inflammatory response in order to 
restore tissue homeostasis. Part of the repertoire of inflammatory and cytotoxic 
molecules secreted by M1 macrophages, are reactive nitrogen and oxygen species 
(RNS and ROS respectively)49, which play normal physiological roles in anti-
microbial defence. However, the secretion of molecules such as ROS and RNS 
generates a mutagenic inflammatory environment in cancer49. Due to the highly 
mutagenic capacity of ROS and RNS, this environment induces mutations in 
adjacent epithelial cells and mediates genomic instability in the developing 
tumour49,50.  The requirement of macrophages in the promotion of tumorigenesis can 
also be seen in mouse models of cancer using chemical carcinogenesis. The two-
stage cutaneous DMBA (7,12-dimethylbenathracene) / TPA 
(2-O-tetradecanoylphorbol 13-acetate) skin carcinogenesis protocol51 uses a low dose 
of the carcinogen DMBA to induce an oncogenic mutation in the skin. This mutation 
is not sufficient however to initiate tumorigenesis and frequent topical application of 
pro-inflammatory TPA is required. The inflammatory response generated by TPA is 
dominated by macrophages. This pro-tumorigenic inflammatory response mediated 
by TPA is caused by TNF-α signalling through NFκB, and acts directly on epithelial 
cells and on inflammatory cells, in particular macrophages within the surrounding 
microenvironment52.  
 
2.1.1.2 Macrophage functions in the primary tumour 
As primary tumours progress and develop, intra-tumoural macrophage populations 
revert from the inflammatory phenotype seen in tumorigenesis, to trophic/M2 
macrophages seen in tissue repair and development31,53-55. After the initial stages of 
tumorigenesis, NFκB signalling in TAMs become inhibited by the constitutive 
expression of p50 homodimers, which in turn inhibits M1 inflammatory responses 
and induces a M2 macrophage phenotypic switch56. The induction of an 
M2 phenotype by p50 can be seen in vitro45, and can also be found in cancers that 
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lack the characteristic inflammatory response, such as breast cancer where 
M2 macrophages are recruited in high numbers before metastatic transition both in 
humans57 and in mouse models31,58. 
Macrophages play a number of roles in the primary tumour. M2 Macrophages induce 
angiogenesis and mediate the ‘angiogenic switch’ (an enhancement of vascular 
density observed following benign to malignant transition)59,60 (2.2.1). Evidence 
supporting this notion comes from a number of studies. Null mutations in the 
macrophage CSF1 gene reduce vascular density61, while overexpression of CSF1 
promotes a premature increase in the number of macrophages and leads to an early 
angiogenic switch that accelerates tumour malignant progression59,61,62. Work in 
mice reflects clinical observations seen in breast cancer that correlates increased 
macrophage infiltration with increased micro-vessel density and poor prognosis31,63. 
Tie2, a protein constitutively expressed on endothial cells and enriched on 
macrophages within the tumour64,65, has been observed to mark a population of 
macrophages proximal to angiogenic vessels, and transcriptional profiling of Tie2+ 
macrophages65 highlighted an enrichment of pro-angiogenic molecules66. Tie2+ 
macrophages have features of M2-polarized macrophages32, promote both tumour 
and developmental angiogenesis67,68 and are required for the formation of blood 
vessels64,65,69.  
Macrophages also function to aid tumour progression and contribute to increase 
tumour invasion, migration and intravasation. Macrophage-induced tumour cell 
invasion has been observed in the MMTV-PyMT mouse model of breast cancer 
using intravital optical imaging techniques, which correlate with work seen in human 
breast xerograph studies70. Macrophages aid tumour cell migration by a paracrine 
signalling axis that exits between tumour cells and macrophages; tumours secrete 
CSF-1, stimulating macrophage migration and secretion of epidermal growth factor 
(EGF), which in turn induces tumour cell migration71. Inhibition of either the 
macrophage restricted CSF-1 or the tumour cell restricted EGF results in the 
perturbation of migration and chemotaxis in both cell types in the tumour 
microenvironment31,71,72.  Furthermore, in study of breast cancer by Qian et el73, 
CCR2+ macrophages promote the extravasation, seeding and growth of tumour cells 
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at distant metastatic sites73. Inhibition of CCR2 signalling reduces metastatic 
progression and the recruitment of inflammatory monocytes, associate with an 
increase in survival of tumour-bearing mice74,75.  
CCR2 has also been shown to be required for the recruitment of splenic-derived 
macrophages and macrophage progenitors76. The spleen may therefor act as reservoir 
for TAM recruitment and differentiation, and data suggests that it is source of most 
TAMS within the microenvironment, continuously supplying the tumour though out 
its development76. Although select roles for splenic-derived macrophages have not as 
yet been elucidated, their mobilization increases, mediated by chemotactic signals 
such as M-CSF, GM-CSF and IL-377-80 after chemotherapy and radiotherapy, and 
may also increase resisitance to DNA-damaging chemotheraeutics81 
 
2.1.1.3 Macrophage involvement in tumour responses to anti-cancer 
therapies 
A number of published works have studied the involvement of macrophages in 
determining the outcome of anti-cancer therapies. The effects of anti-cancer agents 
on macrophage polarization, recruitment and proliferation can determine tumour 
resistance or sensitivity to therapy. However, results are conflicting, and it is 
becoming clear that whether macrophages enhance or limit responses to 
chemotherapy depends on the cytotoxic agent and the mouse model used. 
Chemosensitivity is enhanced when cytotoxic agents increase the cytotoxic capacity 
of M1 macrophages or decrease the numbers of total macrophages, monocytes or M2 
macrophages82. This can be seen in a number of mouse models; treatment with 
doxorubicin induces M1 cytotoxic activity in models immunogenic lymphoma83; 
docetaxel treatment promotes M1 macrophage expansion in 4T1 mammary 
transplantable mouse models84; trabectedin depletes protumoural monocytes and 
TAMs in 3-methylcholantrene induced and transplantable fibrosarcoma85 models. In 
all three of these studies, macrophages enhance the efficacy of the respective 
chemotherapeutic agent through different mechanisms. However, treatment of 
MMTV-PyMT transgenic model of breast cancer with doxorubicin increased tumour 
infiltration of M2-macrophages, resulting in resistance to doxorubicin in this model, 
contrasting with results in immunogenic lymphoma.  Resistance to chemotherapy 
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correlates with increased M2 macrophage tumour infiltration in a number of mouse 
models including paclitaxel, gemcitabine and 5-fluorouracil86 treated EL4 
transplantable model of lymphoma, and MMTV-PyMT transplanted and transgenic 
breast cancer models treated with paclitaxel87,88. 
High numbers of intra-tumoural TAMs also correlate with poor tumour responses to 
irradiation82,89. Following tumour-induced DNA damage, Abelson murine leukaemia 
viral oncogene homologue-1 (ABL-1) kinase activation promotes CSF1 gene 
transcription and increases levels of CSF1 within the tumour90. This in turn increases 
the recruitment of myeloid cells, including TAMs that express CSF1R, which induce 
tumour regrowth and repair following irradiation90. Inhibition of CSF1R90 or 
antibody depletion of CD11b+ myeloid cells91 increased the efficacy of irradiation 
and reduced post-therapy tumour regeneration.  
Further to this, it has since been established that M2 macrophages may help to 
stimulate tumour regrowth after chemotherapy.  Tumour relapse after therapy is a 
major clinical problem, and Hughes et al92 have identified a subpopulation of M2 
TAMs (MRC1+ TIE2+ CxCR4hi) which accumulate around blood vessels in tumours 
after chemotherapy. Here, they promote tumour revascularization and relapse by a 
mechanism, which in part involves the release VEGF, and pharmacological blockade 
of CxCR4 pathway reduce the number of M2 TAMs after chemotherapy, leading to a 
reduction in tumour revascularization and regrowth92. This offers an exciting clinical 
opportunity, and implies potentially novel roles for other immune populations in 
determining the frequency of cancer relapse.    
 
2.1.2 The impact of T-cell activation and tolerance on tumour survival 
 
T-cells (CD45+ CD3+ cells) are major contributors to the anti-tumour immune 
response. They exist in two major classes, CD8+ cytotoxic T-cells and CD4+ ‘helper’ 
T-cells. Following exposure to antigen, naïve T-cells activate and expand, becoming 
effector T-cells (CD44hi CD62Llo)93. Effector T-cells secrete chemokines and 
cytokines such as IL-2, which binds its cognate receptor IL-2R in a paracrine 
signalling axis that leads to the activation of PI3K/AKT-mTOR proliferative 
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signalling pathways94.  Effector T-cells thus begin to proliferate rapidly, reaching 
optimal density around 2 weeks after initial exposure to antigen, and subsequently 
play a number of critical functions in driving the anti-tumour immune response 
(discussed below)95. After peak effector T-cell proliferation, approximately 90-95% 
of cells undergo apoptosis, whilst the remaining effector population matures into 
memory T-cells (CD44hi CD62hi)93,96,97. Memory T-cells are a long-term cell 
population that persist for several years or even decades after initial antigen 
exposure. Upon repeat exposure to a specific antigen, memory T-cells expand and 
regain higher effector functions. This occurs more rapidly than for naïve T-cells, 
typically resulting in an asymptomatic response96,98. This archetypal T-cell response 
is the basis of most vaccinations96; controlled exposure to a non-pathogenic or 
weakened strain of the pathogen is recognised by the immune system, destroyed and 
the resultant memory T-cells provide nascent asymptomatic protection against 
subsequent re-exposure.  
Immunogenicity, the capacity to induce an adaptive immune response in vivo, has 
been widely investigated in cancer using transplantable mouse models. Cancer cell 
immunogenicity can be classified into three grades; 1) Highly immunogenic cancer 
cells that are rejected after transplantation into naïve syngeneic mice, 2) intermediate 
immunogenic cell models that require host mice to be immunized against the specific 
expressed antigen prior to transplantation in order for tumour regression, or 3) 
non-immunogenic cancer cells that are not rejected following immunization99. 
Tumours are generally weakly immunogenic due to the selective pressure of the 
immune system as the tumour progresses. Despite this, sporadic immunogenic 
tumours may still progress, indifferent to the presence of CD8+ T-cells specific for 
that transplantable antigen100. These data imply that cytotoxic immune responses can 
be converted into non-destructive T-cell responses. These responses aid in tumour 
progression and in the evasion of the anti-tumour immune response. However, this 
also implies that seemingly non-immunogenic tumours may be converted to become 




2.1.2.1 Dendritic cells (DCs) orchestrate T-cell activation and anergy 
DCs are pivotal to the anti-tumour immune response as they either prime or anergize 
naïve T-cells in primary lymphatic organs, leading to either anti-tumour immunity or 
peripheral tolerance101,102. DCs, as well as macrophages, act as antigen presenting 
cells (APCs) both at peripheral lymphoid tissues and at the tumour site. APCs 
present processed antigenic peptides via the major histocompatibility complexes 
(MHC) expressed on their surface14. Presented antigen is identified by antigenically 
committed T-cells, leading to their rapid clonal expansion, raising a highly specific 
and effective adaptive immune response. The multi-molecular complex between 
APCs and naïve T-cells, called the immunological synapse is a highly regulated 
complex of surface expressed ligands and concomitant receptors that simultaneously 
act not only to activate T-cells, but to control and suppress their activity14 (called 
T-cell anergy; Figure 2.2). On the surface of APCs, MHC-presented antigen binds to 
its concomitant CD3/T-cell receptor (TCR) complex exclusively expressed on a 
specific T-cell subset. Concurrent binding of the TCR co-receptor CD8/CD4 is 
required for optimal TCR activation of CD8+ cytotoxic T-cell or CD4+ T-cells 
respectively103. DCs modulate the nature of the T-cell response within the 
immunological synapse by expressing of a series of co-stimulatory receptors that are 
required either promote a T-cell mediated immune response, or to restrict T-cell 
activity by inducing T-cell anergy and eventual apoptosis (Figure 2.2). 
APC-expressed B7 molecules CD80 and CD86 (B7.1 and B7.2 respectively) bind to 
T-cell CD28 in parallel with TCR stimulation, leading to T-cell activation and 
induction of T-cell effector functions. Induction of either CD28 or TCR signaling 
without activation of the other parallel pathway results in the induction of T-cell 
anergy. Activation of other receptor/ligand pairs directly induces T-cell anergy. 
These inhibitory pathways, called immune checkpoints are crucial for maintaining 
self-tolerance and modulating the duration and amplitude of physiological immune 
responses104 (discussed below). 
Further to antigen presentation by APCs, host cells present tolerized autologous or  
‘self’ antigen of which the immune system is educated to disregard. All cell types 
express autologous antigens by MHC molecules, and foreign antigens can be 
detected directly by T-cells eliciting the activation of a cytotoxic CD8+ T-cell 
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response. In this regard, autochthonous cancer cells have been shown to express 
repertoires of mutated or modified self-antigens and a number of these result from 
oncogenic mutations; mutant N-ras105, B-raf106 and CDK4107 have all be found as 
TAA on melanoma cells, mutant K-ras108 has been reported as a TAA on pancreatic 
ductal adenocarcinoma (PDAC) and the BCR-Abl fusion protein B3a2 has been 
shown to be expressed as four different TAA peptides in chronic myeloid 
leukemia109-111. This raises the question as to why these cancers are not destroyed by 
the adaptive immune response. T-cells with high avidity for self-TAAs are typically 
deleted during the thymic T-cell selection process112, and thus T-cells within the 
tumour microenvironment are highly susceptible to mechanisms of peripheral 
tolerance and immunosuppression.  
Downstream of TCR engagement, TCR-associated CD3 becomes phosphorylated by 
Src family kinases Fyn and Lck leading to binding of Zeta-chain-associated protein 
kinase 70 (ZAP-70)113, and downstream activation of NFκB, NFAT and Ca2+ influx 
pathways. These pathways drive a variety of different T-cell effector functions 
within the tumour microenvironment.  
  
Figure 2.2 I The immunological synapse mediates T-cell activation, anergy and 
exhaustion. Left panel APCs present antigenic peptides via MHC molecules. T-cell activation 
requires the engagement of the concomitant T-cell TCR, stabilization of this signal by lineage 
dependent co-receptors CD8 and CD4 and binding of co-stimulatory molecule CD28 with APC 
expressed CD80/86. Right panel APC expressed co-stimulatory molecules may induce T-cell 
anergy / exhaustion. Lack of CD80/86 stimulation of CD28 after TCR engagement, sequestration 
of CD80/86 and activation of CTLA4 and PD-1 binding with its ligands PD-L1/2 all induce anergy 




2.1.2.2 Effector T-cell functions within in the tumour microenvironment 
Upon activation within the tumour microenvironment, CD8+ and CD4+ T-cells 
exhibit distinct effector functions (Figure 2.3).  Effector CD8+ T-cells are highly 
cytotoxic, and although all CD8+ T-cells require MHC class I–antigen–TCR 
interactions to target a cell to be killed, a CD8+ T-cell can kill a cell by engagement 
of Fas ligand with its receptor, or by the localised release of cytotoxins14 (Figure 
2.3). Direct induction of cell death occurs after surface expressed Fas ligand 
(FasL/ApoL1), which is upregulated on effector CD8+ T-cells, binds to its 
concomitant receptor (Fas/Apo1) expressed on tumour cells. This induces the 
recruitment of the death-induced signalling complex (DISC) to Fas, which results in 
the caspase cascade and subsequent tumour cell apoptosis14. CD8+ T-cells may 
induce cell death by the localized release of cytotoxins namely perforin, granzymes, 
and granulysin14. Perforin and granulysin form pores or increase the permeably of the 
target cell membrane respectively, which allows granzymes to enter the cytoplasm, 
causing the target cells serine proteases to induce the caspase cascade14,114.  
Upon activation, CD4+ T-cells differentiate into a number of distinctive 
subpopulations including TH1, TH2, TH17 and Tregs, determined by the presence of 
different chemokines and cytokines within the tumour microenvironment 
(Figure 2.3). Each of these effector CD4+ T-cell sub-states function differently 
within the tumour microenvironment, and play very different roles in enhancing or 
suppressing immune mediated tumour destruction. TH1 and TH2 are the first-defined 
and best-characterised T-cell linages. Distinct chemokines, cytokines and membrane 
expressed molecules displayed by these cell types promote matched effector 
functions of other cells of the adaptive and innate arms of the immune response115. 
TH1 lineage cells are the classical ‘T-helper’ cells, and are induced by IFN-γ and 
IL-12 mediated activation of the transcription factor T-Bet116.  Activation of T-Bet 
upregulates IFN-γ and CCL2, that acts to increase the anti-tumour immune response 
in the tumour microenvironment. TH1 cells enhance the cytotoxic activity of CD8+ T-
cells, increasing M1 macrophage activation and the recruitment of NK cells and 
macrophages to the tumour site117. TH2 lineage cells are associated with allergic 










 T-cells following activation by 
APCs. Following antigen presentation, effector CD8+ T-cells have two distinct cytotoxic 
mechanisms and may induce tumour cell apoptosis either directly by Fas ligand or indirectly by the 
secretion of granzymes, perforin and granulysin. CD4
+
 T-cells differentiate upon activation into a 
number of sub-sets with different pro-tumorigenic or anti-tumorigenic functions, depending on the 
presence of secreted inflammatory chemokines and cytokines within the tumour microenvironment. 
Each subset is regulated by a specific transcription factor that determines its phenotype. APC = 




and IL-33 induces the TH2 phenotype, which leads to the upregulation of IL-13, IL-5 
and IL-4118. The role of TH2 cells in cancer is poorly understood, but anti-tumour 
effects of IL-4 have been attributed to an increase in intra-tumoural eosinophils and 
macrophages119,120. Contrary to this, the frequency of CD4+ cells expressing IL-5 
correlates with increased melanoma and renal cell carcinoma progression121, 
suggesting that TH2 mediated effects on tumour growth may be context dependant.  
Identification and classification of T-cell subsets has helped to develop 
understanding of the functions of CD4+ T-cells within the tumour microenvironment, 
beyond the archetypal TH1 – TH2 binary polarization models, and TH17 cells and 
Tregs are examples of this. TH17 subsets depend on the transcription factor RORγt, 
and are characterized by the production of IL-17122. Induction requires stimulation by 
TGFβ and IL-6, but differentiated TH17 populations are sustained and maintained by 
IL-23123. The functions of TH17 cells within the tumour microenvironment are not 
yet fully understood, despite being identified in a number of human cancers 
including ovarian124, gastric125, prostrate126, pancreatic and renal cell carcinomas127. 
TH17 cells represent a polyfuctional CD4+ effector T-cell phenotype that may both 
aid and hinder immune cell-mediated tumour destruction. IL-17 can induce the 
expression of CCL2, CxCL7 and CCL20 which act as pro-inflammatory and 
pro-angiogenic mediators to increase tumour growth and survival128,129. But IL-17 
may also act in conjunction with IFN-γ to stimulate CxCL19 and CxCL10 
production to increase anti-tumour effector CD8+ T-cells and to stimulate TH1 CD4+ 
T-cell differentiation127,130. Some studies however have identified that the anti-
tumour capabilities of TH17 cells are in part due to genomic reprograming events that 
instil a longer life span, increased plasticity and ability to self renew in some TH17 
cells within the tumour microenvironment131. This re-programmed TH17 cell 
population reassemble stem cell-like memory cells (TSCM) which differs to other 
anti-tumour CD4+ responses that display genetic signatures consistent with terminal 
differentiation117,132. This increase in plasticity implies that the functions of TH17 
cells with the microenvironment are potentially highly context dependant, with as yet 




Tregs are a highly immunosuppressive population that depend on the expression of 
the FoxP3 transcription factor. Tregs are highly immunosuppressive cells that exist 
in two distinct subpopulations, tTregs and iTregs. Thymic-originated Tregs (tTregs) 
are derived during T-cell maturation and education. Immature single positive CD4+ 
T-cells receive TCR stimulation from antigen presenting-APCs, and the avidity and 
response time of the TCR signal determines CD4+ T-cell fate. Upon reception of a 
high TCR signal, most CD4+ T-cells undergo apoptosis and low TCR signal induces 
maturation into a conventional CD4+ T-cell133. However, immature CD4+ T-cells that 
respond with an intermediate TCR avidity may induce FoxP3 expression and 
differentiate into tTregs in the presence of IL-2133-136. Indeed, if levels of IL-2 are 
high enough, CD4+ T-cells with high avidity can escape destruction and become 
tTregs but this is rare135,136. tTregs are recruited to sites of inflammation by 
chemoattractant CCL5/CCR5 signalling axis137, which also enhances there ability to 
suppress CD8+ T-cells138. Disruption of this axis in mice, reduces the number of 
intra-tumoural Tregs leading to increased tumour survival and growth137. 
Peripherally induced Tregs (iTregs) differentiate withih the lymph node and at sites 
of inflammation from effector CD4+ T-cells. The induction and maintenance of 
iTregs requires repeat antigenic exposure and cognate iTreg TCR activation, and also 
requires the chemokines and cytokines TGFβ and IL-10139. The effector functions of 
tTregs and iTregs appear to be the same, but tTregs can be distinguished by the 
expression of Neuropillin-1 (NRP-1) and Helios140, although it is debated whether all 
tTregs express these markers. The immunosuppressive functions of Tregs are 
discussed in detail below (2.1.3.2), but they generally act to induce T-cell anergy and 
thus promote tumour survival and the evasion of an active anti-tumour immune 
response. Other types of CD4+ regulatory T-cell also exhibit immunosuppressive 
capabilities, including Foxp3- type 1 regulatory (Tr1) cells that secrete 
immunosuppressive IL-10141.    
It is widely accepted that tumours are immunogenic, as tumour-mediated T-cell 
responses occur frequently in cancer in the autochthonous host, in both cancer 
patients and mouse models99. The behavior of T-cells in cancer is frequently 
compared with the adaptive response in chronic viral infection, which share the 
capacity to establish highly antigenic and immunosuppressive environments unseen 
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in acute conditions93. The fundamental differences between these two pathogeneses 
are that viral antigens are often exogenous and highly immunogenic, unlike the 
endogenous and weakly immunogenic TAAs. The immunogenicity of a tumour is 
dependant on the repertoire of tumour-associated antigens (TAA) expressed142 but 
also on a number antigen-independent immunomodulatory factors. In a number of 
cases is the antigen-independent immunomodulatory factors which give tumours the 
capacity to avoid an activated cytotoxic CD8+ response. 
 
2.1.2.3 Mechanism of peripheral tolerance: T-cell anergy and 
exhaustion. 
After lymphocytes encounter their cognate antigen, mechanisms of peripheral 
tolerance are critical in the restraint of the T-cell response in order to avoid 
potentially fatal autoimmune reactions. Tumours hijack these responses in order to 
evade immune mediated destruction by activated CD8+ T-cells. Lack of adequate 
signalling from CD28 co-stimulatory receptors (Figure 2.2) with persistent 
MHC-TCR-antigen signalling induce T-cell anergy143, a form of T-cell 
hyporesponsiveness characterised by the lack of IL-2 expression and downstream 
TCR activity144. An anergic state may also be induced by inhibition of mTOR145, 
required for effector cell proliferation, or by the deprivation of nutrients or energy, 
determined by the activation of deprivation pathways such as the AMPK pathway146. 
Other T-cell co-stimulatory molecules can provide direct negative signals to inhibit 
T-cell responses and induce T-cell tolerance (Figure 2.2). Immune checkpoint 
mediator programmed cell death protein-1 (PD-1) and its ligands PD-L1 and PD-L2 
are master regulators of T-cell anergy. Binding of T-cell expressed PD-1 with 
PD-L1/2 alongside concurrent TCR stimulation, increases the recruitment and 
activation of Src homology region 2 domain-containing phosphatase (SHP) 1 and 2, 
leading to the dephosphorylation of proximal signaling complexes. These 
dephosphorylation events attenuate the activation of PI3K/AKT proliferative 
pathways, reducing T-cell proliferation and inhibiting downstream mechanisms of 
TCR activation117,147. The impact of PD-1 regulation of T-cells can be see with 
genetic ablation of PD-1 (Pdcd1-/-) in mice, which live for approximately 1 year 
until they develop systemic lupus erythematosus-like autoimmune disease, 
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manifesting as glomerulonephritis or dilated cardiomyopathy on C57BL/6 and 
BALB/c backgrounds respectively148,149. Work in a number of mouse models has 
shown that PD-1 also plays critical roles in regulating T-cell effector functions and 
T-cell tolerance at later time points in peripheral tissue sites. The breakdown of PD-1 
mediated tolerance can result in a number of tissue specific pathogeneses; PD-L1 
upregulation in allogeneic pregnancies leads to fetal abortion150, PD-1 regulates 
autoimmune diabetes in the pancreas of non-obese diabetic (NOD) mice151,152 and 
experimental autoimmune encephalomyelitis (EAE) mouse models of human 
multiple sclerosis have shown that PD-1 and PD-L1/2 heavily influence EAE 
pathogenesis153.  
T-cell PD-1 expression is also indicative of T-cell exhaustion, which results after 
chronic TCR over-stimulation such as occurs in cancer147.  T-cell exhaustion is a 
hierarchal multi-step process; as antigenic load increases, T-cells progress through 
various stages of dysfunction, reducing the expression of IL-2, TNF-α and IFN-γ, 
and progressively losing cytotoxic and proliferative potential, eventually subsiding to 
apoptosis154.  This is accompanied by a progressive upregulation of 
immune-suppressive receptors, such as PD-1, LAG-3 and CD244 and secretion of 
immuno-modulating cytokines IL-10 and TGFβ154. T-cell exhaustion is especially 
prevalent in cancer due to constant exposure of T-cells to antigen within the tumour 
microenvironment, and so it is likely that T-cell exhaustion is a major mechanism 
contributing to T-cell dysfunction in cancer patients154,155. T-cell exhaustion is not a 
terminal process, and reversing it has been achieved using PD-1 blocking therapy. 
However, PD-1 expression levels on exhausted T-cells is linked to the efficacy of 
these therapeutics. T-cells expressing low and intermediate levels of PD-1 are noted 
to respond to therapy, while those expressing higher levels of PD-1 did not156. 
Combinations of PD-1 and LAG-3 blocking therapies have shown better efficacy. 
However, again T-cells expressing high levels of PD-1 and LAG-3 were still 
unaffected155, stressing the importance of early clinical intervention in achieving 
optimal response to therapy.  
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is another well-characterised 
immune checkpoint protein that acts to regulate the amplitude of early T-cell 
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activation and also regulates T-cell exhaustion. Although CTLA4 and PD-1 belong 
to the same family of molecules and are both co-inhibitory, evidence suggests they 
use distinct non-redundant mechanisms to inhibit T-cell activation. CTLA4 knockout 
mice die after 4 weeks from a lethal hyper-lymphoproliferative disorder resulting in 
multi-organ tissue failure157, compared with the less severe lupus-like symptoms seen 
after 1 year in PD-1 knockout mice. CTLA4 shares identical ligands with CD28 
(CD80 and CD86) but with much higher affinity, thus outcompeting CD28 and 
reducing CD28-medaited T-cell activation (Figure 2.2). Downstream of CTLA4 
activation, recruitment of SHP1/2 leads to the dephosphorylation of proximal 
signaling complexes as with PD-1, but the recruitment phosphatase PP2A is unique 
to CTLA4, which acts directly to inhibit AKT phosphorylation104. Thus, CTLA4 
expression acts with dual-immunosuppressive capabilities, both to sequester cognate 
ligands of CD28 and to down-regulate T-cell proliferative and survival signalling 
pathways. Further more, CTLA4 is a target gene for the transcription factor FoxP3104, 
a critical factor in determining Treg lineage and is constitutively expressed on the 
surface of Tregs.  
 
2.1.3 Tregs and MDSCs suppress anti-tumour immune response 
 
Mechanisms of peripheral tolerance and the two-signal requirement for T-cell 
activation appear insufficient to counter the threat of autoimmune reactions, without 
the need for immunosuppressive cells. Acting in trans, Tregs and myeloid derived 
suppressor cells (MDSCs) suppress immune responses and aid in the active 
resolution of inflammation at sites of injury and distally within peripheral lymphoid 
tissues. In cancer, both these cell types provide tumours with the means of escaping 
immune mediated destruction, and tumour cells use a number of distinct mechanisms 
in order to subvert the physiological functions of Tregs and MSDCs to aid cancer 




2.1.3.1 MDSCs inhibit anti-tumour immune responses 
There are two populations of MDSCs that have been characterised; 
Granulocyte-derived MDSCs (G-MDSCs) and Monocyte-derived MDSCs 
(M-MDSCs)158. G-MDSCs are the most prevalent in tumour-bearing mice, but are 
only weekly immunosuppressive and suppress immune cells by secretion of 
ROS159,160. M-MDSCs suppress the anti-tumour T-cell response primarily by 
enzymes ARG1 and inducible nitric acid synthase (iNOS) as well as through the 
secretion of ROS159,160. Arg1 and iNos both induce T-cell proliferative arrest by 
inhibition of PI3K/mTOR signalling pathways. In human tumours, the levels of 
intra-tumoural M-MDSCs, but not G-MDSCs correlate with immune suppression 
and poor prognosis161.   
 
2.1.3.2 Tregs and Treg-mediated T-cell suppression  
Tregs (CD4+ CD25+ FoxP3+ cells) are characterized by the expression of the 
transcription factor FoxP3 that drives the upregulation of IL-2, IL10, TGFβ and other 
immunosuppressive associated factors. Genetic deletions, or loss-of-function 
mutations in FoxP3, result in hyper-lymphoproliferative disorder leading to 
multi-organ tissue failure in both humans and mice162,163. Tregs are highly 
immunosuppressive cells that exist in two distinct subpopulations, tTregs and iTregs 
described above (2.1.2.2). The transcriptional program of FoxP3 drives the 
immunosuppressive functions of Tregs, and maintenance of FoxP3 expression is 
critical to Treg linage stability139. FoxP3 suppresses the expression of 
pro-inflammatory mediators such as IL-2, TNF-α, IFN-γ, IL-17 and IL-4 by 
Tregs139,164-166, and induces the constitutive expression of CD25 (a subunit of the 
IL-2 receptor), CTLA4, IDO, CD39 and CD73139,167. The understanding of the 
molecular mechanisms of Treg immune suppression is still limited, but some 
putative mechanisms have been described (Figure 2.4). IL-2 is required for T cell 
proliferation, and high levels of Treg-expressed CD25 may act to sequester and 
deprive T-cells of IL-2, subsequently inhibiting T-cell proliferation168. CTLA4 has 
also been implicated in Treg-mediated immune suppression. Treg-specific genetic 
deletion of CTLA4 in BALB/c mice results in greatly increased numbers of activated 
Tregs under inflammatory conditions, yet the immunosuppressive activity of the 
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CTLA4-deleted Tregs was greatly impaired139,169,170. The reduction of Treg 
immunosuppressive function was associated with increased DCs171, due to 
CTLA4-deleted Tregs inability to down-regulate DC-expressed CD80 and CD86 by 
trans-endocytosis (Figure 2.4)170,172. Furthermore, Tregs can induce the expression 
of indoleamine 2,3-dioxygenase (IDO) on DCs, which catalyzes the degradation of 
tryptophan to N′-Formylkynurenine, leading to starvation of effector T cells and 
direct cell cycle arrest167,173,174. However, BALB/c mice are known to be susceptible 
to various immune-mediated disorders. Treg-specific genetic deletion of CTLA4 in 
C56Bl/6 mice did not result in increased numbers of DCs and only partially impaired 
Treg immunosuppressive capacity139, thus CTLA-4 contribution to Treg functions 
can be significantly modified on different genetic backgrounds. Other FoxP3 
 





) either directly or indirectly. The hydrolysis of ATP and 
ADP to adenosine by CD39/73, secretion of immunosuppressive cytokines IL-10 and TGFβ, 
catabolism of tryptophan to N’-formylkynurenine by IDO and sequestration of IL-2 by CD25 
suppresses effCD8
+
 cytotoxic functions directly. Treg surface-expressed CTLA4 may reduce the 
APC surface expression of co-stimulatory molecules CD80 and CD86 and may induce the 
expression of IDO, both of which act to inhibit effCD8
+




mediated CD25/CTLA4 independent mechanisms of Treg suppression have been 
described. Cell-surface molecules CD39 and CD73 are two ectoenzymes that are 
highly expressed on Tregs.  These molecules hydrolyse extracellular ATP and ADP 
to adenosine, and as a result not only directly inhibit effector T-cell proliferation but 
also negatively impact on the function of DCs (Figure 2.4)175,176. Furthermore, Treg 
secreted cAMP may directly inhibit effector T-cell and DC fuction177.  
In cancer, Tregs have been found within tumours and peripheral draining lymph 
nodes in patients with liver178, lung179, head and neck180, breast181, pancreatic181,182, 
gastrointestinal183 and ovarian cancers184,185. Increased levels of Tregs are not 
necessarily indicative of poor prognosis, but rather the ratio between the number of 
effector CD8+ T-cells and intra-tumoural Tregs (effCD8:Treg), where by a low ratio 
correlates with poor prognosis184-186. Tumour cells have developed a number of ways 







2.2 Stromal contributions to the tumour microenvironment 
 
2.2.1 Endothelial cells and angiogenesis within the tumour 
microenvironment 
 
The availability of oxygen, nutrients and serum-derived growth factors are 
prerequisites for all tissues. The extensive vascular network has evolved to supply 
these demands and facilitate immune surveillance. The remodelling of established 
vessels and the production of new ones is a complex program of multiple 
mechanisms, referred to collectively here as angiogenesis. In adult tissues, quiescent 
endothial cells form a monolayer interconnected by juctional molecules such VE-
cadherin and claudins187. This forms a hollow tube ensheathed by pericytes, a 
specialized cell type that maintains vessels and regulates endothelial cell (EC) 
proliferation. When the quiescent ECs sense a pro-angiogenic signal such as vascular 
endothelial growth factor (VEGF), angiopoietin-2 (ANG-2) or fibroblast growth 
factors (FGFs), pericytes detach themselves from the vessel walls and secrete 
proteases such as MMPs to degrade the basement membrane. Juctional adhesions 
between ECs begin to loosen and the nascent vessel dilates. The secretion of VEGF 
by the surrounding milieu increases vascular permeability allowing plasma proteins 
to extravasate and lay down a temporary extracellular matrix (ECM) scaffold187. In 
response to integrin activation by the newly assembled ECM, ECs migrate out and 
begin to remodel the ECM and surrounding milieu to establish a new niche, ready to 
support a developing vessel187,188. One EC is selected to become a tip cell, which 
drives the directional migration of the newly developing vessel in response to VEGF, 
neuropilins and FGFs. The remaining ECs assume subsidiary positions as stalk cells, 
which divide to elongate the developing vessel, and which form the vessel lumen187-
189. Finally, for the newly developed vessel to become functional ECs resume a 
quiescent state, platelet-derived growth factor (PDGF) and TGFβ signaling recruits 
pericytes to ensheath the new vessel and EC juctional adhesions are established187-
189. The matured vascular structure is maintained and protected from insult by VEGF, 
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NOTCH, angiopoietin-1 (ANG-1) and FGFs, emanating from supporting pericytes, 
proximal fibroblasts or autocrine signalling loops directly from ECs187,190,191.  
Established vessels also express oxygen-sensing mechanisms such as 
hypoxia-inducible factor-2α (HIF-2α) and prolyl hydroxylase domain 2 (PHD2) 
which precipitate vascular re-modelling to optimise blood flow to hypoxic 
areas187,188. This is most prevalent in cancer192, where tumours are inherently hypoxic 
and often contain activated fibroblasts and immune cells which secrete 
pro-angiogenic factors. This induction of angiogenesis or ‘angiogenic switch’ 
increases tumour cell proliferation and metastatic progression193,194. Constitutive 
pro-angiogenic signalling in tumours results in a neoplastic vasculature architecture 
that is irregular, unstable and leaky195,196. The lack of matured vessels in tumours can 
impede immune cell function and the distribution of oxygen and anti-cancer 
therapeutics189,197.     
In adults, angiogenesis in the most part occurs only in neoplastic tissue and therefore 
has become the prime subject of microenvironment-targeted anti-cancer therapies.  
Treatment with monoclonal antibody antagonists of VEGF presented promise as an 
anti-tumour therapy in mice, but showed disappointing efficacy in the clinic. 
Numerous preclinical studies (ref. to 198 for full list) has shown a 25 – 90% inhibition 
of tumour growth in mice treatment with A.4.6.1, a monoclonal VEGF antibody. 
These results could not be replicated in humans however, and treatment with the 
human equivalent of A.4.6.1, Bevacizumab (trade name Avastin®) in clinical trails 
of non-small cell lung cancer (NSCLC)199 and metastatic renal cancer200 only showed 
modest improvement in patient outcome201.  The lack of efficacy in human trials has 
been attributed to secondary angiogenic mechanisms which re-establish tumour 
vasculature after VEGF-depletion. In a number of cases the reoccurring vessels 
exceeded the pre-existing vasculature in both vessel quality and tumour coverage, 
increasing both tumor survival and progression189,196. The mechanisms of tumour 
vascular normalization are still unclear. However, angiopoietin receptor Tie2 
expressing macrophages have been shown to improve neovascularization202 and ECs 
can themselves produce other VEGF-independent angiogenic factors. These results 
highlight the fundamental requirement of a vascular network to support tumour 
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survival, growth and progression. Further work focuses on understanding the 
functional redundancy of VEGF in neovascularization and possible therapeutic 
combinations aimed at both VEGF and components of tumour normalization.    
 
2.2.2 The ECM and fibroblasts in cancer  
 
The extracellular matrix (ECM) was believed to be an inert structure involved in the 
compartmentalisation of cells for the delineation of tissue architecture11. It has since 
been shown to be a complex signalling mediator consisting of fibrillar collagens, 
fibronectins, hyaluronic acid and proteoglycans203, which together provide contextual 
information for the surrounding cells204. This is especially the case in cancer as 
neoplastic ECM is distinct from normal tissue ECM205, and contextualises 
transformed cells as ‘tumour cells’. Without tumour-generated ECM, transformed-
cells can integrate into normal tissue206,207 and form tissue-specific structures in 
culture, losing their hyper-proliferative state and function as part of the tissue, 
effectively behaving as a ‘normal’ cell204. These cells still retain the capacity to 
behave as transformed cells (once removed from co-culture they proliferate rapidly 
and formed tumours in vivo) but in the presence of non-tumour ECM they are 
effectively non-tumorigenic204.  
Beyond providing contextual information to the tumour, both quality and quantity of 
ECM has been reported to influence tumour survival, proliferation and 
migration208,209. Tumour cells greatly influence their surrounding ECM both 
quantitatively, by increasing the deposition of matrix, and qualitatively by regulating 
the rigidity of the 3D matrix210. Three major components of the ECM distinctly 
regulate these properties: 
 
i. Collagens are critical components of the ECM involved in modulating ECM 
stiffness and rigidity210. Tumour fibrillar collagen is linearized and matured 
in a mechanism that requires the covalent cross-linking of collagen by lysyl 
oxidase (LOX), expressed initially by fibroblasts but also later by 
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carcinomas in hypoxic conditions211,212. Matured fibres enhance both tumour 
cell migration and invasion, and inhibition of LOX family has been shown to 
reduce tumour growth, migration, invasion and progression213.   
Furthermore, LOX inhibition reduced metastatic spread in a number of 
different models, suggesting that LOX may act at distant metastatic sites to 
predispose the metastatic niche to seeding of circulating tumour cells213,214.  
Collagens within the ECM also mediate the migration, recruitment and 
activation of a number of stromal cells within the tumour microenvironment. 
It has been reported that linear fibrillar type I collagen induced invadosome 
structures on tumour cells, endothelial cells, fibroblasts and macrophages212. 
Invadosomes (referring collectively to invadopodia and podosomes) are actin 
based molecular complexes involved in ECM degradation associated with 
increased cellular migration and invasion210,215.  
 
ii. Fibronectins have been reported to be ligands for a number of integrin 
family members, including α5β1 integrin216, and regulate a number roles 
involved in cell adhesion, migration and growth210,217. Upregulation of 
fibronectins has been associated with increased metastasis of A431 tumour 
cells218, and has been shown to increase metastatic progression of ovarian 
cancer by promoting an association between α5β1 integrin and c-Met, 
leading to a ligand-independent activation of c-Met210,219.  
 
iii. Hyaluronic acid (Hyaluronan) expression has been shown positively 
regulate tumour neovascularisation and EC proliferation by increasing the 
recruitment of tumour-associated macrophages (TAMs)220.  
 
Although most cell types can produce ECM component proteins, fibroblasts are the 
major producers of both ECM components and ECM modulating enzymes. ‘Normal’ 
fibroblasts are typically embedded in the ECM of connective tissue. Upon tissue 
injury, fibroblast activation is induced by secreted growth factors released from 
injured epithelial cells or by infiltrating monocytes and macrophages221. These 
factors include transforming growth factor β (TGFβ), hepatocyte growth factor 
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(HGF) and PDGF221. Activation of fibroblasts in this way is characterised by the 
expression of smooth muscle actin (α-SMA), and these ‘myofibroblasts’ produce 
extensive ECM components and ECM remodelling enzymes. To facilitate this 
increase in protein translation, myofibroblasts undergo a morphological switch from 
the typical fusiform morphology of inactive fibroblasts, to a spindle cell morphology 
containing increased rough endoplasmic reticulum, peripherally located 
smooth-muscle type myofilaments, Golgi apparatus producing collagen-secretion 
granules and fibronexus junctions222. In this manner, myofibroblasts are distinct from 
other fibroblasts and can be identified pathologically. Myofibroblast infiltration has 
been associated with nodular pseudosarcomatous fasciits, inflammatory 
myofibroblastic tumours, dermatofibrosarcoma protuberans, myofibroblastic 
sarcoma, malignant fibrous histiocytoma and spindle-cell carcinoma223. 
A number of different fibroblastic cell types can be present within the developing 
tumour niche, referred collectively as cancer-associated fibroblasts (CAFs); 
tissue-resident fibroblasts proximal to the developing tumour can be recruited 
directly or become activated, alongside mesenchymal stem cells and 
myofibroblasts203. CAFs show distinct phenotypic differences to normal fibroblasts 
within the tumour microenvironment. These include the de novo expression of 
α-SMA and fibronectin as seen in myofibroblast activation, but unlike myofibroblast 
activation, cannot be de-activated and are much longer lived (are not removed 
through apoptosis)210. In breast cancer, normal fibroblasts promote an epithelial-like 
phenotype that suppresses metastasis; whereas CAFs induce a mesenchymal-like 
phenotype and enhance metastasis of both premalignant and malignant mammary 
epithelial cells224,225. CAFs can stimulate anti-apoptotic responses in tumour cell 
through the modulation of the ECM as CAF-derived ECM remodelling proteases 
have the capacity to generate ligands for anti-apoptotic integrins. Furthermore, CAFs 
have been shown to stimulate tumour cell proliferation through the secretion of 
growth factors such as the FGF, HGF, epithelial growth factors (EGFs) and 
insulin-like growth factors 1 and 2 (IGF1/2)13,210,226,227. CAFs may also secrete a 
range of pro-inflammatory cytokines228 that can indirectly act as mitogenic signals by 




2.3 Remodelling the tumour microenvironment to promote tumour 
rejection 
 
Given the influence of the tumour microenvironment on cancer biology and clinical 
outcome, the development of effective therapies that target components of the 
microenvironment is becoming increasingly important. Therapies that promote 
anti-tumour immune responses have shown great promise over the last few years, 
none more so than antibody-based therapies targeting immunosuppressive molecules 
CTLA4 and PD-1. CTLA4 antagonist Ipilimumab has been clinically assessed in a 
number of different cancer models, most notably metastatic melanoma. Anti-CTLA4 
therapy has the potential to target and suppress the immunosuppressive functions of 
Tregs (2.1.3.2) and to re-activate anergic or exhausted T-cells. Ipilimumab 
monotherapy produced objective responses in approximately 15% of patients with 
metastatic melanoma, which include 3 patients who demonstrated complete 
responses229. However, in other instances, Ipilimumab caused severe autoimmune 
complications. Treatment schedules and dose escalation studies have identified 
optimal responses at the highest doses230, which escalates the risk of developing 
autoimmune conditions, manifesting primarily as immune-related toxicity to the skin 
and gastrointestinal tract231. However the benefits to patient survival with 
Ipilimumab treatment in metastatic melanoma, a disease with very few effective 
front line therapies and an average patient-survival rate of 5-10%, vastly out-weigh 
the risk of developing chronic, unmanageable side effects.  
Anti-PD1 therapy also targets exhausted and anergic T-cells to re-activate the anti-
tumour cytotoxic CD8+ T-cell response. PD-1 targeted anybody Nivolumab showed 
moderate success as a monotherapy, but excelled in combination with Ipilimumab. In 
a recently published study232, 53 patients with advanced metastatic melanoma 
received concurrent therapy with Nivolumab and Ipilimumab, and 33 received 
sequential treatment. 53% of patients had an objective response and all showed a 
reduction in tumour size in excess of 80%.  
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The success of immunotherapy has been attributed, in part to the low-immunogenic 
nature of some cancers. The availability of TAA-specific CD8+ T-cells is becoming 
accepted as an essential prerequisite for an objective response to immune checkpoint 
therapies; without the capacity for a CD8+ T-cell response against a TAA, 
reactivation of immune cells by targeting immune checkpoints would not necessarily 
lead to immune-mediated destruction of tumours. The heterogeneity of TAA 
expression, including intratumoral variation and variation across different patients, 
may begin to explain why typically up to 40% of patients respond to immune 
checkpoint inhibitors, and a significant number do not. Although at this point little 
evidence exists to support this hypothesis, work involving immune checkpoint 
inhibition in combination with tumour vaccinations, both by the implantation of 
primed dendritic cells and the injection of tumour-specific antigenic peptides have 
begun to show promise in pre-clinical studies104,233,234.     
 
2.4 Tumour cells and the tumour microenvironment 
 
When I consider ‘the hallmarks of cancer’, there are relatively few tumour cell 
autonomous properties (genome instability and mutation, and enabling replicative 
immortality). To survive and progress, the tumour must recruit, manipulate and 
subvert crucial cell populations. Transformed cells contribute to the generation of the 
tumour microenvironment by secreting signalling molecules or by direct cell:cell or 
cell:ECM contact. Tumour secreted growth factors and chemokines, such as TGFβ, 
PDGF, FGF and MCP1, activate CAFs present in the tumour 
microevironment225,235,236, and tumour cell secreted VEGF can initiate angiogenesis.  
Secreted factors originating for the tumour cell allow the tumour to generate a more 
permissive niche as quickly and efficiently as possible.  
In order to mount an effective adaptive immune response, T-cells require APC 
presented antigen. Tumour cells that undergo apoptosis may generate an antitumor 
immune response through different mechanisms collectively called immunogenic 
programmed-cell death (Figure 2.5). Apoptosis is a mechanism by which the cell in 
response to stress signalling or DNA damage can induce programed cell 
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death237(Figure 2.5a). Activation of the mitochondrial BAX/BAK pathway leads to 
the generation of the cytosolic apoptosome complex, and subsequently the activation 
of caspase 9, triggering the caspase cascade and the induction of apoptosis. A 
consequence of the induction of apoptosis is the up regulation of proteolysis, which 
under certain conditions can lead to the generation novel TAAs. TAAs can then be 
found in the ‘cell blebs’, extracellular vesicles formed in the final phase of apoptosis, 
which can be phagocytised by APCs and the TAAs presented238 (Figure 2.5b). 
 
Figure 2.5 I Mechanisms of immunogenic cell death. Immunogenic cell death is a form of 
apoptosis that induces and primes an immune response. a Intrinsic apoptotic mechanisms 
generate new antigenic peptides. b New antigenic peptides may be released via cell blebbing and 
subsequently phagocytosed and presented by APCs. c Increased permeability of nuclear and cell 
membranes releases DNA, RNA and PTX3 which act to stimulate and regulate the maturation of 
DCs. d Finally further breakdown of cell membranes releases pro-inflammatory molecules into the 




Furthermore, increased proliferation, recruitment and differentiation of APCs can be 
seen at sights of chemotherapy-induced apoptosis, in part due to the release of factors 
from dying cancer cells, such as ATP and DNA which induce DC maturation and 
RAN and PTX3 which stimulate and active DCs respectively239 (Figure 2.5c). 
Furthermore, in the final stages of apoptosis as the cell and nuclear membrane begin 
to break down and cellular components are released, HSP70, uric acid and HSP90 
can induce DC maturation, CD8+ T-cell mediated pro inflammatory responses and 
the stimulation of NK cells240 (Figure 2.5d).  
Tumour cells hijack and manipulate both arms of the immune response in order to 
promote tumour survival and evade immune cell-mediated destruction (Figure 2.6). 
Secretion of chemokines and cytokines into the tumour microenvironment can act on 
multiple immune cell populations simultaneously, to increase pro-tumorigenic and 
immunosuppressive functions and suppress cytotoxic activity. Tumour-secreted 
TGFβ acts to polarize intra-tumoural neutrophils to adopt a more pro-tumorigenic 
phenotype, whilst alongside IL-10, induces Treg expansion from CD4+ effector cells, 
maintains intra-tumoural Treg populations and suppresses CD8+ cytotoxic effector 
functions241-243.  IL-10 also acts with IL-1β, IL-6, IL-11 and VEGF to modulate 
MDSCs, macrophages and DCs. Each molecule may act alone or together to induce 
the expansion of MDSCs and increase their immunosuppressive capacity, polarize 
macrophages into a pro-tumorigenic immunosuppressive M2 phenotype and inhibit 
DC activation, all of which act to increase tumour survival242.  Other tumour-secreted 
factors include IFN-γ and IL1-α that enhance iNOS and ARG1 immunosuppression 
by MDSCs and macrophages. Furthermore, GM-CSF, drives expansion of MDSCs, 
while IL-4 and IL-13 contribute to the recruitment and immunosuppressive capacity 
of MDSCs and macrophages respectively242.  Furthermore, tumour cells can express 
TCR co-stimulatory molecules CTLA4, PD-1, PD-L1/2 and CD80/86, which act to 





Figure 2.6 I Tumours subvert immune responses to aid tumour growth and
survival. Tumour cell expressed and secreted molecules modulate aspects of the adaptive
(top) and innate (bottom) arms of the immune response. Tumour cells may increase the
expansion, recruitment or immunosuppressive capacity of pro-tumorigenic populations such as
M2 macrophages, Tregs, MDSCs and polarized neutrophils and directly evade anti-tumour CD8+
T-cell responses by the suppression of CD8+ effector functions, the induction of T-cell anergy /
exhaustion or by the inhibition of DC-mediated antigen presentation. top Tumour cell may
express co-stimulatory molecules such as PD-1 and CTLA4 which act to induce T-cell anergy
and exhaustion. Secreted factors such as IL-10, TGFβ and CCL5 act to suppress effector CD8+
T-cell functions and increase the recruitment and the immunosuppressive capacity of Tregs.
bottom Some factors act synergistically with both arms of the immune response, namely TGFβ
and IL-10 which not only act to modulate the adaptive immune response, but may also enhance
the pro-tumorigenic polarization of neutrophils and macrophages. Factors such as IL-1, IL-4, IL-6
and IL-11 act to increase the recruitment, expansion and immunosuppressive functions of
MDSCs and M2 macrophages. Others may act to inhibit DC activation and thereby inhibit the
CD8+ T-cell response. MDSC =myeloid-derived suppressor cell; DC= dendritic cell
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3 FAK is a central molecule in the regulation of key cancer cell 
phenotypes. 
FAK is a non-receptor protein tyrosine kinase localised primarily at focal adhesions, 
where it acts a pivotal signalling integrator downstream of integrins and growth 
factor receptors. It consists of 3 functional protein domains; an N-terminal 
Four-point-one, Ezrin, Radixin, Moesin (FERM) domain, a central kinase domain 
and a C-terminal Focal Adhesion Targeting (FAT) domain244 (Figure 3.1). 
Autophosphorylation of tyrosine residue 397 (Y397) reveals a high affinity SH2 Src 
family-binding domain. Upon Src binding, a transactivation mechanism results in the 
phosphorylation of other key tyrosine residues (Y576, Y577, Y862 and Y925), fully 
activating FAK and forming the FAK-Src signalling complex. Further to FAKs 
association with Src, other FAK binding partners include Arp2/3, talin and paxillin, 
VE-cadherin, PI3K/AKT, GRB2 and p53 (Figure 3.1). Through both 
kinase-dependant and independent protein:protein interactions such as these, FAK 
regulates a number of signalling pathways associated with tumour growth and 
metastasis (Figure 3.2) including regulation of invasion245, cell morphology and 
polarization246-248, motility249-251, cell cycle progression252 and proliferation253,254. 
Studies investigating the role of FAK in cancer have thus far identified elevated 
levels of FAK expression in a range of tumours, including breast255-257, colon255,256, 
prostate258, oral259, laryngeal260, skin245, and squamous cell carcinomas261.  Thus 
FAK presents a therapeutic target that is both upregulated in a number of cancer 
models and is critically important in an array of cancer cell processes.  
Tumour cell:ECM contact provides both contextual and survival signals to tumour 
cells. The ECM is commonly deregulated and disorganized in cancer which 
promotes cellular transformation and metastatic progression262. Tumour cells interact 
with the ECM at sites of integrin clustering, known as focal adhesions. Here, 
integrins mediate bi-directional signaling across the plasma membrane by virtue of 
their association with intra-cellular macro-molecular complexes, of which FAK is a 
key component. Downstream of integrins, FAK is known to regulate multiple 
processes in tumour biology, including the invasion, migration and metastasis, and 




3.1 FAK promotes tumour cell invasion and metastasis 
 
Dynamic changes in focal adhesions and in cytoskeletal organisation and 
polymerisation allow tumour cells to polarize, transition to a motile state and invade. 
Canonical FAK signalling is associated with the maturation and turnover of focal 
adhesions263-265. The loss of FAK in cells increases the number of immature focal 
adhesions correlating with decreased cell migration266. Through the recruitment and 
activation of key adaptor proteins such as paxillin267 and talin268, and through an 
association with proteolysis complex CPN2 and Caspase-8269, FAK regulates both 
the disassembly and maturation of focal adhesions at the cell leading and trailing 
edges (Figure 3.2b).   
 
Figure 3.1 I The structure of FAK and key binding partners. The structure of FAK 
consists of three modular domains; an N-terminal four-point-one, ezrin, radixin, moesin (FERM) 
domain, a central kinase domain and a C-terminal focal adhesion targeting (FAT) domain. 
Activation of FAK requires the autophosphorylation of tyrosine (Y) 397, and the subsequent 
phosphorylation of key residues (as shown). Lysine (K) 454 is a critical molecule in the kinase 
activity of FAK and mutation of this residue generates a kinase-deficient FAK analogue. FAK 
complexes with a number of proteins involved in cell motility (dark blue), cell survival (light blue) or 
both functions (dark blue/light blue). Roles involving FAK activation are shown in grey, and 
important contributions to the tumour environment are shown in green. Figure adapted from FAK in 
cancer: mechanistic findings and clinical applications. Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. 




FAK further contributes to migration and cellular polarization by regulating 
cytoskeletal dynamics through interactions with complexes involved in actin 
polymerisation and Rho family signalling modulation263. In a kinase independent 
manner, the FAK-FERM domain binds the Arp2/3 complex, enhancing 
Arp2/3-depandant actin polymerisation. This results in increased protrusive 
lamellipodia formation and cell spreading248. In addition FAK regulates the 
activation of Rho family GTPases; GTPase regulator associated with FAK (GRAF, 
part of the RhoGAP family) and ARHGEF28 (also known as p190RhoGEF) bind to 
the c-terminal domain of FAK, and act to inhibit and activate Rho mediated 
signalling respectively263. Why FAK interacts with complexes that both activate and 
Figure 3.2 I Signaling pathways of FAK that regulate tumour growth and 
metastasis. FAK enhances tumour growth and metastasis through kinase-dependent (blue) or 
kinase-independent (red) functions. Dashed lines represent processes that have yet to be fully 
characterized. a FAK is activated downstream of receptor tyrosine kinases (RTKs), integrins, G-
protein coupled receptors (GPCRs) and cytokine receptors. b Activated FAK increases tumour cell 
invasion and metastasis by remodeling the cytoskeleton, turnover of focal adhesions and the 
transcriptional upregulation and presentation of matrix metalloproteinases (MMPs). c FAK kinase-
independent scaffolding functions interact with endophilin A2 increasing the expression of markers 
of endothelial-to-mesenchymal transition (EMT). d FAK activation increases the levels of cyclin D1 
expression and enhances the inhibition of apoptosis subsequently increasing tumour cell survival 
and growth. e Under conditions of cellular stress, FAK may translocate to the nucleus where is acts 
as a scaffold for the p53/MDM2 complex, targeting p53 for polyubiquitination (Ub) and increasing 
tumour survival and growth. Figure taken from FAK in cancer: mechanistic findings and clinical 




inhibit Rho signalling is not yet understood, but it raises an interesting hypothesis 
that FAK may act to both spatially and temporally regulate actin dynamics by 
alternately associating with both RhoGAPs and RhoGEFs263,270.   
What these data suggest is that FAK is a critical molecule in the regulation of cell 
polarization, motility and invasion. Epithelial to mesenchymal phenotype (EMT) is 
required for the migration and metastatic progression of some caner cells, where as 
come cells migrate collectively. FAK signalling promotes EMT-like transcriptional 
programmes and both TGFβ-271 and SNAIL1-induced272 EMT requires FAK 
expression. Moreover, inhibition of FAK or Src regulates E-cadherin internalization 
in vivo249, stabilizing E-cadherin cell surface expression resulting in a suppression of 
E-cadherin-dependent collective cell migration249,273. Thus FAK plays an important 
role in EMT, invasion and metastatic progression, providing the basis for the 
development of a number of FAK kinase inhibitors as discussed in detail below.  
 
3.1.1 FAK promotes tumour cell survival and growth 
 
FAK promotes tumour cell survival through kinase dependant and independent 
mechanisms (Figure 3.2d). Those that require kinase activity include FAK signalling 
through the PI3K-AKT pathway274. Tumours can prevent death-inducing signals by 
the integrin-mediated activation of the FAK-AKT pathway275. Tumour cells may also 
activate this pathway in times of adhesion stress and inhibit the onset of anoikis274.  
Studies using a kinase deficient mutant of FAK have identified that FAK kinase 
activity is also a requirement for the anchorage-independent 3 dimensional growth of 
squamous cell carcinoma (SCC) cells in vitro, and their growth as xenografts in CD1 
nude mice276.  
FAK activity also regulates cell cycle progression. Loss of FAK decreases levels of 
cyclin D1, and consequently genetic deletion of FAK in tumour cells inhibits G1 to S 
phase transition, reducing tumour cell growth277.  FAK regulates levels of Cyclin D1 
through three separate pathways. Firstly, FAK signals through ERK in a 
Src-dependant manner, and ablation or inhibition of FAK reduces Src-mediated 
p130CAS activation and signalling through ERK in models of breast cancer278,279. 
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Activation of ERK leads to its nuclear translocation and the transcription of CCND1 
(gene encoding Cyclin D1)280.  Secondly, FAK induces the expression of the 
transcription factor KLF8 through the activation of PI3K-AKT pathway, which leads 
the transcription of KLF8 by SP1281. KLF8 directly transcribes CCND1 enhancing 
cell cycle progression, but is also critical in EMT and oncogenic transformation281. 
Finally, FAK can increase levels of Cyclin D1 though interactions with JNK. 
 
3.1.2 FAK and the nucleus 
 
 In addition to its signaling role at focal adhesions, FAK has also been shown to 
display nuclear localization and have distinct functions in the nucleus. The 
emergence of kinase-independent functions of FAK fueled investigation into other 
domains, leading to the discovery of a Nuclear Localization Sequence (NLS) within 
the FAK FERM domain and revealing some of FAK’s nuclear functions282.  It has 
been shown that nuclear FAK forms a tri-molecular complex with p53 and the E3 
ubiquitin ligase mdm2, targeting p53 for degradation, promoting cell cycle 
progression283 (Figure 3.2e). Further nuclear specific studies have shown FAK also 
targets GATA-4 for degradation284, a transcription factor associated with the 
expression of pro-inflammatory protein VCAM-1 amongst others284. This 
relationship between nuclear FAK and transcription factors brings into focus 
numerous potential roles for FAK in direct transcriptional regulation. 	
 
3.1.3 FAK and Pyk2 
 
Proline-rich tyrosine kinase 2 (Pyk2) is a closely related non-receptor tyrosine kinase 
to FAK, and shares approximately 60% sequence homology. Pyk2 and FAK share 
the same modular domain structure, an N-terminal FERM domain, central kinase 
domain and C-terminal FAT domain, with the phosphorylation of critical Pyk2 
tyrosine residues Y402, Y579/580 and Y880 functioning synonymous to FAK Y397, 
Y576/577 and Y925 respectively285. However, Pyk2 displays perinuclear distribution 
and localization, and is only weakly present at focal adhesions. Both proteins do 
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share common protein binding partners, including Grb2, and are associated in a 
trans-activation mechanism with Src family kinases286. FAK is thought to be 
expressed a various levels in most tissues, whereas Pyk2 expression appears 
restricted to epithelial cells, neurons and hematopoietic cells287-291. Pyk2 has a small 
number of unique binding partners, such as the actin associated protein gelsolin, and 
Talin only associates with FAK C-terminal domain and not Pyk2. Pyk2 may act in a 
compensatory manner to FAK, although their expression and regulation are 
distinct292. Due to their sequence similarity many FAK kinase inhibitors also target 
Pyk2 with greater or lesser affinities.  
 
3.2 FAK signalling within the microenvironment  
 
Alongside FAKs roles in tumour cell biology, it is also a central molecule in a 
number of stromal cells within the microenvironment (summarized in Figure 3.3). 
A series of non-cellular microenvironmental cues that influence tumour growth, 
survival, progression and metastasis may act by increasing FAK activity in stromal 
cells in the tumour microenvironment265. Increases in pH correlate with the 
upregulation of FAK Y397 autophosphorylation and focal adhesion maturation293, 
and increased FAK activation has been observed downstream of VEGF binding to its 
receptor. Upregulation of FAK expression in stromal cells can also be controlled by 
these factors. FAK gene expression is regulated in part by active NF-κB294. Signals 
related to cellular stress such as reactive oxygen species (ROS), TNFα295, growth 
factors, and chemokines and cytokines such as IL-1β and IL-8296 activate NF-κB, 
leading to the transcriptional upregulation of FAK. Thus, the influence of FAK 
signalling on tumour cell biology extends beyond the tumour cells themselves and 






Figure 3.3 I The roles of FAK in the tumour microenvironment. FAK play numerous
roles in the each compartment of the tumour microenvironment. In the immune compartment
FAK is required for macrophage, natural killer (NK) cell and neutrophil migration and tumour
recruitment (3.2.1). It may also play a role in signal transduction downstream T-cell receptor
(TCR) activation on T-cells. In endothial cells FAK is involved in increasing angiogenesis,
vascular permeability and tumour cell intravasation (3.2.2). FAK is also required for fibroblast
migration, growth and survival, activation by LOXL2 and cancer associated fibroblast (CAF)
recruitment into the tumour microenvironment (3.2.3). Adapted from FAK in cancer:
mechanistic findings and clinical applications. Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D.
Nature reviews Cancer, 2014
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3.2.1 FAK signaling in immune cells  
 
FAK is expressed in a number of cells from both the adaptive and innate immune 
lineages, including macrophages, neutrophils and T-cells297. Macrophages and 
neutrophils are cell populations of the myeloid lineage, central in mediating the 
immune response at sites of heightened inflammation such as cancer. Typically, the 
first cells to respond to changes in inflammation, they act to phagocytose cell debris 
and aid in angiogenesis and tissue repair. In terms of cancer, the most extensively 
characterised of these cells are macrophages. FAK is upregulated in differentiating 
myeloid cells following GM-CSF stimulation297, and macrophage motility requires 
FAK signaling downstream of α5β1 for haptotaxis toward fibronectin and for 
directional chemotaxis toward M-CSF1298. FAK knockout in macrophages also 
decreases monocyte recruitment to inflammatory sites in vivo299. Treatment with a 
FAK inhibitor in mouse models of breast cancer results in decreased levels of tumour 
associated macrophages (TAMs) and a reduction in primary tumour size300,301.  
Additionally in models of PDAC, without effecting angiogenesis, necrosis or 
apoptosis, FAK inhibition also resulted in a decrease in TAM recruitment302.  
The role of FAK in other myeloid lineages is controversial. In mice with a myeloid 
specific FAK deletion (a Lyzsozyme 2 knock-in cre; B6.129P2-Lyz2tm1(cre)Ifo/J)303, 
neutrophils demonstrated accelerated  spontaneous cell death and reduced phagocytic 
activity303. Other work disputes the role of FAK in myeloid cell differentiation, 
indicating that FAK is decreased in haematopoietic stem cells before commitment 
toward a myeloid lineage, and this shift in haematopoietic homeostasis is linked to 
increased metastasis304.   Furthermore, in a study of acute myeloid leukaemia (AML), 
FAK expression was upregulated in CD34+ AML cells but not in CD34+ normal 
cells305, contradicting previous work identifying FAK upregulation in early myeloid 
progenitors297. Many of the problems associated with addressing the role of FAK in 
myeloid cells, and hence the conflicting data, are due to the involvement of Pyk2. In 
a number of studies involving myeloid cells, FAK upregulation correlates with an 
upregulation of phosphorylated Pyk2 (Y881)305. Therefore, the effects of Pyk2 
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activation need to be further dissected before the role of FAK in myeloid cells can be 
addressed definitively. 
In T-cells, TCR signal transduction involves the Src family kinases Fyn and Lck 
(2.1.2.1), and therefore could imply due to the close association between FAK and 
Src family kinases, that FAK may play an important role in TCR signal transduction. 
However, some data suggests that FAK negatively regulates TCR signalling and 
FAK-/- Jurkat cells upregulate IL-2 production associated with increase ZAP70 
phosphorylation306. In this purposed mechanism, FAK activation recruits C-terminal 
Src kinase (CSK) to the membrane, impairing CSK activation of Lck, and thus 
inhibiting TCR signalling down-stream of Lck306. FAK kinase inhibition with 
PF-562,271 reduces CD4+ T-cell TCR activation, and reduced in the phosphorylation 
of ZAP70 downstream Erk1/2 activation, which was associated with a reduction in 
the proliferation of both murine and human T-cell was reduced following treatment 
with PF-562,271307. However, the conditional deletion of FAK in CD4+ T-cells does 
not impair proliferation, and therefor the mechanism of PF-562,271 could be due to 
inhibition Pyk2.  
What brings many of these finding in to question, is that most of these studies were 
performed in Jurkat cells, and to what extent cell signalling has been effected by the 
immortalisation of these cells has not yet been addressed.  These concerns are 
heightened by primary and in vivo data in which FAK appears not to be expressed in 
T-cells. Furthermore, Pyk2 has distinct and better characterized roles in T-cells.Pyk2 
overexpression in immortalised CD4+ Jurkat cells identified that TCR- and 
CD28-induced JNK and p38 MAPK activation, and subsequent IL-2 production, was 
partially dependant on Pyk2308. T-cell specific deletion of Pyk2 reduced the 
proliferative capacity of T-cells in vitro, and reduced IL-2 and IFN-γ production in 
CD8+ T-cells309. However, similar effects were not as evident in vivo, potentially 
linked to FAK upregulation upon T-cell activation306 and subsequent compensation 
for loss of Pyk2. Pyk2 is also reported to mediate actin cytoskeletal dynamics 
downstream of TCR stimulation, and to play a role in the re-organisation of T-cell 




3.2.2 FAK destabilizes EC cell junctions and promotes EC migration 
and angiogenesis 
 
FAK in ECs is considered a therapeutic target for the treatment of vascular diseases 
including cancer265. Treatment with a FAK inhibitor reduces tumour angiogenesis in 
animal models of colon311, hepatocellular312 and ovarian carcinoma313,314. A number 
of animal models have identified that conditional knockout of FAK315-317 or 
conditional knock-in of a kinase dead (KD) FAK314,318 reduces tumour 
neovascularization, vascular permeability and angiogenesis. Both approaches 
resulted in early embryonic lethality due to multiple vascular defects.  Primary ECs 
isolated from these mice exhibited defects in tubulogeneis, sprouting, migration, 
proliferation and survival in vitro. Further in vitro work identified that RACK1 and 
vimentin associate with FAK during endothelial migration through a 3D collagen 
matrix, and this RACK1-vimentin-FAK signalling complex is hypothesised to 
regulate EC polarization, motility and focal adhesion turnover during the initial 
phases of neovascularization319. Furthermore, FAK mRNA and protein levels are 
upregulated in cancer associated ECs320 concomitant to an increase in FAK Y397 
phosphorylation314. Thus FAK in ECs plays a critical role in establishing the 
neovascular architecture in a developing tumour.   
As described above (2.2.1), the generation of the neovasculature leads to increased 
tumour progression and metastasis. For tumours to progress after local invasion, 
tumour cells must then enter the vasculature in order to circulate and metastasise to 
distant sites in the body. This intravasation requires increased vascular permeability, 
achieved by the dissociation of tight endothelial cell-cell junctions formed by the 
vascular endothial cadherin (VE-cadherin) complex (Figure 3.4). In ECs, FAK 
becomes phosphorylated and activated downstream of integrins and growth factor 
receptor signalling, forming the FAK-Src signalling complex. Following rapid 
localisation of this complex to cell-cell junctions, the FAK FERM domain binds to 
the cytoplasmic tail of VE-cadherin. FAK in turn directly phosphorylates Y142 of 
VE-cadherin associated β-catenin321, leading to the breakdown of the 
VE-cadherin-β-catenin complex and the dissociation of EC adhesion junctions. The 
dissociation of EC adhesion junctions increases vascular permeably and concomitant 
 
 58 
tumour cell intravasation. FAK inhibition reduces the phosphorylation of β-catenin 
and also inhibits the association of FAK to VE-cadherin321. Although the FERM 
domain of FAK mediates this association in a kinase independent-manner, the 
conformational change following FAK phosphorylation is required for 
VE-cadherin-FAK binding, which is blocked following FAK kinase inhibition.  
Further to FAKs role in increasing vascular permeability, FAK mediates 
VEGF-induced angiogenesis in ECs via a paracrine signalling axis involving the 
MAPK pathway (Figure 3.4). Binding of Grb2 to FAK Y925 leads to the formation 
of the Grb2-RAS-RAF-SOS signalling complex and the activation of the MAPK 
pathway, upstream of ERK activation and nuclear translocation. Amongst other 
Figure 3.4 I The roles of FAK in endothelial cells. FAK plays multiple roles in 
endothelial cells in order to increase neovascularization, vascular permeability and 
tumour cell intravasation. a FAK is activated downstream of VEGF stimulation of VEGFR, 
leading to the formation of the FAK-Src signaling complex. FAK-Src signaling complex 
rapidly associates with VE-cadherin at cell-cell junctions, leading to the breakdown of the 
VE-cadherin-β-catenin complex and the dissociation of EC adhesion junctions. b 
activation of the FAK-Src signaling complex generated the formation of the Grb2-RAS-
RAF-SOS signing complex, c resulting in the activation of the MAPK pathway and the 
nuclear translocation of active ERK. d activated ERK upregulates the transcription and 
secretion of VEGF, which e forms a paracrine signaling axis, binding to VEGFR and 
increasing the activation of FAK. 
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nuclear targets of activated ERK, VEGF is transcriptionally upregulated leading to 
increased VEGF secretion into the surrounding microenvironment. Secreted VEGF 
may then bind to its receptor (VEGFR) increasing levels of FAK phophorylation322. 
In this mechanism, ECs can initiate VEGF-directed angiogenesis quickly following 
the amplification of relatively small amount of VEGF, thus repairing damaged 
vessels or indeed establishing neovasculature, as efficiently as possible. Other 
nuclear targets of the ERK signalling cascade include vascular cell adhesion 
molecule 1 (VCAM1) following GATA4-dependant transcription284, and 
E-selectin323, proteins involved in immune cell and tumour cell binding to ECs 
respectively. Although the role of VCAM1 expression on ECs is unclear, E-selectin 
binds tumour cells to ECs mediating tumour cell intravasation. Although work 
continues in order to understand the role of FAK in ECs, what is clear is that FAK 
plays a substantial role in both the development of neovascular architecture and in 
linking tumour cells to ECs, both aiding tumour survival and progression through 
metastasis.  
 
3.2.3 FAK is essential to fibroblast biology, fibroblast activation and 
CAF recruitment. 
 
Much of what is currently known about the role of FAK in stromal cell biology 
originates from work in fibroblasts. In fibroblast cell models, FAK was shown to 
mediate migration, polarisation, cell cycle progression and survival in a manner akin 
to tumour cells (3.1). Fibroblasts exist in multiple different activated states within the 
tumour microenvironment (2.2.2) and FAK is involved in fibroblast differentiation 
and activation. Secreted proteins and growth factors mediate the regulation of 
nascent fibroblast activation resulting in the upregulation of α-SMA expression. 
Lysyl oxidase-like 2 (LOXL2) activates fibroblasts and promotes expression of 
α-SMA in a FAK dependant manner through activation of the AKT pathway213,324. 
Inhibition of LOXL2 greatly reduced metastasis and primary tumour cell invasion in 
both orthotropic and transgenic mouse mammary carcinoma models324. Although this 
study did not investigate these effects in FAK-/- fibroblasts, FAK inhibition was 
shown to reduce AKT activation and α-SMA production, and integrin-mediated FAK 
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Y397 phosphorylation increased in fibroblasts following treatment with recombinant 
LOXL2324. Other studies have shown that FAK may also regulate the ‘deactivation’ 
of myofibroblasts and their differentiation back into fibroblasts by enhancing FGF 
signalling which ultimately decreases α-SMA expression325, which implies that the 
role of FAK in myofibroblast differentiation may be context dependant.. Further to 
FAKs role in fibroblast activation, the recruitment of CAFs into the tumour 
microenvironment is also dependant on FAK. FAK mediates the migration of 
fibroblasts downstream of α5β1 integrin engagement and inhibition of FAK in 
pancreatic ductal adenocarcinoma (PDAC) was associated with a reduction in CAF 




As described in detail above, the role of FAK downstream of integrins has been, and 
continues to be, investigated in a number of cell types, many of which contribute to 
the composition of the tumour microenvironment. Thus, therapeutic targeting of 
FAK has the potential to impact directly on tumour cells, endothelial cells, 
fibroblasts, and some immune cells. However, little has been done to address 
whether FAK signalling in cancer cells has any influence over the composition or 
activation status of cells within the tumour microenvironment. Recently, FAK has 
been identified to translocate to the nucleus under conditions of stress, where its 
function remains largely unknown. Preliminary studies suggest that FAK may be 
able to influence the transcription of some secreted factors, including TGFβ, VEGF, 
angiopoeitin 1, and interleukin-6, implying that it may have an unappreciated 
function in regulating aspects of paracrine signalling between cell types. I therefore 
set out to test whether FAK signalling in tumour cells was involved in the regulation 
of chemokines and cytokines by tumour cells, and if so, whether this could influence 
the immune cell composition of the tumour microenvironment and ultimately tumour 








4.1.1  Cell culture reagents  
 
Supplier: ECRC Central Services  
Sterile PBS  
Sterile PE 
 





MEM vitamins  
MEM non-essential amino acids  
200 mM L-glutamine  
2.5% trypsin solution  
Dispase II  
Fetal bovine serum (FBS) 
 
Supplier: Merck Millipore, Hertfordshire, UK 
Hygromycin B 




Supplier: Qiagen, Crawley, UK  
Miniprep DNA Kit  
Maxiprep DNA Kit  
RNAeasy Kit + On-column DNase addition 
Gel purification Kit  
PCR purification Kit  
 
Supplier: Sigma Chemical Co, Poole, UK  
Polybrene  
Sodium pyruvate  
Doxorubicin hydrochloride 
 




4.1.2 Cell culture plastic-ware  
 
Supplier: Becton Dickinson Biosciences, Oxford, UK  
Falcon vented tissue culture flasks (T25, T150 and T175) 
Falcon tissue culture dishes (60 mm, 90 mm and 120 mm)  





4.1.3 Cell Culture medium 
 
4.1.3.1 SCC and Mel31 
1x GMEM supplemented with  
10% FBS  
2 mM L-glutamine  
1% Non Essential Amino Acids  
1% MEM vitamins  
1% Sodium Pyruvate  
 
4.1.3.2 Panc043, Panc047, Panc117 and Met01 
1x DMEM supplemented with 
10% FBS 
2 mM L-glutamine  
 
4.1.3.3 HEK293FT  
1x DMEM supplemented with 
10% FBS 
2mM L-glutamine  
1% Non Essential Amino Acids  
 
4.1.3.4 Phoenix Ecotropic 











1x DMEM supplemented with 
2% FBS 
 
4.1.3.7 Trypsin  
0.25% trypsin in sterile PE 
 
4.1.4 Animal experiments  
 
Supplier: Sigma Chemical Co, Poole, UK  
Tween 80 
Carboxymethyl cellulose (CMC) 
 
Supplier: Verastem, MA, USA 
VS-4718 
 
Supplier: Charles River, Kent, UK  
FVB/Ncrl (FVB/N) mice 
BALB/cAnNCrl (BALB/c) Mice 
C57BL/6NCrl (C57BL/6) mice 
Crl:CD1-Foxn1nu (CD-1 nude) mice 
All mice were supplied as age matched, 5-week old females and isolated for one 
work after delivery.  
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4.1.5 Immunofluorescence  
 
Supplier: Sigma Chemical Co, Poole, UK  
Formaldehyde  
 
Supplier: Thermo Fisher, Loughborough, UK 
Circular 19mm glass cover slip 
Prolong gold anti-fade mounting media 
 
Supplier: NIH  
ImageJ software  
 
Supplier: Olympus UK Ltd, Hertfordshire, UK  
Olympus FV1000 Confocal microscope  
 
4.1.6 Western Blotting and electrophoresis 
 
Supplier: Bio-Rad Laboratories Ltd, Hertforshire, UK 
4–15% Mini-PROTEAN® TGX™ Precast Protein Gels 
Precision Plus Protein™ WesternC™ Standards 
Trans-Blot® Turbo™ Midi Nitrocellulose Transfer pack 
Mini-PROTEAN® Tetra Cell gel electrophoresis tank 
Trans-Blot® Turbo™ Transfer System 
Clarity™ Western ECL Blotting Substrate 
ChemiDoc MP Imaging System 
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Image LabTM image acquisition and analysis software 
10x TGS buffer 
 
Supplier: Beckman Coulter, Luton, UK 
Beckman DU 650 spectrophotometer  
 
Supplier: Chemicon International, Harrow, UK  
Re-blot kit  
 
Supplier : Sigma Chemical Co, Poole, UK 
Triton X-100 
Sodium Chloride (NaCl) 
Tris base 
Sodium deoxycholate 






Supplier: Thermo Fisher, Loughborough, UK 
Micro BCA protein assay kit  
 
Supplier: Merck Millipore, Hertfordshire, UK 




Supplier : Roche, Hertfordshire, UK 
protease inhibitor cocktail  
phosphatase inhibitor cocktail  
 
4.1.7 Western Blotting and electrophoresis buffers 
 
4.1.7.1 RIPA buffer  
50 mM Tris/HCl, pH 7.6 
150 mM NaCl  
1% Triton X-100  
0.5% Sodium deoxycholate  
0.1% sodium dodecyl sulphate (SDS)  
Protease inhibitor cocktail  
Phosphatase inhibitor cocktail  
 
4.1.7.2 2x Sample buffer  
800 µl 2-mercaptoethanol  
1.3 ml Tris pH 6.8  
2 ml glycerol  
5 ml 10% SDS  
1.3 ml H2O  
Bromophenol blue to colour  
 
4.1.7.3 Wash buffer  




4.1.8 Western Blotting antibodies  
 
Supplier: New England Biolabs, Hertfordshire, UK  
Anti-mouse/horseradish peroxidase conjugate  




Anti-mouse Caspase 3 
 
4.1.9 Antibody purification 
 
Supplier: Thermo Fisher, Loughborough, UK 
Melon™ Gel IgG Purification Kit 
SnakeSkin™ Dialysis Tubing, 10K MWCO, 22 mm 
 
Supplier: Sigma Chemical Co, Poole, UK 
Whatman® qualitative filter paper, 110mm, Grade 1 
 
4.1.10 FACS analysis 
 
Supplier: Becton Dickinson Biosciences, Oxford, UK 
BD FACS Aria II 
Falcon® Round-Bottom Tubes, Polystyrene 
10x Pharm Lyse red blood cell lysis buffer 




Supplier: Thermo Fisher, Loughborough, UK 
Countess automated cell counter 
Countess automated cell counter slide 






Supplier: ECRC Central Services  
Sterile PBS  
 
Supplier:  StarLabs UK Ltd, Milton Keynes, UK 
Sterile 1.2ml Microtubes in Rack  
 
Supplier: Roche, Hertfordshire, UK 
Collagenase D 
 







4.1.11 FACS analysis buffers 
 
4.1.11.1 FACS buffer  
Sterile PBS 
1% FBS 
0.1% Sodium Azide 
 
4.1.11.2 Fc Block 
1 in 200 CD16/CD32 (Fc Blocking anybody) 
 in FACS buffer 
 
4.1.12 FACS analysis antibodies 
 
Supplier: eBioscience, Hatfield, UK 
Anti-mouse CD16/CD32 (Fc Blocking antibody) 
eFluor® 506 conjugated fixable viability dye 
Anti-mouse CD45 – eFluor 450 conjugated 
Anti-mouse CD45 – eFluor 780 conjugated 
Anti-mouse F4/80 – FITC conjugated 
Anti-mouse F4/80 – PE-Cy7 conjugated 
Anti-mouse CD11b – PerPC-Cy5.5 conjugated 
Anti-mouse MMR – APC conjugated 
Anti-mouse Tie2 – PE conjugated 
Anti-mouse Ly6C – eFluor 450 conjugated 
Anti-mouse CD3 – FITC conjugated 
Anti-mouse CD8 – PE conjugated 
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Anti-mouse CD4 – eFluor 647 conjugated 
Anti-mouse CD62L – PE-Cy7 conjugated 
Anti-mouse CD44 – PerCP-Cy5.5 conjugated 
Anti-mouse Gr1 – FITC conjugated 
Anti-mouse PD-L1 – PE conjugated 
Anti-mouse PD-L2 – PE conjugated 
Anti-mouse CD80 – eFluor 780 conjugated 
 
Supplier: Biolegend, London, UK 
Mouse Treg Flow™ Kit (FOXP3 Alexa Fluor® 488/CD4 APC/CD25 PE) 
 
4.1.13 Quantitative RT2-PCR analysis 
 
Supplier: Miltenyi Biotec Ltd, Surry, UK 
Treg isolation kit (130-091-041) 
LD columns 
MidiMACS Separation Kit 
 
Supplier: Qiagen, Crawley, UK  
RotorGene qRT2-PCR System 
RotorGene qRT2-PCR analysis software 
RNAeasy Kit + On-column DNase addition 
RT² Profiler™ PCR Array Mouse Cytokines & Chemokine (PAMM-150Z) 




Supplier: Thermo Fisher, Loughborough, UK 
SuperScript first-strand cDNA synthesis kit 
 
Supplier: Bioline Reagents Limited, London, UK 
SensiFAST™ SYBR® Hi-ROX Kit 
 
Supplier:  StarLabs UK Ltd, Milton Keynes, UK 
96-well semi-skirted PCR plate 
 
4.1.14 Quantitative RT2-PCR Primers 
 
Supplier: Thermo Fisher, Loughborough, UK 
CCL5 forward = CCCTCACCATCATCCTCACT  
CCL5 reverse = CCTTCGAGTGACAAACACGA.   
CxCL10 forward = CCCACGTGTTGAGATCATTG  
CxCL10 reverse =  CACTGGGTAAAGGGGAGTGA.  
B2M forward = GGGAAGCCGAACATACTGAA  
B2M reverse = TGCTTAACTCTGCAGGCGTAT 
 
Supplier: Qiagen, Crawley, UK  
RT² qPCR Primer Assay for Mouse Tgfb2 (PPM02992A) 
 
4.1.15 shRNA mediated knockdown 
 





Supplier: Sigma Chemical Co, Poole, UK  
Polybrene  
 
Supplier: Merck Millipore, Hertfordshire, UK 
0.45 µM Millex-HA filter 
 
Supplier: GE Healthcare, Hertfordshire, UK 
pLKO lentiviral TRC library TGFβ2 shRNA (RMM4534-EG21808) 




All animal experiments were carried out in accordance with the United Kingdom Animal 
Scientific Procedures Act (1986). 
 
4.2.1 Cell lines 
 
4.2.1.1 SCC 
SCC cells were previously developed in the lab by A. Serrels et al276 following the 
two-stage 7,12-dimethylbenz[a]anthracene (DMBA) / 12-O-tetradecanoylphorbol-
13-acetate (TPA) chemical carcinogenesis protocol51,326. Briefly, SCCs were induced 
in the skin of K14CreER FAKflox/flox transgenic FVB/N mice. Six-week-old mice 
were subjected to a single topical application of DMBA followed by twice weekly 
topical applications of TPA for a period of 20 weeks. Benign papillomas were 
observed approximately 6-10 weeks following the first treatment of TPA, with a 
small proportion of papillomas progressing to invasive SCC succeeding 15 weeks 
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onwards. Following surgical excision of carcinomas, small tissue pieces were 
adhered to plastic tissue culture plates and cells were allowed to grow out onto the 
surrounding plastic surface. Tumour pieces and cells were maintained in MEM at 
37 °c / 5% CO2. Outgrowth of cells was observed following one week under normal 
tissue conditions. The genetic knockout of FAK was achieved following treatment 
with 15 µM 4-OHT for 24 hours (SCC FAK-/- cells). Purity of the SCC population 
and efficiency of FAK knockout was determined by PCR and Western Blot analysis 
as shown in 276 (Figure 5.1). SCC FAK-/- cells re-expressing FAK-wt or a kinase 
dead form of FAK (FAK-kd) were generated using retroviral transfection. Phoenix 
Ecotropic cells were transfected with FAK-wt or FAK-kd constructs using 
lipofectamine 2000 (Thermo Fisher) as per manufacturers instructions, as described 
in 276. 24 hours post transfection, cell culture supernatant was removed, filtered 
through a 0.45 µM Millex-HA filter (Merck Millipore), diluted at a 1:1 ratio with 
normal SCC cell culture medium, supplemented with 5 µg/ml polybrene and added 
to FAK-/- SCC cells for 24 hours. A total of two rounds of infection were performed 
to generate each cell line. Cells were cultured at 37 °C / 5% CO2 in Minimum 
Essential Medium (MEM; Life Technologies) supplemented with 2 mM L-
glutamine, MEM vitamins, 1 mM, MEM amino acids, and 10% fetal bovine serum 
(all Life Technologies), and sodium pyruvate (Sigma) and maintained under 
selection using 0.25 mg/ml hygromycin (Merck Millipore. Western blot analysis of 
partental SCC 7.1, SCC FAK-wt, FAK-/- and FAK-kd cells identified a reduction in 
FAK pY397 (see Figure 3.1), indicative of a reduction in kinase activity in SCC 
FAK-kd cells, validating published data idenifing this mutant and kinase dead 
(Figure 5.1c)254,327.  
SCC FAK-wt and SCC FAK-/- cell lines over-expressing GFP-tagged Bcl2 were 
generated using retroviral transfection as described above.  The GFP-Bcl2 construct 





4.2.1.2 Other cell lines 
Mel31, Panc043, Panc047 and Panc117 cell lines were a kind gift from Owen 
Samson (The Beatson Institute for Cancer Research, Glasgow). Met01 were a kind 
gift from Bin-Zhi Qian (Centre for Reproductive Health, University of Edinburgh, 
Edinburgh). 
Mel31 cells were cultured at 37 °C / 5% CO2 in Glasgow Minimum Essential 
Medium (GMEM) supplemented with 2 mM L-glutamine, MEM vitamins, 1 mM 
,MEM amino acids, and 10% FBS (all Life Technologies) and  sodium pyruvate 
(Sigma) 
Panc043, Panc047, Panc117 and Met01 cells were cultured at 37 °C / 5% CO2 in 
Dulbecco’s Minimum Essential Medium (DMEM) supplemented with 2 mM L-
glutamine and 10% FBS (all Life Technologies) 
4T1 cells were cultured at 37 °C / 5 % CO2 in RPMI medium supplemented with 
10% FBS (Life Technologies) 
TIB-207 hybridoma cells (ATCC) were cultured at 37 °C / 5 % CO2 in Iscove's 
Modified Dulbecco's Medium (IMDM) supplemented with 2% FBS (Life 
Technologies) 
TIB-210 hybridoma cells (ATCC) were cultured at 37 °C / 5 % CO2 in Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 2% FBS (Life 
Technologies). 
 
4.2.2 Western blot analysis 
 
To prepare whole cell lysates, cells were washed x2 in ice cold PBS and lysed in 
radioimmuno-precipitation assay (RIPA) buffer (50 mmol/L Tris (pH 7.6), 150 
mmol/L sodium chloride, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, protease 
inhibitor cocktail (Roche), phosphatase inhibitor cocktail (Roche)). Lysates were 
cleared by centrifugation at 13000 rpm for 15 minutes at 4 °C. Protein concentration 
was then determined using Micro BCA protein assay kit (Thermo Fisher). 
Absorbance was measured with a Beckman DU 650 spectrophotometer (Beckman 
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Coulter, Luton, UK) at 562 nm. A total of 20 µg of each sample were aliquoted and an 
appropriate volume of 2x Sample buffer was added and incubated at 95 °C for 5 
minutes. Lysates were resolved by 4 - 15% Bis-Tris gel electrophoresis (Biorad) and 
proteins transferred to (Biorad) using Trans-Blot® Turbo™ Transfer System 
(Biorad). Membranes were then blocked (5% BSA/PBST) for 1 hour at room 
temperature and probed with either anti-Bcl2 (1:1000 in 5% BSA/PBST, Cell 
Signaling Technology), anti-PARP (1:1000 in 5% BSA/PBST, Cell Signaling 
Technology) or anti-caspase3 (1:1000 in 5% BSA/PBST, Cell Signaling 
Technology) primary antibodies over-night at 4 °C. After over-night incubation, 
membranes were washed 3x with PBST and bound antibody was detected by 
incubation with anti-rabbit or anti-mouse HRP-conjugated secondary antibody 
(1/5000 in 5% BSA/PBST; Cell Signaling Technology) for 1 hour at room 
temperature. Following 3x washes with PBST, membranes were prepared for 
chemiluminescent visualization by incubation for 1 minute in Clarity™ Western 
ECL Blotting Substrate (Biorad) and visualized using a ChemiDoc MP Imaging 
System (Biorad). Membranes were rinsed with TBST and distilled water before 
stripping with re-blot plus mild solution (Chemicon International). After washing 
with distilled water, stripped membranes were re-probed with 1:10000 anti-actin 
(Sigma) to check protein loading. 
 
4.2.3 Confocal Immunofluorescence microscopy 
 
SCC FAK-wt and SCC FAK-/- Bcl2-GFP expressing cells were grown on glass 
coverslips, rinsed in PBS and fixed with 3.7% (v/v) formaldehyde for 15 min. Cells 
were examined using an Olympus FV1000 confocal microscope (Olympus UK Ltd). 
 
4.2.4 Purification of CD4 and CD8 depleting antibodies 
 
Anti-mouse CD4 (GK1.5, ATCC TIB-207) and CD8 (2.43, ATCC TIB-210) 
depleting antibodies were purified in-house from conditioned supernatant using a 
Melon Gel IgG purification kit  (Thermo Fisher) as per manufactures instructions. 
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Cells were removed from supernatants by centrifugation (1300 rpm at 4 °C for 
3 minutes). 1 litre of conditioned supernatants were concentrated using 20 mL 
Pierce™ Protein Concentrators (9K MWCO; Thermo Fisher) to a final volume of 
100 ml and dialyzed into 1x Melon Gel purification buffer by 2x 1 hour exchanges 
into fresh 1x Melon Gel purification buffer (SnakeSkin™ Dialysis Tubing, 10K 
MWCO, 22 mm; Thermo Fisher). 1x sample volume of Melon IgG Purification 
Support was equilibrated to room temperature, then added to conditioned 
supernatants and incubated at room temperature for 5 minutes. Mixture of Melon IgG 
Purification Support and conditioned supernatants were then applied to a Buchner 
flask with a pre-soaked 110mm Whatman® qualitative filter paper (Sigma), vacuum 
was applied and the eluted purified antibody was collected. 
Antibody purification was validated by protein visualisation using TGX stain-free 
gel electrophoresis (Biorad). Samples were resolved by 4 – 15% TGX Bis-Tris gel 
electrophoresis (Biorad) and UV light was applied to each gel and gels were 
visualized using a ChemiDoc MP Imaging System (Biorad). 
 
4.2.5 Animal experiments 
 
4.2.5.1 Subcutaneous tumour growth 
Cells were injected subcutaneously into both flanks of either CD-1 nude mice (2.5 x 
105 cells) or FVB/N, BALB/c or c57BL/6 mice (1 x 106 cells) and tumour growth 
measured twice-weekly using calipers. Animals were sacrificed when tumours 
reached maximum allowed size, or more commonly when signs of ulceration were 
evident. Group sizes ranged from 3 – 5 mice each bearing two tumours, and tumour 
volume calculated in Excel using the formula v = 4/3πr3. Statistics and graphs were 
calculated using Prism (Graphpad). For studies involving treatment with VS-4718, 
drug was prepared in 0.5% carboxymethyl cellulose (CMC) + 0.1% Tween 80 
(Sigma) and mice treated at 75 mg/kg BID by oral gavage. Animals were visually 
monitored for signs of toxicity and weighed prior to each dose with VS-4718. No 




4.2.5.2 Tumour growth following re-challenge 
1 x 106 SCC FAK-/- cells were injected subcutaneously into the left flank of FVB/N 
mice and tumour growth measured twice weekly as described above. Following 
tumour regression, mice were left for 7 days before being challenged with 1 x 106 
SCC FAK-wt or SCC FAK-/- cells injected subcutaneously into the right flank. 
Tumour growth was measured twice-weekly using calipers. Control groups were 
injected subcutaneously into both flanks at day 28 using mice that had not been 
pre-challenged with SCC FAK-/- cells. Tumour volume was calculated in Excel 
using the formula v = 4/3πr3. Statistics and graphs were calculated using Prism 
(Graphpad). 
 
4.2.5.3 CD4+, CD8+ and CD25+ T cell depletion  
Anti-mouse CD4 (GK1.5, ATCC TIB-207) and CD8 (2.43, ATCC TIB-210) 
depleting antibodies were purified in-house (3.2.3) or purchased from eBioscience. 
Rat IgG isotype control antibody and CD25 depleting antibody was both purchased 
from eBioscience. T-cell depletion was achieved following intra-peritoneal (IP) 
injection of 150 µg of depleting antibody (same for all antibodies) into female age-
matched FVB/N mice for 3 consecutive days, and maintained by further IP injection 
at 3 day intervals until the study was terminated. 1 x 106 SCC FAK-wt or 
SCC FAK-/- cells were injected subcutaneously into both flanks 6 days after initial 
antibody treatment and tumour growth measured twice weekly using calipers. The 
extent of T-cell depletion was determined at the end of the study using FACS 
analysis from disaggregated spleen and thymus tissue (see below)  
 
4.2.6 FACS analysis of tissues 
 
Tumours established following injection of 1 x 106 SCC cells into both flanks of an 
FVB/N mouse were removed at day 7 into RPMI (Sigma) supplemented with 10% 
fetal bovine serum (Life technologies).  Tumour tissue was mashed into a pulp using 
a scalpel and re-suspended in DMEM (Sigma) supplemented with 2 mg/ml 
collagenase D (Roche). Samples were incubated for 1 hour at 37 °C, pelleted by 
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centrifugation at 1600 rpm for 5 minutes at 4°C, and re-suspended in 5 ml of 1x red 
blood cell lysis buffer (Pharm Lysis Buffer, Becton Dickinson). Samples were 
incubated for 5 minutes at 37 °C, then pelleted by centrifugation at 1600 rpm for 5 
minutes at 4 °C, re-suspended in PBS and passed through a 70 µm cell strainer 
(Becton Dickinson). The resulting single cell suspension was pelleted by 
centrifugation at 1600 rpm for 5 minutes at 4 °C and re-suspended in FACS buffer 
(PBS + 1% FBS + 0.1% sodium azide). This step was repeated a total of three times. 
A sample of the suspension was counted using trypan blue exclusion and the 
remaining cell suspension pelleted by centrifugation at 1600 rpm for 5 minutes at 
4 °C and re-suspended in FACS buffer at a concentration of 1 x 106 viable cells/ml. 
100 µl of each sample was pipetted into each well of a 96-well plate and the plate 
centrifuged at 1600 rpm for 5 minutes at 4 °C. Cell pellets were re-suspended in 50 
µl of Fc block (1 in 200 dilution of Fc antibody (eBioscience) in FACS buffer) and 
incubated for 15 minutes at 4 °C. 50 µl of antibody mixture was added to each well 
and the samples incubated for 30 minutes in the dark at 4 °C. All antibodies were 
from eBioscience and used at a concentration of 1 in 200. The plate was then 
centrifuged at 1600 rpm for 5 minutes at 4 °C and the cells re-suspended in FACS 
buffer and analyzed using a BD FACS Aria II (Becton Dickinson).  
Treg staining was performed using a Treg staining kit (Biolegend) as per 
manufacturers instructions. Tumours were disaggregated and incubated in Pharm 
lysis buffer (Becton Dickinson) as above. Samples were then re-suspended in 1x 
FOXP3 Fix/Perm buffer and incubated in the dark for 20 minutes at room 
temperature. Samples were then washed 3 times by centrifuged at 1600 rpm for 5 
minutes at 4 °C and re-suspension in 1x FoxP3 Perm buffer. Samples were then 
stained with antibody cocktail containing anti-mouse FOXP3 Alexa Fluor® 488, 
CD4 APC and CD25 PE conjugated antibodies for 1 hour in the dark at room 
temperature. Stained samples were washed 3x in FACS buffer prior to analysis using 
a BD FACS Aria II (Becton Dickinson).   
Staining of spleen and thymus tissue was performed as above.  
Data analysis was performed using FlowJo software. Statistics and graphs were 
calculated using Prism (Graphpad).  
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For absolute counting, the same protocol as above was used, except tumours were 
weighed following surgical removal, and prior to FACS analysis samples were 
resuspended in varying volumes of FACS buffer (dependent on weight) containing 
CountBright Absolute Counting Beads (Life Technologies). 
 
4.2.7 FACS analysis of cultured cells 
 
Cells were cultured in 90 mm Falcon tissue culture dishes (Becton Dickinson). Cells 
were removed using 1x non-enzymatic cell dissociation solution (Sigma) and 
pelleted by centrifugation at 1600 rpm for 5 minutes at 4 °C, re-suspended in PBS 
and passed through a 70 µm cell strainer (Becton Dickinson). The resulting single 
cell suspension was pelleted by centrifugation at 1600 rpm for 5 minutes at 4 °C and 
re-suspended in FACS buffer (PBS + 1% FBS + 0.1% sodium azide). This step was 
repeated a total of three times. A sample of the suspension was counted using trypan 
blue exclusion and the remaining cell suspension pelleted by centrifugation at 1600 
rpm for 5 minutes at 4 °C and re-suspended in FACS buffer at a concentration of 1 x 
106 viable cells/ml. 100 µl of each sample was pipetted into each well of a 96-well 
plate and the plate centrifuged at 1600 rpm for 5 minutes at 4 °C. Cell pellets were 
re-suspended in 50 µl of Fc block (1 in 200 dilution of Fc antibody (eBioscience) in 
FACS buffer) and incubated for 15 minutes at 4 °C. 50 µl of antibody mixture was 
added to each well and the samples incubated for 30 minutes in the dark at 4 °C. All 
antibodies were from eBioscience and used at a concentration of 1 in 200. The plate 
was then centrifuged at 1600 rpm for 5 minutes at 4 °C and the cells re-suspended in 
FACS buffer and analyzed using a BD FACS Aria II (Becton Dickinson).  
Data analysis was performed using FlowJo software. Statistics and graphs were 






4.2.8 Gene expression profiling 
 
RNA was prepared from SCC FAK-wt and SCC FAK-/- cells using an RNAeasy kit 
(Qiagen) according to the manufacturer’s instructions. RNA was analyzed using the 
GeneChip Mouse Genome 430 2.0 Array (Affymetrix). Array data were background 
corrected, quantile normalized and log transformed. Data for differentially expressed 
genes (P < 0.01) were median centered and subjected to unsupervised agglomerative 
hierarchical clustering on the basis of Euclidean distance computed with a 
complete-linkage matrix using Cluster 3.0 (C Clustering Library, version 1.37) 328. 
Clustering results were visualized using Java TreeView (version 1.1.1) 329. 
Functional enrichment analysis against the mouse genome background was 
performed using ToppGene 330. 
 
4.2.9 Quantitative RT2-PCR array analysis of cytokine, chemokine, and 
chemokine receptor expression 
 
RNA was isolated and purified using RNeasy kit with on column DNAse digestion 
(Quiagen). RNA prepared from SCC cells using and was analyzed using the mouse 
cytokine and chemokine RT2 Profiler PCR Array (PAMM-150Z; Qiagen) and that 
from isolated Tregs (isolated using Treg isolation kit, 130-091-041; Miltenyi 
Biotech) was analyzed using the mouse chemokine and receptor array (PAMM-22Z; 
Qiagen) according to the manufacturer’s instructions. Relative gene expression 
(2−ΔCt) values were log transformed, median centered and subjected to hierarchical 
clustering as for microarray analysis. For interaction network analysis, an 
interactome of chemokine ligands and receptors was constructed using the 
IUPHAR/BPS Guide to Pharmacology database 331,332 and curated from the literature 
333, onto which expression data for detected genes were mapped and visualized using 
Cytoscape (version 3.0.2) 334.  
In addition, expression of selected cytokine and chemokine genes was assessed by 
standard quantitative RT-PCR. cDNA was prepared from RNA using SuperScript 
first-strand cDNA synthesis kit, as per manufactures instructions. cDNA reaction 
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mix consisted of 5 µg of RNA, 1 µL random hexamer primers (50 ng/µL), 1 µL of 10 
mM dNTP stock mix, 4 µL of 25 mM MgCl2,  2 µL of 0.1 M DTT, 1 µL of 
RNaseOUT (40 U/µL) and 1 µL SuperScript® III RT (200 U/µL) + 1x RT buffer to a 
final volume of 20 µL.  Reactions were incubated for 10 minutes at 25 °C followed 
by 50 minutes at 50 °C. Reactions were terminated by incubation at 85 °C for 5 
minutes, followed by the addition of 1 µL of RNase H to each tube and a final 
incubation for 20 min at 37 °C, after which cDNA reaction were stored at -20 °C 
until used. 
TGFβ2 specific primers were purchased from Qiagen (Cat Number PPM02992A).  
CCL5 primers used were: forward, CCCTCACCATCATCCTCACT and reverse, 
CCTTCGAGTGACAAACACGA.  Cxcl10 primers used were: forward, 
CCCACGTGTTGAGATCATTG and reverse, CACTGGGTAAAGGGGAGTGA. 
B2M primers used were: forward, GGGAAGCCGAACATACTGAA and reverse, 
TGCTTAACTCTGCAGGCGTAT.  Briefly, a reaction mix consisting of 10 µl 
SensiFAST SYBR Hi-ROX reagent (Bioline), 0.4 µl of 10 µM stock forward primer, 
0.4 µl of 10 µM stock reverse primer, 4.4 µl water, and 4 µl of 20 ng/µl stock random 
hexamer primed cDNA was run on a Rotorgene qRT-PCR machine using the 
following cycling conditions: 94°C for 10 minutes; 40 cycles of 94°C for 10 seconds, 
57°C for 20 seconds, 72°C for 20 seconds; and 72°C for 7 minutes.  Analysis was 
performed using rotorgene software and expression relative to B2M calculated using 
Microsoft Excel. 
 
4.2.10 Treg Isolation 
 
Single cell suspensions were generated from both SCC FAK-wt tumours and mouse 
Thymus as described above. A sample of the suspension was counted using trypan 
blue exclusion and the remaining cell suspension pelleted by centrifugation at 1600 
rpm for 5 minutes at 4 °C and re-suspended in FACS buffer at a concentration of 1 x 
107 viable cells/40 µL.  Tregs were isolated using Treg isolation kit (130-091-041; 
Miltenyi Biotech) as per manufacturers instructions, using LD columns and 




4.2.11 shRNA mediated TGFb2 and CCL5 knockdown 
 
To generate lentiviral particles 2 x 106 HEK293FT cells were transfected with a 
mixture of 10 µg shRNA (TGFβ2 = RMM4534-EG21808; CCL5 = 
RMM4534-EG20304; GE Healthcare), 6.5 µg HIV, and 3 µg VSVG plasmid DNA 
using Lipofectamine 2000 (Thermo Fisher) as per manufacturers protocol. 24 hours 
post transfection, media was removed and filtered through a 0.45 µM Millex-AC 
filter (Millipore) and mixed at a 1:1 ratio with normal SCC growth media.  This 
mixture was supplemented with polybrene to a final concentration of 5 µg/ml and 
added to the SCC for 24 hours.  Cells were subject to two rounds of lentiviral 
infection prior to selection with puromycin at a final concentration of 2ug/ml. All 
shRNA constructs used were part of the pLKO lentiviral TRC library (GE 
Healthcare). 
 
4.2.12 Statistical analysis 
 
To determine the number of mice required to reach statistical significance in tumour 
growth experiments, preliminary data for SCC FAK-wt and SCC FAK-/- tumour 
growth were used in power calculations. 1 x 106 SCC FAK-wt and SCC FAK-/- cells 
were implanted into both flanks of FVB animals (n=5) and tumour growth was 
measured twice weekly, and tumour volume was calculated as described in 4.2.5.1.  
The means of SCC FAK-wt (mean = 237.3 mm3) and SCC FAK-/- 
(mean = 47.3 mm3) tumours, with a standard deviation of 47.1 were compared using 
a 2-sample, 2-sided equality power calculation (see 335). Sample size was calculated 
as 3 mice when using a power of 0.99 and a Type I error rate of 1%.   
The number of mice required to reach statistical significance in drug-treated and 
antibody-treated experiments were determined as above, with a final calculated 
sample size of 5. The number of experiment repeats in all cases equal 2.  
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All statistical analysis was calculated using GraphPad Prism 6.0c for Mac. Normality 
of data was determined using D’Agostino and Pearson omnibus normality test. For 
FACS analysis, unmatched, ordinary, one-way Anova with Sidak’s multiple 
comparison test was used to determine statistical significance involving three or 
more populations (stacked bar graphs), or between SCC FAK-wt, SCC FAK-/- and 
SCC FAK-kd populations. When analyzing only two populations, an unpaired, 
parametric t test with Welch’s correction was used. For growth curves, matched, 
two-way Anova with Tukey’s multiple comparisons test was used to determine 






5 Identification of a novel role of FAK in enabling tumour cell 




I set out to investigate whether FAK signalling in tumour cells influences the 
immune compartment of the tumour microenvironment. To address this, I used a 
syngeneic mouse model of squamous cell carcinoma (SCC) previously developed in 
the lab by A. Serrels et al276. SCCs were induced in the skin of K14CreER 
FAKflox/flox mice by the two-stage 7,12-dimethylbenz[a]anthracene (DMBA) / 
12-O-tetradecanoylphorbol-13-acetate (TPA) chemical carcinogenesis protocol51,326. 
These mice were developed on an FVB/N background due to the increased 
susceptibility of FVB/N mice to DMBA/TPA treatment336. DMBA is a topical 
carcinogen, which when applied to the skin induces an irreversible A to T 
transversion on codon 61 of proto-oncogene Harvey-ras (Ha-Ras). Treatment with 
DMBA alone is not sufficient to induce tumours and requires the repeat application 
of tumour-promoting agents such as TPA. The pro-inflammatory phorbol-ester TPA, 
binds and activates protein kinase C (PKC)337 and induces the expression of 
pro-inflammatory cytokine IL-1α338. With repeated application after DMBA 
treatment, TPA activates stromal fibroblasts, increases macrophage and neutrophil 
recruitment and results in the generation of benign papillomas that, in some cases 
progress to carcinoma. 
The coding exons of the fak gene span over 225 kb, and so it was not feasible to 
delete the entirety of the fak gene339. K14CreER FAKflox/flox mice were developed so 
that loxP sites flank a critical codon in the FAK kinase domain (amino acids 
413-444), and Cre-mediated excision results in a frame shift mutation in the adjacent 
exon, that precludes the production of a functional FAK protein339. A K14 
skin-specific promoter drives the expression of a modified estrogen receptor–Cre 
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fusion protein (CreER) that translocates to the nucleus only after exposure to 
4-hydroxytamoxifen (4OHT). Previous studies in the lab have showed that 
DMBA/TPA treatment does not induce papillomas after the deletion of fak in 
K14CreER FAKflox/flox mice in vivo339, and therefore to develop an SCC FAK-/- cell 
line, SCC cells were derived and fak deleted in vitro. Following DMBA/TPA 
treatment, carcinomas were surgically excised and SCC cells were derived using 
selective cell culture conditions276. SCC cells were then cultured in the presence of 
4OHT for 48 hours, single cell cloned and screened for FAK deletion by 
immunoblotting and PCR276. FAK constructs were then re-expressed back into SCC 
FAK-/- clones and a clone pair was selected that stably expressed FAK in a manner 
similar to exogenous levels determined by immunoblotting and PCR. This approach 
produced two syngeneic cell lines that were genetically identical apart for the 
expression of FAK, called SCC FAK-wt and SCC FAK-/-. This approach also allows 
other FAK constructs to be expressed in SCC FAK-/- cells, in order to investigate the 




• To investigate whether SCC FAK-wt and SCC FAK-/- tumours exhibit 
host-dependant characteristics 
• If so, to identify whether components of the adaptive immune system are 
involved in regulating tumour growth 








5.3.1 SCC FAK-/- cells exhibit host-dependent growth characteristics 
 
SCC cells were generated by A. Serrels as described in 4.2.1.1. The purity and 
efficiency of FAK knockout in the selected SCC FAK-/- clone was determined by 
PCR (Figure 5.1a) and Western Blot anlysis (Figure 5.1b). A kinase-deficient form 
of FAK was first described and characterised by Schlaepher et al340, and 
subsequently SCC FAK-kd cells were made as described above. The loss of kinases 
activity was determined by Western blot anlysis of FAK pY397 (Figure 5.1c). 
Using the SCC cell model described above I first set out to determine the growth 
characteristics of SCC FAK-wt and SCC FAK-/- cells in both CD-1 nude 
immuno-deficient mice and immuno-competent FVB/N mice. 2.5 x 105 and 1 x 106 
SCC FAK-wt and SCC FAK-/- cells were implanted using bilateral subcutaneous 
injection into CD-1 nude (Figure 5.2a) and FVB/N mice (Figure 5.2b) respectively, 
and tumour growth was measured twice weekly using callipers. Tumour volume was 
calculated using the formula 4/3πr3.  
 
Figure 5.1 I Validation of SCC FAK-wt, SCC FAK-/- and SCC FAK-kd cell lines. 
a PCR of Cre and FAK in SCC 7.1 and SCC FAK-/- cells following 4OHT treatment. 
GAPDH was sued as a loading control. b Western blot of ACC FAK 7.1 and SCC FAK-/- 
cells. c Validation of the expression of FAK in SCC FAK-wt and SCC FAK-kd cells and 
the loss of pY397 FAK in SCC FAK-kd cells. Tubulin was used as a loading control 
Figure taken from The role of focal adhesion kinase catalytic activity on the proliferation 
and migration of squamous cell carcinoma cells. Serrels et al. Int J Cancer, 2012.   
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In CD1-nude mice (Figure 5.2a), SCC FAK-wt tumour growth reached an average 
tumour volume of 190.28 ± 24.246 mm3 10 days post implantation, and a final 
average tumour volume of 407.35 ± 53.182 mm3 after 14 days at which point the 
mice were sacrificed due to signs of ulceration. In comparison, SCC FAK-/- tumours 
showed a significant growth delay by day 10 and day 14 (average tumour volume = 
93.759 ± 8.6705 mm3, p value = 0.0091 and 207 ± 28.058 mm3, p value = <0.0001 
respectively), and continued to grow eventually reaching the same size as the SCC 
FAK-wt tumours (Figure 5.2a).  
In contrast, bilateral subcutaneous injection of SCC FAK-wt or SCC FAK-/- cells in 
immune-competent FVB/N mice revealed a striking difference in tumour growth 
kinetics (Figure 5.2b). SCC FAK-wt tumours grew until day 14 reaching an average 
volume of 246.03 ± 55.544 mm3, but also showing signs of ulceration requiring this 
experimental group to be terminated. In contrast, SCC FAK-/- tumours grew for an 
initial period of 7 days reaching an average volume of 71.745 ± 8.1837 mm3, after 
which tumour growth stalled and complete regression occurred by day 21 
(Figure 5.2b). No tumour regrowth was observed following monitoring of these 
animals for a further 6 months (data not shown). 
The observed difference in growth kinetics between SCC FAK-wt and 
SCC FAK-/- tumours on immune-competent and immune-deficient hosts suggested a 
potential role for the host immune status in dictating tumour outcome. CD-1 nude 
mice, via disruption of the FOXN1 gene, are rendered athymic and as a consequence 
lack functional T-cells but retain functional B-cells, NK-cells and myeloid cells341. In 
contrast, FVB/N mice are fully immune-competent. Therefore, I hypothesised that 
FAK expression in SCC tumour cells may enable them to evade T-cell detection / 
destruction by one of 3 mechanisms; 1) FAK expression may protect cells from 
undergoing apoptosis leading to a reduction in the available antigen released into the 
microenvironment, 2) FAK may regulate the expression of tumour associated antigen 
(TAA) or 3) FAK expression in cancer cells may somehow influence the 













































Figure 5.2 | SCC FAK-/- tumours show host-dependent growth characteristics. a 
SCC FAK-wt and SCC FAK-/- tumour growth in CD1-nude mice.  2.5 x 10
5
 SCC FAK-wt and SCC 
FAK-/- cells were implanted into CD1-nude mice by bilateral subcutaneous injection (n = 6). SCC 
FAK-wt tumours grew until day 14 at which point the animals were sacrificed due to signs of 
ulceration. SCC FAK-/- tumours showed a significant growth delay compared to the SCC FAK-wt 
tumours. b SCC FAK-wt and SCC FAK-/- tumour growth in FVB/N mice. 1.0 x 10
6
 SCC FAK-wt and 
SCC FAK-/- cells were implanted into FVB/N mice by bilateral subcutaneous injection (n = 6). SCC 
FAK-wt tumours grew until day 14 at which point signs of ulceration were observed and the animals 
were sacrificed. SCC FAK-/- tumours grew until day 7 at which point tumour growth stalled and was 
followed by complete regression by day 21. Tumours did not reoccur within 6 months post-
regression (data not shown). Statistical significance was determined by matched, two-way Anova 
with Tukey’s multiple comparisons. Data are represented as mean ± s.e.m. P-value = Not 




5.3.2 SCC FAK-/- tumour clearance is not due to increased 
Bcl-2-dependent apoptosis 
 
FAK is known to promote cell survival under different conditions of adhesion 
stress264,327, and apoptotic cell death can under certain conditions elicit an immune 
response (2.4). I therefore hypothesised that SCC FAK-/- cells may be subject to 
increased apoptosis, resulting in greater availability of TAAs within the 
microenvironment. A key ‘point of no return’ during apoptosis is the release of 
Cytochrome C from the mitochondrial membrane through large pores generated by 
the oligomerization of BAX/BAK proteins. This is antagonised by the anti-apoptotic 
protein Bcl-2342,343. Thus, to test our hypothesis I stably overexpressed a Green 
Fluorescent Protein (GFP) tagged Bcl-2 in both SCC FAK-/- and SCC FAK-wt cells 
using retroviral transfection and antibiotic selection (Figure 5.3). The extent of 
GFP-Bcl-2 overexpression was visualised by confocal imaging (Figure 5.3a) and 
expression levels determined using immunoblotting (Figure 5.3b). To confirm that 
Bcl-2 overexpression was able to protect SCC cells from apoptosis, cells were treated 
with increasing concentrations of doxorubicin, a cytotoxic DNA intercalating agent, 
for 24 hours and the induction of apoptosis measured by immunoblotting for 
caspase 3 activation and PARP cleavage (Figure 5.3c). These results showed that 
treatment with doxorubicin increased levels of active caspase 3 and cleaved PARP in 
both SCC FAK-wt and SCC FAK-/- cell lines compared to untreated controls, and 
further highlighted that SCC FAK-/- cells exhibit greater sensitivity to doxorubicin-
induced apoptosis, supporting the observations of others regarding the anti-apoptotic  
functions of FAK344,345. Bcl-2 over-expression in both cell lines resulted in a marked 
reduction in caspase 3 activation and PARP cleavage at all doxorubicin 
concentrations tested (Figure 5.3c). Thus, overexpression of Bcl-2 protected both 
SCC FAK-wt and FAK-/- cells from doxorubicin-induced apoptosis. Despite this, 
there were no differences observed in the tumour growth kinetics in FVB/N mice 
from either SCC FAK-wt or SCC FAK-/- Bcl-2 overexpressing tumours when 
compared to controls (Figure 5.3d). Furthermore, Fluorescent Activated Cell Sorting 
(FACS) of disaggregated SCC FAK-wt and SCC FAK-/- tumours formed at day 7 in 
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Figure 5.3 | Generation and characterization of GFP-Bcl-2 expressing SCC FAK-wt 
and SCC FAK-/- cells. a Representative confocal images of SCC FAK-wt and SCC FAK-/- cells 
expressing GFP-Bcl-2. b Western blot of endogenous Bcl-2 expression (26 KDa) and exogenous 
GFP-Bcl-2 (53 KDa) in SCC FAK-wt and SCC FAK-/- cells. c Validation of apoptotic protection of 
GFP-Bcl-2 expression in SCC FAK-wt and SCC FAK-/- cells after doxorubicin treatment. SCC FAK-
wt, SCC FAK-/- and GFP-Bcl-2 expressing SCC FAK-wt and SCC FAK-/- cells were treated with 
increasing concentrations of doxorubicin. Doxorubicin-induced apoptosis was determined by 
immunoblotting for active caspase 3 and cleaved PARP. SCC FAK-wt and SCC FAK-/- cells 
expressing GFP-Bcl-2 showed lower levels of active-caspase 3 and cleaved PARP after 
doxorubicin treatment compared to controls. d GFP-Bcl-2 expression did not rescue SCC FAK-/- 
tumour clearance in FVB/N mice. 1.0 x 10
6
 SCC FAK-wt, SCC FAK-/- and GFP-Bcl-2 expressing 
SCC FAK-wt and SCC FAK-/- cells were implanted into FVB/N mice by bilateral subcutaneous 
injection (n = 6). Tumour diameter was measured twice weekly and tumour volume calculated using 
the formula 4/3πr
3
. Statistical significance was determined by matched, two-way Anova with 





63.67% ± 0.6199; FAK-/-, 64.18% ± 0.3457), as measured by the uptake of an 
eFluor® 506 conjugated fixable viability dye (Figure 5.4). These data imply that 
Bcl-2-antagonized apoptosis is not responsible for, or a contributing factor to, the 



























Figure 5.4 | Loss of FAK expression did not effect cell viability in vivo. FAK 
expression did not influence cell viability in early SCC FAK-wt and SCC FAK-/- tumours. 1.0 x 10
6
 
SCC FAK-wt and SCC FAK-/- cells were implanted into FVB/N mice by bilateral subcutaneous 
injection. SCC FAK-wt and SCC FAK-/- tumours were disaggregated at day 7, stained with fixable 
viability dye eFluor® 506 and analyzed by FACS (n = 12). Data are represented as mean ± s.e.m. 
SCC FAK-wt, 63.67% ± 0.6199; SCC FAK-/-, 64.18% ± 0.3457. Statistical significance was 
determined by an unpaired, parametric t test with Welch’s correction.  P-value = Not significant 




5.3.3 CD8+ T-cells drive SCC FAK-/- tumour regression 
 
Having ruled out Bcl-2-antagionised apoptosis, I next sought to definitively 
determine the role of T-cells in the clearance of SCC FAK-/- tumours. To do so, I 
utilised antibodies targeting CD8+ and CD4+ T-cells to deplete these populations in 
tumour bearing mice, and measure the impact on SCC tumour growth.   
 
5.3.3.1 Purification and dose-optimization of T-cell depleting antibodies 
Anti-mouse CD8 and CD4 depleting antibodies were purified from supernatants of 
rat hybridomas GK1.1 (ATCC TIB-207) and 2.41 (ATCC TIB-210) respectively 
using Melon IgG purification columns (Thermo Scientific) as described in the 
methods section. Briefly, hybridoma culture supernatant containing secreted 
antibody was concentrated, dialysed into ‘binding buffer’ and incubated with Melon 
IgG resin. Melon IgG resin contains a proprietary ligand that retains proteins found 
in cultured supernatants, allowing enrichment of IgG passing over it. Incubation of 
the beads in ‘elution buffer’ elutes a fraction containing purified IgG. The eluted 
fraction was collected and the efficiency of purification assessed using TGX stain-
free protein gels (Biorad). These gels contain trihalo-compounds that react with 
tryptophan residues resulting in a fluorescent signal when activated by UV-exposure. 
Aliquots from each purification stage were visualised alongside concentrated 
supernatant and a commercially available Low Endotoxin Azide Free (LEAF) 
purified antibody control for both CD8 and CD4. A serial dilution BSA 
concentration standard was used to determine final antibody concentration. The 
resulting gels showed that both CD8 (Figure 5.5a) and CD4 (Figure 5.5b) 
antibodies were enriched in the final eluted fraction compared to the concentrated 
media in each case. Neither antibody was detected in the wash elutes (FT1, FT2 or 
FT3), and the final concentration as determined by the BSA gradient was 
approximately 1 mg/ml. However, comparison of the eluted fractions with the 
commercial control antibody showed that purified elutes contained a number of high 
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whether the antibody preparations were functionally active and sufficient for 
purpose, or whether further purification would be required, I compared their capacity 
to deplete CD8 and CD4 T-cells with that of the commercial preparations. FVB/N 
Mice were treated for 3 consecutive days (Figure 5.6) with a single intraperitoneal 
(IP) injection of 150 µg of either commercial or purified individual antibodies, or a 
duel treatment of both CD4 and CD8 antibodies. Following a 2-day rest period, mice 
were culled and FACS analysis of disaggregated spleen and thymus used to 
determine the levels of CD45+ CD3+ CD4+ CD8- and CD45+ CD3+ CD4- CD8+ cells 
(Figure 5.7). Both the commercial and purified antibodies selectively depleted their 
target population from the spleen, without disrupting T-cell development in the 
thymus. The CD4 purified antibody depleted more CD4+ cells in the spleens than the 
commercial antibody (Figure 5.7 red arrow). The CD8 purified antibody lead to the 
substantial reduction of CD8+ cells in the spleen but did not deplete the entirety of 
the CD8+ cells unlike the commercial CD8 antibody (Figure 5.7 green arrow). Also 
a CD8+ CD4+ T-cell population was retained after depletion with CD8 purified 
antibody (Figure 5.7 blue arrow). I concluded that our own purified antibodies 
behaved similarly to the commercially available antibodies with respect to the 
depletion of T-cell sub-populations and thus I continued to use purified antibody for 
the remainder of our experiments. I hypothesised that the differences observed 
between the commercial and purified antibodies was likely due to the inaccuracies in 
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Figure 5.6 | Schematic describing the treatment schedule and dose validation 
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antibodies, or a combination of both by IP injection. Antibodies were either purified in house or 
purchased commercially. After a 2 day rest period, the spleens and thymus were removed from 


































































antibodies antibody-mediated T-cell 
depletion in FVB/N mice from both commercially available antibodies and in-
house purified antibodies. FACS analysis of spleen and thymus tissue from non-tumor 
bearing animals 6 days after commencing antibody treatment. Cohorts of FVB/N mice (n = 5) 




 depleting antibodies, or a 
combination of both, by IP injection. After a 2 day rest period, the spleens and thymus were 





 antibodies selectively depleted each T-cell population respectively and in 
combination depleted all circulating T-cells in the spleen without affecting T-cells in the thymus; 
green arrows CD8
+
 T-cells; red arrows CD4
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5.3.3.2 Effects of T-cell depletion on SCC tumour growth 
Using purified antibody preparations, I set out to address whether T-cell depletion in 
FVB/N mice could rescue SCC FAK-/- tumour growth. Mice were treated for 3 
consecutive days with a single IP injection of 150 µg of CD8, CD4 or a combination 
of both depleting antibodies, or with a rat IgG Isotype control antibody (eBioscience; 
Figure 5.8). After a 2-day rest period, 1 x 106 SCC FAK-wt or SCC FAK-/- cells 
were implanted by bilateral subcutaneous injection in to both flanks of FVB/N mice 
and tumour growth measured twice weekly. T-cell depletion was maintained by IP 
injection of 150 µg of antibody every 3 days. Sustained T-cell depletion was 
validated after each study had terminated by FACS analysis of the spleen and thymus 
of tumour bearing animals (Figure 5.9). Depletion of CD4+ and CD8+ T-cells was 
less in tumour-bearing mice than in non-tumour bearing animals seen previously, 
possibly due to the heighted inflammatory response induced following tumour cell 
implantation. However comparison of CD4 and CD8 depleting antibody-treated mice 
with untreated controls showed that a substantial proportion of both CD4+ and CD8+ 
T-cells were depleted (Figure 5.9).  
  
        
untreated ‘control’ group 
SC injection of 
SCCs 
monitor tumour volume 
Day 1 Day 2 Day 3 
2-day rest period 
150 μg IP of antibody 
Day 6 
monitor tumour volume 
Every 3 Days 
150 μg IP of antibody 
FACS analysis of 
spleen and thymus 
Figure 5.8 | Schematic describing the treatment regime for FVB/N antibody-





 T-cells influence SCC tumour growth, cohorts of FVB/N mice were treated daily 




 depleting antibodies or a combination of 
both by IP injection. After a 2 day rest period, 1 x 10
6
 SCC FAK-wt or SCC FAK-/- cells were 
implanted by bilateral subcutaneous injection into each flank. Tumour diameter was measured 




T-cell depletion was 
maintained by 150 μg IP injection of antibody every 3 days until the end of the experiment, at 
which point T-cell depletion was confirmed following FACS analysis of disaggregated spleen and 
thymus of each animal. SC = subcutaneous. 
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In FVB/N mice treated with CD4 depleting antibodies SCC FAK-/- tumour growth 
was unaltered (Figure 5.10a). In contrast, depletion of CD8+ T-cells alone or in 
combination with CD4+ T-cells was sufficient to restore SCC FAK-/- tumour growth. 
Therefore I conclude that CD8+ T-cells are responsible for the clearance of SCC 
FAK-/- tumours (p value = <0.0001; Figure 5.10a), and that CD4+ T-cells are not 
required for SCC FAK-/- immune clearance.  
T-cell depletion in FVB/N mice bearing SCC FAK-wt tumours (Figure 5.10b) 
highlighted two observations; 1) CD8+ depletion alone or in combination with CD4+ 
T-cell depletion significantly increased SCC FAK-wt tumour growth when compared 
to either the Isotype treated or untreated control groups at day 14 (p value = 
<0.0001), and 2) depletion of CD4+ T-cells alone resulted in the clearance of SCC 
FAK-wt tumours in a manor akin to SCC FAK-/- tumour clearance. These data 
indicate that SCC FAK-wt tumours are under negative pressure from CD8+ T-cells 
and are thus likely subject to an underlying immune response. Further, they imply a 
role for the CD4+ T-cell compartment in conferring protection of SCC FAK-wt 
































Figure 5.9 | Validation of sustained CD8 and CD4
 
T-cell depleting antibodies in 
tumour bearing FVB/N mice. FACS analysis of T-cell populations from spleen (top) and 
thymus (bottom) tissue from tumour bearing animals at the end of T-cell depletion studies 
described in Figure 5.10; green arrows CD8
+
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SCC FAK-wt CD4 Depleted
SCC FAK-wt CD8 Depleted
SCC FAK-wt CD4 + CD8 Depleted










 T-cell depletion. a SCC FAK-/- 
and b SCC FAK-wt tumour growth in T-cell depleted FVB/N mice. Cohorts of FVB/N mice (n = 5) 









in combination as per the dosage scheduled referred to in Figure 5.8. Both untreated and isotype 
control treated groups were included. 1 x 10
6
 SCC FAK-wt or SCC FAK-/- cells were implanted by 
bilateral subcutaneous injection into each flank. Tumour diameter was measured twice weekly and 
tumour volume calculated using the formula 4/3πr
3
. Statistical significance was determined by 
matched, two-way Anova with Tukey’s multiple comparisons. Data are represented as mean ± 





5.3.3.3 SCC FAK-/- tumour cells induce immunological memory that 
does not permit regrowth of SCC FAK-/- or SCC FAK-wt 
tumours after rechallenge 
Having characterised that SCC FAK-/- tumour regression was CD8+ T-cell 
dependent, and that increased apoptosis was not a contributing factor in priming the 
anti-tumour immune response, I set out to test whether FAK expression resulted in 
regulation of TAA that could enable SCC FAK-wt cells to evade immune 
recognition. To do so, I took advantage of the SCC FAK-/- tumour regression 
characteristics, and performed a rechallange experiment in animals following SCC 
FAK-/- tumour clearance (Figure 5.11). I hypothesised that following SCC FAK-/- 
tumour clearance the host would remain immunised against further challenge with 
tumour cells expressing the same antigen, and as a consequence would mount a 
strong and fast secondary response that would not permit tumour growth. Thus, if 
Rechallenge with  
SCC FAK-wt 
Rechallenge with  
SCC FAK-/- 
subcutaneous injection 
of 1 x 10
6
 SCC FAK-/- 
cells 
7 day rest after complete 
regression of SCC FAK-/- 
tumour 
Day 1 ~ Day 21 
SCC FAK-/- tumours progress 






SC injection with either   
SCC FAK-/- or SCC FAK-wt 
Control Cohorts 
Rechallenged Cohorts 
Figure 5.11 | Schematic detailing SCC FAK-/- rechallenge experimental setup. FVB/N 
mice were split into rechallenged and control cohorts for SCC FAK-wt and SCC FAK-/-. 
Rechallenged cohorts were first implanted with 1 x 10
6
 SCC FAK-/- cells by subcutaneous 
implantation in to the left flank of each mouse. SCC FAK-/- tumours were allowed to grow and 
completely regress (by ~ Day 21). After 7 days tumour-free rest period, these cohorts were 
rechallenged with either 1 x 10
6
 SCC FAK-wt (n = 5) or SCC FAK-/- cells (n = 5) by subcutaneous 
implantation in to the right flank. Resulting tumour volume was measured twice weekly. Control 
cohorts were not exposed to initial SCC FAK-/- tumour implantation. 1 x 10
6
 SCC FAK-wt (n = 5) or 
SCC FAK-/- cells (n = 5) were implanted by subcutaneous implantation into the left flank. Resulting 




SCC FAK-wt cells share a common antigen with SCC FAK-/- cells, then growth of 
these tumours will not be permitted in animals immunised using a primary challenge 
with SCC FAK-/- cells. To test this, I subcutaneously implanted 1 x 106 SCC FAK-/- 
cells into the left flank of FVB/N mice, and allowed the tumours to undergo 
complete regression. I then re-challenged these mice with either 1 x 106 SCC 
FAK-wt cells or 1 x 106 SCC FAK-/- cells on the right flank and monitored tumour 
growth (Figure 5.12). After the initial regression of the primary SCC 
FAK-/- tumour, and following a tumour-free period of 7 days, animals re-challenged 
with SCC FAK-wt (middle graph, Figure 5.12) or SCC FAK-/- cells (bottom graph, 
Figure 5.12) did not develop tumours. SCC FAK-wt and SCC FAK-/- cells 
implanted into unchallenged mice at day 28 grew as expected (top graph, Figure 
5.12). In all cases except the SCC FAK-wt controls, animals were subsequently 
monitored for a further 6 months for tumour growth, and no tumour reoccurrence 
was observed (data not shown).  
  
Figure 5.12 | Tumour rechallenge implies common antigen between SCC FAK-wt 
and SCC FAK-/- cells. Growth of rechallenged SCC FAK-wt and SCC FAK-/- tumours in FVB/N 
mice after clearance of SCC FAK-/- tumours. Experimental outline referred to in Figure 5.11.. Top 
and center panels Tumour growth of FVB/N mice rechallenged with SCC FAK-wt or SCC FAK-/- 
cells. 1 x 10
6
 SCC FAK-/- cells were implanted into cohorts of FVB/N in the left flank by 
subcutaneous injection (day 0) and resultant tumours were allowed grow and regress (day 21). 
After a 7 day rest period, 1 x 10
6
 SCC FAK-wt (top; n = 5) or SCC FAK-/- (center; n = 5) cells were 
implanted into the right flank by subcutaneous injection (day 28). Bottom panel SCC FAK-wt and 
SCC FAK-/- tumour growth controls. 1 x 10
6
 SCC FAK-wt (n = 5) or SCC FAK-/- (n = 5) cells were 
implanted by bilateral subcutaneous injection in to the flanks of FVB/N mice at day 28 Tumour 
diameter was measured twice weekly and tumour volume calculated using the formaula 4/3πr
3
. 
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Together, these data imply that both SCC FAK-wt and SCC FAK-/- tumours share a 
common antigen. The heightened immune mediated clearance of SCC FAK-wt and 
SCC FAK-/- tumour cells after initial exposure to SCC FAK-/- cells, and the 
subsequent lack of any tumour-reoccurrence after 6 months, also suggests that 
regression of SCC FAK-/- tumours results in the generation of immunological 
memory that recognises both SCC FAK-/- and SCC FAK-wt cells.  
 
5.3.4 FAK kinase activity is required for SCC tumour survival 
 
FAK is a non-receptor protein tyrosine kinase of current clinical interest due to its 
role in regulating a number of tumour promoting processes, including proliferation, 
apoptosis, migration, invasion, EMT and angiogenesis. Small molecule FAK kinase 
inhibitors are being developed, with a number already being tested in early (phase 1 
and 2) clinical trials. Hence, I set out to determine whether the survival of SCC 
FAK-wt tumours required FAK kinase activity and could therefore potentially be 
targeted with FAK kinase inhibitors. To address this, I used a previously reported 
lysine (K) 454254,327 kinase-deficient mutant of FAK, re-expressed in SCC 
FAK-/- cells (SCC FAK-kd cells). 1 x 106 SCC FAK-wt, SCC FAK-/- and SCC 
FAK-kd cells were implanted by bilateral subcutaneous injection in to both flanks of 
FVB/N mice and tumour growth was measured twice weekly (Figure 5.13). SCC 
FAK-wt and SCC FAK-/- tumours grew in a similar manner to previous 
experiments; however, SCC FAK-kd tumours grew in a manor akin to SCC 
FAK-/- tumour growth. These data suggest that FAK kinase activity is required for 
sustained SCC FAK-wt tumour survival and growth, and therefore treatment with a 







In immune-competent FVB/N mice, SCC FAK-/- tumours undergo 
immune-mediated tumour regression in a manner dependent on CD8+ T-cells. 
Further, following complete regression host mice remain immunised against further 
tumour challenge, including when this secondary challenge is with SCC FAK-wt 
cells, implying expression of a common antigen that is independent of FAK 
expression levels. FAK kinase activity is required for SCC cells to evade immune 
mediated tumour clearance, raising the possibility that FAK kinase inhibitors may 
drive FAK-wt tumour regression.  
The primary model used in this thesis is the DMBA/TPA generated model of SCC276. 
As described in 276, 4.2.1.1 and 5.1, SCC FAK-/- and SCC FAK-wt cells originate 
from the same clone of a heterogeneous parental SCC population, which generates a 
genetically identical background into which FAK-wt is stably expressed at 
. 



















Figure 5.13 | FAK kinase activity is required for SCC tumour growth and survival. 
Tumour growth of SCC FAK-wt, SCC FAK-/- and SCC FAK-kd tumours in FVB/N mice. 1 x 10
6
 
SCC FAK-wt, SCC FAK-/- or SCC FAK-kd cells were implanted by bilateral subcutaneous injection 
into both flanks of FVB/N mice (n = 6). Tumour diameter was measured twice weekly and tumour 
volume calculated using the formula 4/3πr
3
. Statistical significance was determined by matched, 
two-way Anova with Tukey’s multiple comparisons. Data are represented as mean ± s.e.m. P-value 
= Not significant >0.05,  * <0.05, ** <0.01, *** <0.001, **** <0.0001 eekly and tumour volume 
calculated using the formaula 4/3πr
3
. Data are represented as mean ± s.e.m. 
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comparable levels to endogenous expression. The selection and purification of the 
parental SCC population is achieved by selective cell culture conditions, which aim 
to sustain the growth of the transformed population, and not the un-transformed 
stromal populations such as fibroblasts, endothelial cells etc. Although this technique 
is well characterised and has led to a large number of publications with this model, 
more stringent purification could have been achieved using FACS. However, due to 
the length of time required not only to generate but also to maintain cells in culture, it 
is highly unlikely that an untransformed population could have survived within the 
parental population. Furthermore, the single cell cloning of the SCC FAK-/- and 
FAK-wt cells further increases the likelihood of a pure SCC population within both 
the SCC FAK-/- and SCC FAK-wt cell lines. 
One potential caveat regarding the generation of the SCC FAK-wt and SCC FAK-/- 
cells is that a sham transfection was not undertaken when expressing the FAK-wt 
construct. A sham transfection exposes SCC FAK-/- cells to the same transfection 
protocol as the resulting FAK expressing cells, without the expression of FAK. This 
controls for possible phenotypic changes induced by the transfection reagent or 
transfection protocol that would not have occurred in untreated SCC FAK-/- cells. 
Although it is therefore a valid assumption that the phenotypic defences observed 
between SCC FAK-wt and SCC FAK-/- cells could be as a result of SCC FAK-wt 
cell transfection and not due to the expression of FAK, SCC FAK-kd cells have 
undergone transfection, and appear to mimic the SCC FAK-/- phenotype in all 
experiments undertaken throughout this thesis. Although it would have been more 
scientifically sound to produce sham transfected SCC FAK-/- cells, in this case, the 
contribution of FAK kinase activity to tumour growth and survival appear genuine.       
Although the clonal nature of this model increases the confidence of a pure SCC 
population, one criticism of this technique is that the cell culture conditions and 
single cell cloning may be selective for the more aggressive SCC clones. These 
clones would be more likely to survive in time of stress (the transition to cell 
culture), at times of low confluence (during single cell cloning) and would be the 
first population to migrate out onto plastic cell culture plates. Heterogeneity within 
the isolated clones must also be considered, and thus a single clone may not be 
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representative of the heterogeneous population. Multiple clones from the parental 
population should be taken forward to compare the response to our SCC model, or 
alternatively other inducible transgenic models may offer the opportunity to study the 
of roles of FAK in an autochthonous host. 
One further complication with the DMBA/TPA SCC model involves whether the 
resultant chemically induced SCC tumours are atypical of non-chemical induction. 
As stated above, TPA is a phorbol ester which induces a macrophage-dominated 
inflammatory response required to induce tumorigenesis in this model. TPA also acts 
to inhibit macrophage metabolic activity, which in turn reduces the phagocytic 
activity of macrophages346. The phagocytic activity of macrophages not only acts to 
kill tumour cells, but is also required for macrophage APC activity through the 
phagocytic ingestion and presentation of antigen14. This raises the question as to 
whether the clonal and antigenic heterogeneity of the DMBA/TPA model is less 
restricted than in other non-chemical models which may contain phagocytic 
macrophages. Without the selective pressure ensued by a competent macrophage 
response, both in its anti-tumour activity and in the presentation of antigen to the 
innate immune response, immunogenic neoantigens could survive in in a 
DMBA/TPA induced microenvironment, but not in a non-chemically induced 
microenvironment. Although macrophage APC activity is sustainably less than that 
of DCs which are unaffected by TPA, the potential for the selection of an atypically 
immunogenic cell line should be considered.   
Furthermore, the restriction of neoantigen through single-cell cloning of this model 
may enhance the anti-tumour efficacy of immunomodulatory therapies. The 
evolution of tumour neoantigen heterogeneity determines how the immune system 
responds to tumour cells throughout tumour development and the efficacy of 
immunotherapy347; a more restricted range of immunogenic neoantigens increases 
the chance of an effective response to immunotherapy, where as a more diverse 
range creates a more resilient tumour. This is due to the evolution of neoantigens 
within a developing tumour, and the retention of mutated proteins which provide 
survival benefits for tumour cells, but which may also be recognized by an immune 
response347. This response is based on APC presentation of antigens early within 
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tumour development, therefore limiting the number of tumour cells that can rebuff 
the anti-tumour immune response. In this regard, it could also be possible that SCC 
tumours from this model appear more immunogenic due to the restriction of 
neoantigen through single cell cloning. This could be investigated by returning to the 
parental SCC cell line form which the SCC FAK-wt and SCC FAK-/- cell originate 
(SCC 7.1) and determining how this cell line responds to the potential 
immunomodulatory effects of FAK inhibition.         
Using the SCC model, SCC FAK-wt and SCC FAK-/- tumours display different 
immune-mediated host-dependant growth kinetics. It should be noted that although 
CD1-nude mice are considered immune-deficient animals, partly due to the fact that 
this model mirrors immune-suppressed patients, CD1-nude mice still retain the 
capacity for an innate immune response. As SCC FAK-/- tumour growth is 
characterised by a growth delay in this host, contrasting the tumour regression 
observed in an FVB/N animal, the involvement of the innate immune system in 
immune-mediated regression of SCC FAK-/- tumours should not be disregarded. 
Cross-talk between the innate and adaptive immune responses has been shown to be 
required for optimal activation of both arms of the immune response, and as such the 
innate immune response could play a significant role in the immune-mediated 
clearance of SCC FAK-/- tumours. Furthermore, CD1-nude mice lack functional 
B-cell responses due to the lack of T-cell involvement in B-cell activity, which 
should also be considered when assessing tumour growth characteristics in 
CD1-nude mice.  
Generation of the SCC model on a FVB/N background has the advantages of being 
more efficient, due to the highly susceptible nature of FVB/N mice to DMBA/TPA 
treatment compared to other genetic backgrounds such as c57BL/6 mice, which are 
inherently resistant to DMBA/TPA treatment. One disadvantage to using FVB/N 
mice however is the lack of available genetic and inducible knockout models for 
immune cell populations, such as the diphtheria toxin-inducible knockout systems 
that are almost exclusively on a c57BL/6 background. Although antibody-mediated 
depletion used throughout this thesis is a competent method of depletion as shown in 
Figure 5.9, it should still be noted that antibody-mediation depletion is not specific. 
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As such depletion of CD8+ and CD4+ population may not only deplete CD8+ and 
CD4+ T-cells, but may also deplete DCs, which have been shown to express both 
CD8 and CD4348. One may expect that depletion of DCs would cause tumour to 
survive, as a lack of DCs would reduce antigen presentation and therefor inhibit 
CD8+ T-cell activation. The clearance of SCC FAK-/- tumours following CD4 
antibody treatment indicates that CD4+ DCs are not involved in this phenotype 
however, but CD8+ DCs cannot be disregarded.  Treatment with an anti-CD3 
antibody would deplete both CD8+ and CD4+ T-cells simultaneously, but also would 
provide a control for the possible involvement of CD8+ DCs.  
Further to this, following antibody-mediated depletion of CD8+ and CD4+ T-cells, 
CD8+ cells were shown to be responsible for the clearance of SCC FAK-/- tumours, 
independent of CD4+ cells. Considering the role of CD4+ T-cells in facilitating and 
increasing the effectiveness of the cytotoxic CD8+ T-cell response, it was surprizing 
that CD4 depletion did not affect SCC FAK-/- tumour clearance. Although 
CD8+ T-cell activation is not dependant on CD4+ T-cell involvement349, these data 
may indicate that CD8+ T-cells help themselves, or interact with pre-activated DCs 
activated directly by SCC cells without CD4+ T-cell involvement350.  CD8+ T-cells 
can self-activate by responding to antigen presented on MHC class I. Following the 
subsequent observation of CD8 directly binding to MHC class I proteins351, it has 
become accepted that that the colligation of CD8 with the TCR alone, independent of 
DC or CD4+ T-cell activation, can augment the effectiveness of CD8+ T-cell TCR 
engagement and subsequent activation352. However, as determined in Figure 5.12, 
FAK does not regulate the expression of antigen and it would therefore seem 
unlikely that FAK would regulate CD4-independant activation of DCs, a process 
highly regulated by, and dependant on the availability of antigen. Also, although 
FAK may regulate MHC class I proteins, this also seems unlikely, both by the 
selective pressure of CD8+ T-cells to SCC FAK-wt tumours and their requirement for 
the immune-mediated clearance of SCC FAK-/- tumours (Figure 5.10), and the 
clearance of SCC FAK-wt tumours in SCC FAK-/- challenge mice (Figure 5.12). 
Therefor it appears that the CD8+ T-cell responses seen in both SCC FAK-wt and 
SCC FAK-/- tumours are activated by CD4+ T-cell independent mechanisms, most 
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likely due to the direct binging of antigen primed MHC class I molecules to CD8+ 
T-cells, a process that is independent of FAK expression.   
Furthermore, considering the requirement for CD4+ T-cells in SCC FAK-wt tumour 
growth, and that the depletion of CD8+ T-cell alone or in combination with CD4+ 
T-cells increased SCC FAK-wt tumour growth, these data indicate that the selective 
pressure by the immune system on SCC FAK-wt tumours is dependant on CD8+ 
T-cells, and the presence of CD4+ T-cells does not increase CD8+ T-cell activity, but 
drastically inhibits it.  These results identify a novel role for FAK in regulating the 
anti-tumour immune response, and highlight the need to investigate the composition 
of the immune cell infiltrate within the tumour environment. Thus, further work 
focused on the generation and optimisation of a tumour disaggregation and staining 
protocol for FACS, which included a number of multicolour FACS stains targeting a 




6 Optimisation of a tumour disaggregation and staining protocol 




Fluorescence activated cell sorting (FACS) is a specialized type of flow cytometry 
that provides a method of sorting a heterogeneous mixture of cells, one cell at time, 
based on the specific fluorescent and light-scattering properties of each cell. Each 
cell that passes through the flow cytometer will scatter light from an incoming laser 
by different degrees, in different directions, proportional to the dimensions of that 
cell; large round cells will scatter more light in all directions than smaller round cells, 
but elliptical cells will scatter more light in only one dimension than small round 
cells. In this regard, cells can be analysed based on size alone, but this is not 
sufficient to identify specific cell populations from a heterogeneous mixture of cells. 
Thus, cells are stained with fluorescently labelled antibodies that corresponded to 
specific lineage expressed proteins or proteins expressed upon cell activation 
(Table 6.1). In terms of immune cells, all leukocytes express CD45 and can be 
differentiated by this marker. Others include CD3 that is primarily expressed on 
lymphocytes, and CD11b, a marker for monocytic cells. Using this strategy it is 
possible to identify a variety of cell populations within each sample and quantified 
their abundance and relative proportions, enabling comparisons between different 
sample conditions, such as different tumours or different time points within tumour 
progression.  
One caveat of FACS analysis is that samples must be prepared and disaggregated 
into single cell suspensions. There a number of possible methods for tissue 
disaggregation; mechanical disaggregation involves samples being forced through 
filters, enzymatic disaggregation involves the digestion of a sample by proteases that 
degrade key proteins found in the ECM, or a mixture of both. Mechanical 
disaggregation is the more gentle approach, but often leaves large sections of sample 
 
 110 
whole. Enzymatic disaggregation is much more efficient and disaggregates the entire 
sample, but proteases may also cleave cell surface expressed molecules which in 
some instances might not be desirable. Therefore I set out to optimise a 
disaggregation protocol based on a combination of mechanical and enzymatic 
disruption for FACS analysis of SCC FAK-wt, SCC FAK-/- and SCC FAK-kd 




• To evaluate and optimise tumour disaggregation protocols  
• Design multi-colour FACS stains that cover a wide range of immune 
populations  
• Determine a time point for further tumour studies by measuring inherent 




6.3.1 Collagenase D treatment of FVB/N spleens required for CD11b+ 
cell detachment 
 
In order to optimise a tissue disaggregation protocol suitable for FACS analysis of 
immune cell populations I used the spleens of naïve mice. Initially I tested 
mechanical disaggregation by mashing spleens from FVB/N mice through 70 µm 
filters to generate single cell suspensions. These suspensions were stained with 
fluorescent antibodies for CD45, CD11b, F4/80, CD3, CD8 and CD4, in order to 
identify a number of immune cell populations from both the adaptive and innate 
immune systems (Table 6.1). Samples were then analysed by FACS  (Figure 6.1).  
Using this protocol I observed a number of CD45+ CD3+ CD8- and CD45+ CD3+ 
CD8+ T-cells in the FVB/N spleens. However, only a small number of CD45+ 
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CD11b+ monocytes, and no CD45+ CD11b+ F4/80+ macrophages, were detected 
(Figure 6.1). Thus, either FVB/N spleens contained few CD11b+ monocytes and no 
CD11b+ F4/80+ macrophages, or alternatively, additional disaggregation methods 
were required to release these cell populations from the spleen.  
Enzymatic disaggregation with Collagenases degrades collagen fibres leading to the, 
helping to release myeloid cells into suspension353. Of the available Collagenases, 
Collagenase D has the lowest tryptic activity, a key property that needs to be 
considered when staining for surface exposed proteins and retaining cell viability354. 
Indeed, tryptic activity is known to cleave some cell surface markers, and if not 
carefully validated could inadvertently yield misleading results. Thus, I tested a 
combination of mechanical and enzymatic disaggregation. Spleens from FVB/N 
Population Markers
Monocyte CD45+ CD11b+
Macrophage CD45+ CD11b+ F4/80+
T-cell CD45+ CD3+
CD4+ T-cell CD45+ CD3+ CD8-
CD8+ T-cell CD45+ CD3+ CD8+
Table 6.1 | Markers used for FACS analysis to determine how different tissue 






























Figure 6.1 | Mechanical disaggregation was not sufficient to release monocytes 
and macrophages from FVB/N mice spleens. FVB/N spleens were mashed through a 70 
μm filter to generate single cell suspensions, and stained for CD45, CD11b, F4/80, CD3 and CD8 






























mice were filtered through 70 µm filters, and samples split into two groups: 1) an 
untreated control group, and 2) a group treated with 2 mg/ml Collagenase D for 1 
hour at 37 °C. Both treated and untreated samples were stained with fluorescent 
antibodies for CD45, CD11b, F4/80, CD3, CD8 and CD4, (Table 6.1) and samples 
analyzed by FACS (Figure 6.2).  I observed substantially higher levels of 
CD45+ CD11b+ monocytes and CD45+ CD11b+ F4/80+ macrophages in the 
Collagenase D treated samples when compared with untreated controls. Levels of 
CD45+ CD3+ CD8- and CD45+ CD3+ CD8+ T-cells were unaffected by enzymatic 
treatment. Thus, I conclude that a combination of mechanical and Collagenase-D-





















































Figure 6.2  | Collagenase D treatment released monocytes and macrophages from 
FVB/N spleens. FVB/N spleens (n = 3) were mashed through 70 μm filters and treated with 2 
mg/ml Collagenase D for 1 hour at 37 °C. Controls (n = 3) were mashed through 70 μm filters only. 
Both collagenase D treated and untreated samples were stained for CD45, CD11b, F4/80, CD3 






























6.3.2 Disaggregation of FVB/N spleen and thymus with Collagenase D, 
Dispase and Hyaluronidase resulted in the loss of T-cell markers.  
 
As described in the introductory section 2.2.2, tumours contain a complex network of 
extracellular matrix (ECM) proteins including collagen, fibronectin and hyaluronic 
acid. Treatment with Collagenase D, Dispase, and Hyaluronidase has been shown to 
degrade these, and provide an efficient method of tumour disaggregation355. Thus, I 
sought to determine the impact of this disaggregation cocktail on immune cell release 
and surface marker retention using both spleen and thymus tissue from FVB/N mice. 
Tissues were mashed through 70 µm filters then treated with either 2 mg/ml 
Collagenase D + 4 mg/ml Dispase + 0.1% Hyaluronidase, or 2 mg/ml Collagenase D 
alone, and incubated for 1 hour at 37 °C. Samples were then stained with 
fluorescently conjugated antibodies for CD45, CD11b, F4/80, CD3, CD8 and CD4, 
(Table 6.1) and analysed by FACS (Figure 6.3). Treatment of both the spleen and 
thymus with a cocktail of Collagenase D, Dispase and Hyaluronidase resulted in a 
marked reduction in CD3+ T-cells, resulting in no CD45+ CD3+ CD4+ CD8- (Figure 
6.3 blue arrows) or CD45+ CD3+ CD4- CD8+ T-cells (Figure 6.3 red arrows) being 
detected when compared to the Collagenase D only treated controls. CD45+ CD11b+ 
monocytes and CD45+ CD11b+ F4/80+ macrophages were unaffected (Figure 6.3). 
Thus, I conclude that treatment with a cocktail of Collagenase D, Dispase and 
Hyaluronidase results in cleavage of important surface exposed T-cell markers, and 
that a combination of mechanical disaggregation alongside 2 mg/ml Collagenase D 
treatment represents a more optimal strategy for tissue disaggregation prior to 

















































































Figure 6.3 | Tissue disaggregation with Collagenase D, Dispase and 
Hyaluronidase reduced CD3, CD4 and CD8 expressing cells. FVB/N spleens 
and thymus (n = 3) were mashed through a 70 μm filter and treated with either 2 mg/ml 
collagenase D, 4 mg/ml dispase and 0.1% hyaluronidase (a) or 2 mg/ml Collagenase D 
(b). Samples were stained for CD45, CD11b, F4/80, CD3 and CD8 (Table 6.1). green 
arrow CD3
+
 , red arrow  CD8
+





6.3.3 FACS analysis of SCC FAK-wt tumours indicate an inflammatory 
switch 10 days post implantation  
 
Tumour ulceration represents a recognized stage of SCC progression, occurring after 
increased necrosis causes the primary tumour nodule to slough, forming an ulcer 
which commonly does not heal356. I observed that SCC FAK-wt tumours appeared 
redder in colour around day 10, and that signs of ulceration began to show at day 14. 
Thus, I set out to investigate whether SCC progression and ulceration influenced the 
tumour immune infiltrate, and if so to identify any changes that correlated with the 
visual onset of ulceration. This information was important, as no ulceration was 
visually evident in SCC FAK-/- tumours at days 10 and 14.  Therefore it was 
important to define a time-point with the following criteria: 1) little to no ulceration 
in any tumour samples, 2) sufficiently developed to contain an established and 
activated T-cell population, and 3) large enough in size to enable sufficient cell 
numbers to be released for FACS analysis.  This was so that enough of each sample 
could be collected and processed, and comparisons could be made between SCC 
FAK-wt and SCC FAK-/- tumours. Furthermore, I wanted to expand our analysis to 
Table 6.2 | Immune populations  and the markers used to identify them by FACS 
analysis.   
Population Markers
Blood	Monocyte CD45+ CD11b+ F4/80- Ly6C-
Inflammatory	Monocyte CD45+ CD11b+ F4/80- Ly6C+
Inflammatory	Macrophage
(polarization)




CD45+ CD11b+ F4/80+ Ly6C-
(Tie2hi/lo MMRhi/lo)
CD4+ T-cell CD45+ CD3+ CD4+ CD8-
CD4+ Central	 Memory	T-cell	 CD45+ CD3+ CD4+ CD8- CD62L+ CD44+
CD4+ Effector	Memory	T-cell CD45+ CD3+ CD4+ CD8- CD62L- CD44+
CD8+ T-cell CD45+ CD3+ CD4- CD8+
CD8+ Central	 Memory	T-cell	 CD45+ CD3+ CD4- CD8+ CD62L+ CD44+
CD8+ Effector	Memory	T-cell CD45+ CD3+ CD4- CD8+	CD62L- CD44+
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include a number of activation states for each population of immune cells 
(Table 6.2). Incorporation of Ly6C, MMR and Tie2 allowed us to differentiate 
between different monocyte populations and to investigate changes in macrophage 
polarization. The inclusion of CD62L and CD44 allowed us to determine any 
potential differences in T-cell effector, central memory and naïve activation states. 
Thus, I implanted 1 x 106 SCC FAK-wt cells by bilateral subcutaneous injection in to 
both flanks of FVB/N mice, and sacrificed cohorts of animals 7 days, 10 days or 14 
days post implantation. Tumours were removed, disaggregated, and stained with 
Stains 1 and 2 (Table 6.3). Cell viability marker eFluor® 506 conjugated fixable 
viability dye was also included enabling dead cells to be excluded from the analysis; 
due to the break down of surface proteins, dead cells can adhere to antibodies 
resulting in false positive staining and so must be excluded. Samples were then 
analysed by FACS. Due to the more complex nature of the FACS analysis, a 





















Table 6.3 | FACS stains used to identify immune populations described in Table 
6.2. Stain 1 (left panel) was used to determine the number of blood monocytes, inflammatory 
monocytes, inflammatory macrophages and resident macrophages. Both inflammatory and 














 T-cells and the activation status (effector memory and central 



























































































Figure 6.4 | Gating strategy and FMO controls for FACS analysis of myeloid 
cells and their polarization status. a Gating strategy applied to Stain 1 (Table 6.3), which 
was used to determine the number of blood monocytes, inflammatory monocytes, inflammatory 
macrophages and resident macrophages. Both inflammatory and resident macrophage 









 = M2 macrophage). See Table 6.2 for full list of immune populations and their 
respective markers markers. b FMO control samples used to determine macrophage sub-
populations. Each FMO control sample contains every marker in Stain 1 (Table 6.3) except for 
the named marker. FMO controls were used to determine the correct gating positions in FACS 
analysis to exclude false positive results. FMO = Fluorescence minus one; SCC  = side scatter; 










































































Figure 6.5 I Gating strategy and FMO controls for FACS analysis to identify T-cells
and their activation status. a Gating strategy applied to Stain 2 (Table 6.3), which was used to
determine the number of CD8+ and CD4+ T-cells and the activation status (effector memory and
central memory) of both populations. See Table 6.2 for full list of immune populations and their
respective markers. b FMO control samples used to determine T-cell sub-populations. Each FMO
control sample contains every marker in Stain 2 (Table 6.3) except for the named marker. FMO
controls were used to determine the correct gating positions in FACS analysis to exclude false
positive results. FMO = Fluorescence minus one; SCC = side scatter; FSC= forward scatter
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FACS analysis of SCC FAK-wt tumours highlighted an increase between days 7 and 
10 in CD45+ CD11b+ F4/80- Ly6C+ inflammatory monocytes (mean ± s.e.m = 
2.427%  ± 0.2339 and 4.612% ± 0.3805) and CD45+ CD11b+ F4/80+ Ly6C+ 
inflammatory macrophages (mean ± s.e.m. = 18.62% ± 0.849 and 25.57% ± 1.509) 
as a percentage of total CD45+ cells (Figure 6.6).  This correlated with a 10% 
decrease in CD45+ CD11b+ F4/80+ Ly6C- resident macrophages between days 7 and 
10 (mean ± s.e.m = 31.89% ± 1.324 and 21.48% ± 0.7170; Figure 6.6).  Both 
inflammatory and resident macrophage populations showed a marked increase in 
MMR- and Tie2- M1 polarized macrophages between these time points 

































































*** **** **** **** **** 
Figure 6.6 | Increase in intra-tumoural Ly6C
+
 myeloid cells in SCC FAK-wt 
tumours. 1 x 106 SCC FAK-wt cells were implanted into the flanks FVB/N mice by bilateral 
subcutaneous injection. Tumours were removed from mice (n = 3) 7, 10 and 14 days post-
implantation. Tumours were disaggregated and stained for FACS analysis (Table 6.3). Gating 





populations (upper panel) and their quantification (lower panels). The number of each cell 
population was determined and the statistical significance between each time point was 
calculated by one-way Anova with Tukey’s multiple comparisons. Bar height = mean, Error bars = 
s.e.m.  Comparison between days 10 and day 14 not shown. P-value = Not significant >0.05,  * 
<0.05, ** <0.01, *** <0.001, **** <0.0001. 
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resident macrophages = mean ± s.e.m = 15.47% ± 1.255 and 73.58% ± 2.095 
respectively; Figure 6.7). An increase in CD45+ CD3+ CD4- CD8+ T-cells of 
approximately 20% were seen across all three time points (mean ± s.e.m = 7.33% ± 
0.8017, 13.38% ± 0.7457 and 27.43% ± 1.843 for days 7, 10 and 14 respectively; 
Figure 6.8b), but levels of CD45+ CD3+ CD4- CD8+ CD44+ CD62L- effector CD8+ 
T-cells peaked at day 10 indicative of an activated cytotoxic population (Figure 
6.8c). Althogh tthere was no significant difference between the  levels of CD45+ 
CD3+ CD4+ CD8- (Figure 6.8d), CD45+ CD3+ CD4+ CD8- CD44+ CD62L- effector 
CD4+ T-cells increased significantly at day 10 (Figure 6.8e). SCC FAK-wt tumours 
showed obvious signs of ulceration at day 14 and the loss of inflammatory 
macrophages and monocytes at this time point is likely due to the increased 
proportion of CD8+ T-cells as a consequence of increased ulceration. Therefore, I 
hypothesised that the increases in inflammatory Ly6C+ immune cell populations, 
along side the increase in effector CD8+ T-cells at day 10 of SCC FAK-wt tumour 
growth, were indicative of the initial stages of tumour ulceration. Therefore day 7 
was selected as the most suitable time point for valid comparison between SCC 
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SCC FAK-wt cells were implanted into the flanks FVB/N mice by bilateral subcutaneous 
injection. Tumours were removed from mice (n = 3) 7, 10 and 14 days post-implantation. 
Tumours were disaggregated and stained for FACS analysis (Table 6.3). Gating was as 
described in Figure 6.4. The number of each cell population was determined and the statistical 
significance between each time point was calculated by one-way Anova with Tukey’s multiple 
comparisons. Bar height = mean, Error bars = s.e.m.  Comparison between days 10 and day 14 
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Figure 6.8 | Effector CD8
+ 
T-cells were increased  7, 10 and 14 days post 
implantation.  1 x 106 SCC FAK-wt cells were implanted into the flanks FVB/N mice by bilateral 
subcutaneous injection. Tumours were removed from mice (n = 3) 7, 10 and 14 days post-
implantation. Tumours were disaggregated and stained for FACS analysis (Table 6.3). Gating 











 population (lower left 
panel). b FACS quantification of total intra-tumoral CD8
+



















 T-cell subpopulations 




 only).The number of each cell population was determined 
and the statistical significance between each time point was  calculated by one-way Anova with 
Tukey’s multiple comparisons. P-value = Not significant >0.05, * <0.05, ** <0.01, *** <0.001, **** 




; M = central 








Together these data show that tissue disaggregation with collagenase D, dispase and 
hyaluronidase appears to cleave surface-expressed markers, and thus tissue 
disaggregation with collagenase D alone was best suited for use with FACS analysis. 
Using this protocol, a number of immune populations could be identified within 
SCC FAK-wt tumours and changes in these populations at different time points of 
tumour growth could be quantified.  
So that valid comparisons between two different tumours can be made using FACS 
analysis, tumours are matched by age and size in order to account for factors that 
may adversely influence the tumour immune milieu, including signs of tumour 
ulceration, bias in tumour size, different tumour histopathological stage etc. 
Ulceration of SCC tumours is a recognised histopathologicical indicator of disease 
progression356 and early signs of the onset of ulceration was observed in SCC FAK-
wt tumours 10 days post implantation into FVB/N mice. In a number of cases, SCC 
FAK-wt tumours appeared redder in colour, an observation that crucially was absent 
from SCC FAK-/- tumours at the same time point.  Although the changes in the 
immune mileau of SCC in response to ulceration have not as yet been characterised, 
increases in Ly6C+ immune populations and increases in CD8+ T-cell populations 
have been observed concurrent with the onset of ulceration in melanoma357 and in a 
number of different skin ulcerative diseases358-360.  
FACS analysis of SCC FAK-wt tumours dectected an increase in the levels of 
inflammatory Ly6C+ immune populations and revealed a switch in the polarisation of 
both inflammatory and resident macrophage populations from pro-tumorigenic M2 to 
an anti-tumorigenic M1 phenotype45,361. Increasing numbers of total numbers of 
CD8+ T-cells were observed across the time course. CD62L362 and CD44363 are 
adhesion proteins required for T-cell homing to non-lymphoid peripheral tissue, and 
are used to differentiate between effector (CD44+ CD62L-) and memory (CD44+ 
CD62L+) due to the requirement of CD44 alone or both CD44 and CD62L for 
homing respectively. This analysis indicated that effector CD8+ T-cell population 
increased across the time course, indicative of increased cytotoxic activity in SCC 
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FAK-wt tumours that may not be present in SCC FAK-/-. It was concluded that these 
data were indicative of tumour ulceration and thus any potential changes in the 
immune milieu driven by FAK would be masked. Thus, day 7 was the optimal time 
point to provide the most valid comparison between SCC FAK-wt and SCC FAK-/- 
tumour immune milieu.  
These data presented in this chapter identified that proteolytic degradation of surface 
expressed markers can result in the detection of very different immune landscapes. 
Both thymus and spleen predominantly contain T-cell populations14, which were 
undetectable in samples prepared with collagenase D, dispase and hyaluronidase. 
This therefore highlights the need to include a selection of immune markers, capable 
of identifying a broad number of immune populations from both the adaptive and 
innate arms of the immune response. Furthermore, if this analysis had been 
conducted exclusively on tumour tissue, would would have been unable to elucidate 
the prescience of T-cells in our phenotype. This not only highlights the essential 
requirement to validate disaggregation techniques on tissues where the inflammatory 
landscape is known (i.e the large T-cell populations in both the spleen and thymus), 
but also emphasizes the need for further evaluation of the enzymes used for tissue 
disaggregation, and their potential to degrade surface-expressed targets.  
As shown here, there is a requirement to use enzymatic disaggregation to release 
monocytes and other immune cells for tissue, but the effect on surface-expressed 
markers has to be considered. Therefore, a broad immunophenotyping approach 
alongside tissue disaggregation with collagenase D appears to be the most valid, one 
which incorporates markers for the identification and characterisation of a wide 
range of immune populations, and therefore can determine whether disaggregation 
has any effect on these targets, especially within tumours where the immune 
landscape is unknown. This approach has been used in a number of human studies, in 
which tissue sample is less abundant than in animal studies, to immunophenotype 
breast tumours35,87. Although the differences in sequences between mouse and 
human immune markers means that they are differentially effected by enzymatic 
degradation, and therefor a marker cleaved in a human sample may not be cleaved in 
 
 125 
a mouse tumour, these studies highlight the capabilities of larger 
immunophenotyping approaches.  
One potential caveat within the FACS analysis presented in this chapter is the 
presentation of FACS data as a percentage of CD45+ cells, and not as the absolute 
number of cells within the sample. This method of presenting FACS data can suffer 
from changes in immune populations being observed not because they themselves 
change, but because another population has changed. For example, an increase in 
CD8+ T-cells may be observed, but in fact the macrophage population has decreased 
and thereby increasing the proportion of CD45+ cells that are CD8+ T-cells, without 
actually effecting the total number of CD8+ T-cells within the tumour. Changes such 
as these can be identified, but nevertheless must be considered when drawing 
conclusions from data presented in this manner.  
This is not the case when presenting data as the absolute number of immune cells 
within a sample; populations will not change proportionally to each other and 
therefore a reduction in macrophages will not change the proportion of T-cells. 
However, one of the main issues with presenting data in this manor is that the 
absolute number of cells is directly related to the volume of the tumour and the 
tumour mass, and therefore surgically excised tumours must be weighted and 
measured after excision, and the FACS results normalized to these values. Another 
issue with this method is that counting beads have to be used to ensure that the 
sample concentration can be determined; if a greater volume of one sample is 
analysed when compared to another, this will not represent the absolute number of 
cells, and therefore invalidate the experiment.  
The requirement for both tumour weight post-excision and the inclusion of counting 
beads means that analysis of the absolute number cannot be performed 
retrospectively, and although would have been beneficial to conduct a comparison of 
both percentage CD45+ and absolute number methods here, this could not be 
completed. However, even though at day 7 SCC FAK-wt and SCC FAK-/- tumours 
are approximately the same volume, any increase in the tumour size of SCC FAK-wt 
tumours compared to SCC FAK-/- will introduce bias into the analysis, and therefor 
FACS data is presented as a percentage of CD45+ cells within this thesis.    
 
 126 
7 FAK expression results in generation of an 




Following the observation that SCC FAK-/- tumour clearance was dependent on 
CD8+ T-cells, and that cells of the CD4+ T-cell compartment played a role in 
protecting SCC FAK-wt tumours from clearance, I set out to understand in more 
detail the composition of the tumour immune infiltrate. In doing so, I sought to 
identify whether CD8+ T-cells were present in all tumour types, and if so, whether 
there was any evidence of other immune cell types within the tumour that had the 
potential to modulate CD8+ T-cell function. A number of immune cell types with 
intrinsic immuno-suppressive capabilities are known to infiltrate extensively into 
tumours, including macrophages, myeloid derived suppressor cells (MDSCs), and 
regulatory T-cells (Tregs). Through a variety of mechanisms (described in detail in 
section 2.1.3) these cells can disarm the cytotoxic functions of antigen-primed CD8+ 
T-cells and promote tumour survival and progression. Therefore I set out to study 
these populations in SCC FAK-wt, FAK-/-, and FAK-kd tumours 7 days post-
implantation, with the aim of identifying changes that may be responsible for the 




• To characterise the T-cell response and determine T-cell activation status 
• To determine whether FAK regulates the recruitment of immunosuppressive 







7.3.1 SCC FAK-wt tumours contain infiltrating activated T-cells  
 
Having established a role for T-cells in the SCC tumour growth, I wanted to further 
characterise the T-cell population in our model. To address this, 1 x 106 SCC 
FAK-wt, SCC FAK-/- and SCC FAK-kd cells were implanted into the flanks of 
FVB/N mice by bilateral subcutaneous injection. Tumours were grown for 7 days, 
removed and disaggregated. Samples were then stained with Stains 1 and 2 (Table 
6.3) and analysed by FACS. This analysis revealed T-cells in SCC FAK-wt, SCC 
FAK-/- and SCC FAK-kd tumours (Figure 7.1a). The levels of CD8+ T-cells were 
significantly increased in SCC FAK-/- (mean ± s.e.m. = 3.272% ± 0.423%)) and 
SCC FAK-kd (mean ± s.e.m. = 3.066% ± 0.329%) tumours compared to 
SCC FAK-wt (mean ± s.e.m. = 1.76% ± 0.18%; Figure 7.1b). Further in-depth 
analysis into the activation status of the CD8+ T-cell populations, highlighted a 
significant increase in CD45+ CD3+ CD4- CD8+ CD44+ CD62L- cells in SCC FAK-/- 
(mean ± s.e.m. = 48.39% ± 1.591) and SCC FAK-kd  (mean ± s.e.m. = 67.04% ± 
1.942) tumours, when compared to SCC FAK-wt tumours (mean ± s.e.m. = 42.28% 
± 1.798; Figure 7.1c). This increase was greater after effector CD8+ T-cell numbers 
were normalized to account for the observed changes in total CD8+ T-cells and 
presented as a ‘fold change’ (Figure 7.1d). Normalized effector CD8+ T-cells were 
2-fold increased in SCC FAK-/- tumours, and approximately 3-fold increased in SCC 






Figure 7.1. FAK-depleted tumours exhibit a heightened CD8
+
 T-cell response. 1 x 
10
6 
SCC FAK-wt, SCC FAK-/- or SCC FAK-kd cells were implanted into the flanks of FVB/N mice 
by bilateral subcutaneous injection (n = 3). Tumours were removed after 7 days, disaggregated 
and stained for FACS analysis with Stain 1 (Table 6.3). Gating was as described in Figure 6.5. a 




 cells (left panel) from SCC FAK-wt, 
SCC FAK-/- and SCC FAK-kd tumours. The activation status of CD8
+
 T-cell (center panel) and 
CD4
+
 T-cells (right panel) is also shown. b FACS quantification of total intra-tumoral CD8
+
 T-cells. 
































 T-cells when normalized to total CD8
+
 T-cell percentage. e FACS 
quantification of total intra-tumoral CD4
+
























 only). The number of each cell population was determined and the statistical 
significance between each cell type was calculated by one-way Anova with Tukey’s multiple 
comparisons. Comparision of SCC FAK-/- and SCC FAK-kd not shown P-value = Not significant 
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CD4+ T-cell levels did not change between SCC FAK-wt, SCC FAK-/- and SCC 
FAK-kd tumours (mean ± s.e.m. = SCC FAK-wt, 16.54% ± 1.022; SCC FAK-/-; 
20.88% ± 2.099; SCC FAK-kd, 19.88%; Figure 7.1e). However, I did observe a 
significant increase in the proportion of effector CD4+ T-cells in SCC FAK-/- and 
FAK-kd tumours (SCC FAK-/- = mean ± s.e.m. = 63.12% ± 2.037; SCC FAK-kd = 
mean ± s.e.m. = 70.84% ± 1.816; p value = <0.0001<0.0001) when compared to 
FAK-wt tumours (mean ± s.e.m. = 49.78% ± 2.164; Figure 7.1f). 
These data imply that an activated CD8+ and CD4+ T-cell response is present in all 
tumour types, raising the question as to why SCC FAK-wt tumours do not succumb 
to CD8+ T-cell mediated clearance.  
 
7.3.2 FAK expression promotes an immunosuppressive 
microenvironment 
 
Recruitment of immune cell populations with intrinsic immuno-suppressive 
capabilities, including M2 macrophages, MDSCs and Tregs has been shown to 
suppress the anti-tumour immune response and promote tumour 
deveoplement364,365,366 (2.1.3). Thus, I set out to identify whether changes in these 
populations could explain the tumour growth characteristics of the SCC FAK-wt, 
FAK-/-, and FAK-kd tumours. 1 x 106 SCC FAK-wt, SCC FAK-/- or SCC FAK-kd 
cells were implanted into the flanks of FVB/N mice (n=5). Tumours were removed 
after 7 days and disaggregated. To identify M2 Macrophages (CD45+ CD11b+ F4/80+ 
MMRhi Tie2hi; Table 6.2), both subpopulations of MDSCs, G-MDSCs (CD45+ 
CD11b+ F4/80- LyC6lo Gr1hi) and M-MDSCs (CD45+ CD11b+ F4/80- LyC6hi Gr1lo) 
and Tregs (CD4+ CD25+ FoxP3+; Table 7.1a), samples were stained with Stain 1 
(Table 6.3), Stain 3 and Stain 4 (Table 7.1b) respectively. Samples were then 






7.3.2.1 Changes in macrophage polarization do not correlate with the 
tumour regression phenotype. 
SCC FAK-wt, SCC FAK-/- and SCC FAK-kd tumours stained with Stain 1 (Table 
6.3) were analysed as described in Figure 6.4. Levels of total macrophages were 
unchanged across SCC FAK-wt, SCC FAK-/- and SCC FAK-kd tumours (Figure 7.2 
height of stacked bar graph; mean ± s.e.m. = 50.511% ± 5.905, 50.456% ± 4.307 and 
49.845% ± 3.984 respectively). The proportion of inflammatory macrophages within 
the total population significantly increased in SCC FAK-/- and SCC FAK-kd 
tumours compared to SCC FAK-wt (mean ± s.e.m. = 22.900 ± 3.200, 27.989 ± 5.600 
and 18.622 ± 2.550 respectively; p value =  <0.05 and <0.001 respectively; Figure 
7.2 black bars).  
Analysis of macrophage polarization indicated that both inflammatory and resident 
macrophage populations were highly M2 polarised in both the SCC FAK-wt and 
SCC FAK-kd tumours compared to the SCC FAK-/- tumours (Figure 7.3 centre and 
right panels respectively, grey bars). Levels of M2 inflammatory macrophages were 










M-MDSC CD45+ CD11b+ F4/80- Ly6Chi Gr1lo
G-MDSC CD45+ CD11b+ F4/80- Ly6Clo Gr1hi
Treg CD4+ FoxP3+ CD25+
Stain 4
Fluorophore





Table 7.1 | Markers and FACS stains used to identify immunosuppressive intra 
tumoural MDSC and Treg populations. a Markers required to identify both subpopulations of 
immunosuppressive MDSCs  (M-MDSCs and G-MDSCs) and Tregs. b Stain 3 (left panel) was 




1.989% and 68.056 ± 1.202% respectively; Figure 7.3 centre panel, grey bars). 
Significantly lower levels were seen in SCC FAK-/- tumours (mean ± s.e.m. = 
37.611 ± 4.249%; p value = <0.0001). This same trend was also observed in the 
resident macrophage population. SCC FAK-wt and SCC FAK-kd tumours showed 
equivalent levels of M2 polarised resident macrophages (mean ± s.e.m. = 84.589 ± 
1.231 and 86.033 ± 0.971 respectively; Figure 7.3 right panel, grey bars), and this 
population was significantly decreased in SCC FAK-/- tumours (mean ± s.e.m. = 































































Figure 7.2. Intra-tumoural macrophages in SCC FAK-wt, SCC FAK-/- and SCC 
FAK-kd tumours. FACS plots of Ly6C and F4/80 expression on CD45+ CD11b+ populations 
(left panel) and their quantification (right panel). 1 x 10
6
 SCC FAK-wt, SCC FAK-/- or SCC FAK-
kd cells were implanted into the of flanks FVB/N mice by bilateral subcutaneous injection. 
Resulting tumours were removed from cohorts of mice (n = 3) 7 days post-implantation. 
Tumours were disaggregated and stained for FACS analysis (Table 6.3). Gating was as 
described in Figure 6.4. The number of each cell population was determined and the statistical 
significance between each cell type was calculated by one-way Anova with Tukey’s multiple 
comparisons. Bar height = mean, Error bars = s.e.m. P-value = Not significant >0.05,  * <0.05, ** 
<0.01, *** <0.001, **** <0.0001; height of stack = Mean total number of macrophages; Statistics 
shown for comparisons of Ly6C
+






These data showed that increased polarization towards M2 macrophages occurred in 
SCC FAK-wt and SCC FAK-kd tumours but not SCC FAK-/-. Two conclusions 
were drawn from this. Firstly, this implied that the presence of M2 macrophages 
were not sufficient to prevent SCC FAK-kd tumour regression, and therefore these 
cells were not the primary immunosuppressive population capable of evading a CD8+ 
T-cell response. Secondly, this highlighted a potential kinase-independent role of 
FAK in modulating macrophage polarization. Although I chose not to investigate this 
further as these results did not correlate with tumour regression, this could potentially 
provide a novel therapeutic opportunity. The disruption of M2 macrophages and 
TAMs is of great clinical interest due to their multiple roles in tumour growth, 












































































































b c a 
Figure 7.3 I M2 polarized macrophage populations did not correlate with 
tumour clearance characteristics. 1 x 106 SCC FAK-wt SCC FAK-/- or SCC FAK-kd 
cells were implanted into the flanks FVB/N mice by bilateral subcutaneous injection. Tumours 
were removed from mice (n = 3) 7 days post-implantation. Tumours were disaggregated and 
stained for FACS analysis (Table 6.3). Gating was as described in Figure 6.4.  a FACS plots 










 populations and 
their quantification (right panel). The number of each cell population was determined and the 
statistical significance between each cell type was calculated by one-way Anova with Tukey’s 
multiple comparisons. P-value = Not significant >0.05,  * <0.05, ** <0.01, *** <0.001, **** 













7.3.2.2 Intra-tumoural MDSC levels did not correlate with tumour 
regression characteristics. 
I next focused on both subsets of MDSCs. M-MDSCs and G-MDSCs have been 
shown to have distinct functions, but M-MDSCs have been shown to have greater 
immunosuppressive capabilities159 (2.1.3.1). Samples were stained with Stain 3 
(Table 7.1) and analysed by FACS as described in Figure 7.4.  Intra-tumoural 
M-MDSCs significantly increased in SCC FAK-/- tumours (means ± s.e.m. = 
11.044 ± 1.937 compared to SCC FAK-wt (means ± s.e.m. = 7.9717 ± 3.255 and 
8.5655 ± 2.803 respectively; p value  = <0.0001; Figure 7.5). No significant 
difference was observed between SCC FAK-wt and SCC FAK-kd tumours (p value 
= >0.05). 
The levels of intra-tumoural G-MDSCs were considerably less than M-MDSCs, but 
the comparison across all three-tumour types followed a similar trend. G-MDSCs 
were significantly increased in SCC FAK-/- tumours (means ± s.e.m. = 4.0125 ± 
1.4477) compared to SCC FAK-wt (means ± s.e.m. 1.082 ± 0.667; p value = 
<0.0001) and SCC FAK-kd tumours (means ± s.e.m. = 1.9425 ± 0.604; p value = 
<0.001; Figure 7.5). No significant difference was observed between SCC FAK-wt 
and SCC FAK-kd tumours (p value = >0.05). 
These data showed that both MDSC subpopulations were elevated in SCC FAK-/- 
tumours compared to SCC FAK-wt and SCC FAK-kd tumours. I concluded 
therefore, that neither M-MDSCs not G-MDSCs cells were the primary 
immunosuppressive population capable of evading a CD8+ T-cell response. 
However, as levels of both populations in SCC FAK-kd tumours were comparable to 
the levels in SCC FAK-wt tumours, it was possible the FAK negatively regulated 
levels of intra-tumoural MDSCs in a kinase independent manner, or as a 
consequence of Kinase-independent regulation of other immune component, MDSCs 






Figure 7.4 I MDSC FACS gating strategy. a Stain 3  (Table 7.1) was used to determine 
the total number of MDSCs and M-MDSCs and G-MDSCs subpopulations. See Table 7.1 for 
full list of immune populations and their respective markers. b FMO control samples used to 
determine correct gating for MDSC sub-population identification. . M-MDSC = Monocytic 
Myeloid Derived Suppressor Cell; G-MDSC = Granulocytic Myeloid Derived Suppressor Cell; 



























































7.3.2.3 Intra-tumoural Tregs were increased in SCC FAK-wt tumours 
and are required for SCC FAK-wt tumour growth.   
Having ruled out M2 macrophages and MDSCs, I next focused on Tregs. Samples 
were stained with Stain 4 (Table 7.1) and prepared for FACS analysis. Samples were 
analysed as described in Figure 7.6. Stain 4 is a commercially available stain that 
includes cell permeablising buffers required for intracellular FoxP3 staining, and 
thus, FMO controls were not possible with this stain.  SCC FAK-wt tumours showed 
a significant increase in the number of intra-tumoural Tregs (mean ± s.e.m. = 
22.973 ± 2.614) compared to SCC FAK-/- and SCC FAK-kd tumours (mean ± s.e.m. 
= 6.8989 ± 5.2165 and 6.3800 ± 2.299 respectively; p value  = >0.0001; Figure 
7.7a). This increase resulted in a decrease in the ratio between effector CD8+ and 

































































Figure 7.5 I FACS analysis of MDSC populations did not correlate with tumour 
clearance characteristics. 1 x 106 SCC FAK-wt, SCC FAK-/- or SCC FAK-kd cells were 
implanted into the flanks FVB/N mice by bilateral subcutaneous injection. Resulting tumours were 
removed from cohorts of mice (n = 3) 7 days post-implantation. Tumours were disaggregated and 
stained for FACS analysis with Stain 4 (Table 7.1). FACS analysis was gated as described in 







populations (left panel) and their quantification (right panel). The number of each cell population 
was determined and the statistical significance between each cell type was calculated by one-way 
Anova with Tukey’s multiple comparisons. P-value = Not significant >0.05, * <0.05, ** <0.01, *** 
<0.001, **** <0.0001 Bar height = mean; Error bars = s.e.m 
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the proportion of Tregs correlated with tumour regression characteristics, suggesting 
that this may be a potentially important population in mediating SCC FAK-wt 
tumour survival.  There is an ever-expanding body of evidence that implicates Treg 
involvement in tumour immune evasion (2.1.3.2). Tregs (CD4+ CD25+ FoxP3+ cells) 
are a highly immunosuppressive population whose primary function is to suppress 
activated CD8+ T-cells in order to limit harmful immune responses to self-antigen. 
Thus, I wanted to further investigate whether Tregs were the immunosuppressive 
population that instilled SCC FAK-wt tumours with the capacity to evade a CD8+ 
T-cell response.  I had previously established that CD4+ T-cells were required for 
SCC FAK-wt tumour survival (Figure 5.10). Treatment with CD4 depleting 
antibodies would reduce levels of Tregs, further supporting a role for Tregs in SCC 
FAK-wt survival. However, I wanted to take a more Treg-specific approach, and 
therefore used a CD25 depleting antibody. FVB/N mice were treated with 150 µg of 
CD25 depleting antibody (n = 5) or with Isotype control (n=5) by IP injection, and 
dosed as described in Figure 5.8. 1 x 106 SCC FAK-wt cells were implanted into 
mice after 5 days of treatment, and into an untreated control group, by bilateral 
subcutaneous injection in to both flanks.  1 x 106 SCC FAK-/- cells were also 
implanted into untreated animals as a control. Tumour diameter was measured twice 
weekly and tumour volume calculated using the formula 4/3πr3. 
Untreated SCC FAK-wt and SCC FAK-/- tumours, and Isotype control treated SCC 
FAK-wt tumours grew as expected (Figure 7.8) and no significant difference was 
observed between SCC FAK-wt untreated and Isotype control treated animals 
















Figure 7.6 I Treg FACS gating strategy.Stain 4 (Table 6.1) was used to determine the
number of CD4+ CD25+ FoxP3+ Tregs. Stain 4 is a commercially available antibody cocktail,
which incorporates cell permeablising buffers required for intracellular FoxP3 staining, and thus,
FMO controls were not possible with this stain
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normally until day 7, where tumour growth stalled, leading to complete tumour 
regression by day 21 (Figure 7.8). Following cessation of antibody treatment 25 
days post tumour-cell implantation, tumours did not reappear after 6 months of 
observation (data not shown). 
Having established that SCC FAK-wt tumour growth required CD25+ and CD4+ 
cells, I concluded that Tregs were the cell population responsible for SCC FAK-wt 




























































































Figure 7.7 I Increase in the number of intra-tumoural Tregs in SCC FAK-wt 
tumours.      1 x 106 SCC FAK-wt, SCC FAK-/- or SCC FAK-kd cells were implanted into the 
flanks FVB/N mice by bilateral subcutaneous injection. Resulting tumours were removed 
from cohorts of mice (n = 3) 7 days post-implantation. Tumours were disaggregated and 
stained for FACS analysis with stain 4 (Table 7.1). FACS analysis was gated as described in 
Figure 7.6. a FACS plots of intra-tumoural Treg populations (left panel) and their respective 
quantification (right panel). b CD8
+
 T-cell to Treg ratio calculated using mean values from 
Figures 7.1 and 7.7. The number of each cell population was determined and the statistical 
significance between each cell type was calculated by one-way Anova with Tukey’s multiple 
comparisons. P-value = Not significant >0.05,  * <0.05, ** <0.01, *** <0.001, **** <0.0001; 







These data imply that antigen-primed CD8+ T-cells infiltrate into all tumour types 
and therefore the lack of CD8+ T-cell infiltration is not the underlying mechanism for 
continued growth of SCC FAK-wt tumours. Treg levels were observed to be elevated 
in SCC FAK-wt tumours when compared to SCC FAK-/- and FAK-kd tumours, and 
specific depletion of these cells using anti-CD25 antibodies led to complete 
regression of SCC FAK-wt tumours.  Thus, increased Treg infiltration is required to 
protect SCC FAK-wt tumours from immune-mediated clearance.  The ratio of CD8+ 
T-cells to Tregs has been reported as a prognostic indicator of clinical outcome, with 
a low ratio linked to poor prognosis.  Comparing the ratio of CD8+ T-cells to Tregs 
in SCC FAK-wt, FAK-/- and FAK-kd tumours revealed a substantially lower ratio in 
SCC FAK-wt tumours, which in our model correlated with poor prognosis.  
















SCC FAK-wt CD25 Depletion
SCC FAK-/-
SCC FAK-wt
SCC FAK-wt Isotype Ctrl
**** 
**** 
Figure 7.8 I SCC FAK-wt tumour clearance after antibody depletion of CD25
+
 
cells.  SCC FAK-wt tumour growth in CD25 depleted FVB/N mice. FVB/N mice (n = 5) were 
treated with CD25
+
 depleting antibody as per the dosage scheduled referred to in Figure 5.7. 
Control animals were treated with Isotype control antibody or were untreated. 1 x 10
6
 SCC FAK-
wt or SCC FAK-/- cells were implanted by bilateral subcutaneous injection into each flank. 
Tumour diameter was measured twice weekly and tumour volume was determined by 4/3πr
3
. 
Statistical significance was determined by matched, two-way Anova with Tukey’s multiple 
comparisons. Data are represented as mean ± s.e.m. P-value = Not significant >0.05,  * <0.05, 
** <0.01, *** <0.001, **** <0.0001. 
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Therefore, one outcome of elevated FAK expression in tumours may be to alter the 
ratio of CD8+ T-cells to Tregs in favour of tumour tolerance. Further work will be 
required to understand the broad relevance of these findings and to identify how 
FAK can influence Treg levels within tumours. 
Levels of inflammatory and resident macrophages were unchanged across SCC 
FAK-wt, SCC FAK-/- and SCC FAK-kd tumours, but approx. 70% were M2 
polarised in SCC FAK-wt and SCC FAK-kd tumours, and M1 polarised in SCC 
FAK-/-. While these changes in the polarity of macrophages were observed, they did 
not correlate with the regression phenotype and thus are unlikely to be the primary 
factor supporting continued growth of SCC FAK-wt tumours. However, these 
changes may be clinically relevant as M2 macrophages have been shown to be a 
pro-tumorigenic population indicative of poor clinical outcome, and may provide the 
tumour protection from chemotherapy and radiotherapy43,57,82,85,92. The difference 
between SCC FAK-/- tumours and SCC FAK-wt and SCC FAK-kd tumours can be 
attributed to the presence of FAK kinase-independent functionality, which is still 
retained in SCC FAK-kd cells. The kinase-independent roles of FAK have been 
shown to influence cell migration, adhesion, invasion, metastasis, growth and 
survival244,247,249,264,339,367,368 (Figure 3.2), and do so through the scaffolding 
functions of the FAK FERM domain244,274,284,321,369-373 (Figure 3.1).  A number of 
these functions have been shown to be modulated by chemokines and cytokines. 
Therefore, it’s possible to speculate that FAK FERM domain-mediated regulation of 
chemokines and cytokines may attribute to the differences observed between SCC 
FAK-/- and SCC FAK-kd tumours, and that the FERM domain regulates the 
expression of mediators of macrophage polarization. 
The factors leading to the differential polarization of macrophages, and indeed 
MDSCs, are to date poorly characterised. However, some work has identified factors 
such as IFNγ and IL-4 to differentially stimulate M1 and M2 macrophage 
polarization respectively361,374.  IFNγ and IL-4 are two of the main drivers of Th1 and 
Th2 immune responses respectively, and many of FAK kinase-independent functions 
lead to the upregulation of growth factors and chemokine and cytokine 
signalling265,282,284. This therefore raises the possibly that FAK kinase-independent 
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functions play a role in the modulation of these factors, which could have greater 
implications as to the inflammatory environment of a FAK-expressing tumour. 
Indeed, it may be possible that FAK-expression within tumours infer a Th2 
inflammatory microenvironment, which in the absence or downregulation of Th1 
mediating factors such as IFNγ could generate a more permissive environment for 
tumour development375.  
Although this hypothesis is intriguing, no significant differences were observed in 
the total numbers or the activation status of CD8+ T-cells between SCC FAK-/- and 
SCC FAK-kd tumours (Figure 7.1 b-d). Thus, the more likely hypothesis is that 
FAK may regulate the expression other chemokines and cytokines that affect 
macrophage polarization without the major effects on Th2 immunity. IL-21 has been 
shown to be an inducer of M2 polarization through the activation of STAT-3 
signalling in macrophages, but only moderately mediates Th2 induction376. The lack 
of an induced Th2 response by Il-21 is attributed to its effects in increasing the 
frequency of a subset of antigen-specific CD8+ T-cells, which produce IL-2 in 
response to IL-21, and thus increase Th1 mediated immunity377.  
Although further work must be done to investigate the mechanisms by which the 
kinase-independent function of FAK may regulate macrophage polarization, few 
tools exist which are capable of inhibiting scaffolding functionality. To interrogate 
this phenotype further however, the disruption of FAK FERM domain interactions 
would be required, and this could be achieved using nanobodies. Nanobodies are 
short, single chain immunoglobulins found in camelids (such as llamas), which 
contain only heavy and light immunoglobulin variable domains378. The lack of the 
immunoglobulin constant domains (seen in most other mammalian 
immunoglobulins) generates antibodies which are small enough to perturb 
protein:protein interactions directly with high avidity and specificity378. Modified 
derivations of these antibodies have been used in the clinic in the form of bispecific 
t-cell engaging antibodies (BiTEs) targeting both CD3 and TAA (CD19) in B-cell 
lymphomas, and have been shown to have excellent pharmacodynamics properties,  
specificities and anti-cancer properties379-383. Although using these molecules as 
inhibitors of protein:protein interactions has yet to be trialled in vivo in either humans 
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or mice384, they have been shown to have excellent inhibiting capacity in vitro385-387 . 
Thus, it may be possible to disrupt FAK kinase-independent FERM interactions with 
nanobodies, and begin to interrogate the mechanisms by which the FAK FERM 
domain has the capacity to polarize macrophages. This may prove to be highly 
important in the long-term implications of FAK-based therapies. 
Kinase-independent polarisation is also observed in both MDSC populations of SCC 
FAK-wt and SCC FAK-kd tumours, but it should be noted that the interpretation of 
the MDSC data is more difficult than for macrophages. Current definitions of 
immunosuppressive cell populations by FACS are not always specific. This is the 
case for MDSCs; M-MDSCs cannot be defined specifically at this point, and 
currently share the same markers are inflammatory monocytes (CD45+ CD11b+ 
F4/80- Ly6Chi; Table 7.1). New methods, such as NanoString® aims to improve on 
this by combining both RNA sequencing and protein profiling into a single reaction, 
allowing immune cell populations to be more accurately identified by both the 
expression of proteins and RNA388,389. This technology increases the specificity of 
detecting immune populations by analysis of specific transcriptional and proteomic 
profiles consisting of many more markers than FACS, and therefor allows for a more 
accurate definition of immune populations. Although this is a significant 
advancement for immunoprofiling, this technology still relies on current identifiable 
markers, and for immune populations such as MDSC and DCs that have no unique 
identifiable markers, identification of these population will always be demanding 
until more work has been done on characterising them.    
Having excluded both M2 macrophages and MDSCs as the immunosuppressive 
populations responsible for SCC FAK-wt tumour survival, work turned to 
identification and characterisation of the Treg population (CD4+ CD25+ FoxP3+). It 
has been shown however that CD4+ FoxP3+ cells also have immunosuppressive 
capabilities, and are often referred to as Tregs in the literature. Although these cell 
can be immunosuppressive, due to the lack of CD25 they may not have the same 
suppressive capacity as double positive FoxP3+ CD25+ cells. Because of this, Tregs 
are defined only as CD4+ FoxP3+ CD25+ cells within this thesis, and are stained by a 
commercially available kit that allows for the intracellular staining of FoxP3. This 
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does raise question as to whether the use of CD25 depleting antibodies (Figure 7.8) 
is an effective method to depleting Tregs. Indeed, CD4+ FoxP3+ cells will not be 
affected by this treatment, leaving the potential for residual immunosuppressive cells 
to be retained after CD25 depletion390. CD25 has also been shown to be upregulated 
on activated CD8+ T-cells, and thus depletion of Tregs in this manner may also 
reduce cytotoxic activity391. Although both of these possibilities appear unlikely, as 
residual immunosuppression or reduction in cytotoxic activity would retain tumour 
tolerance after CD25 treatment, other possibilities would in fact lead to tumour 
rejection. For example, CD25+ CD8+ suppressor cells (CD8+ TSups) would also be 
depleted by CD25 treatment; CD8+ Tsups are a functionally defined, 
immunosuppressive population, and therefore CD25 depletion could cause tumour 
rejection if targeting this populations392. Many of the issues surrounding CD25 
antibody-meditated depletion of Tregs would be resolved, albeit only transiently by 
using FoxP3DTR knockin mouse, whereby Treg ablation follows treatment with 
diphtheria toxin (DT)393. Although these points must be considered when evaluating 
the data presented in this chapter, CD8+ Tsups are typically found at very low 
abundance in tumours, and so the hypothesis that the rejection of SCC FAK-wt 
tumours after anti-CD25 is due to the lost of Tregs appears most likely. 
The work presented in this chapter focuses on SCC FAK-wt tumours in order to 
better understand the immunomodulatory roles of FAK in SCC FAK-wt tumour 
survival. This work identifies the essential role of Tregs in SCC FAK-wt tumour 
tolerance, and correlates the absence of Tregs with SCC FAK-/- and SCC FAK-kd 
tumour rejection. However, to further substantiate this hypothesis, experimental 
evidence is required to show a stronger functional link between the lack of Tregs and 
the clearance of SCC FAK-/- and SCC FAK-kd tumours. This could be achieved by 
increasing the number of Tregs within SCC FAK-/- and SCC FAK-kd tumours by 
adoptive transfer of Tregs from SCC FAK-wt tumours. Two caveats with this 
technique are the requirement for in vitro expansion, which can prove difficult with 
Tregs and isolating a pure Treg population. As discussed above, the transcription 
factor FoxP3 is established as the best marker for Tregs, as CD25 expression is not 
restricted to Tregs alone. However, due to the permeabilization and fixation required 
for intracellular FoxP3 staining, purification by CD25 expression must be used to 
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achieve a final viable cell population. This raises difficulties around attaining a pure 
Treg population. Other methods of increasing Tregs include anti-CD45RB treatment, 
which increases endogenous splenic Tregs in vivo. Although the mechanism of 
action of anti-CD45RB treatment has been shown to act due to the specific 
enhancement of tTreg proliferation in response to antigen394, this work is 
unsubstantiated and has yet to be tried in cancer setting, but offers an opportunity to 
increase Tregs in vivo without the requirement for expansion or purification.  
 
  





8 FAK regulates chemokines and cytokines that increase the 




Having established that intra-tumoural Tregs were increased in SCC FAK-wt 
tumours, and that they were required to avoid SCC FAK-wt tumour regression, I set 
out to investigate the molecular mechanisms by which FAK could regulate intra-
tumoural Treg levels. Tumour cells have been shown to upregulate a number of 
factors that act to increase the differentiation of Tregs from effector CD4+ T-cells 
(TGFβ and IL-10; Figure 2.6) or to increase the recruitment of tTregs and their 
retention within the microenvironment (CCL5; Figure 2.6). Thus, working with Dr 
Adam Bryon and Dr Alan Serrels (Frame Group) we undertook a screening approach 
in order to determine transcriptomic changes between SCC FAK-wt and SCC FAK-/- 
cells, focussing on differentially expressed cytokines and chemokines, and then 
concentrated our experiments on selected chemokines and cytokines that are known 




• To determine whether FAK regulates the expression of factors that could 
influence Treg levels in tumours 








8.3.1 FAK regulates the transcription of chemokines and cytokines 
involved in the peripheral induction, recruitment and retention of 
Tregs 
 
To further investigate how FAK expression was linked to elevated intra-tumoural 
Treg levels, we used global transcriptional profiling of SCC cells. Using Affymetrix 
GeneChip Mouse Genome 430 2.0 microarrays that cover over 39000 transcripts, we 
compared the transcriptome of SCC FAK-wt cells in vitro to that of SCC FAK-/- 
cells in vitro (Figure 8.1). Analysis of the resulting data identified a set of 498 
upregulated genes, and 598 downregulated genes in the SCC FAK-wt cells compared 
to SCC FAK-/- (Figure 8.1a). Gene ontology analysis on the upregulated gene set 
indicated that FAK expression was significantly associated with a number of 
biological processes including cell migration, secretion, wounding, and ovulation, 
and that the most overrepresented gene family within this gene set was chemokine 
ligands (Figure 8.1b).  
 
Figure 8.1 I Transcriptional profiling of SCC FAK-wt and SCC FAK-/- cells reveled 
a number of upregulated chemokine ligands in SCC FAK-wt tumours. a Heat map 
of transcriptional changes between SCC FAK-wt and SCC FAK-/- cells. b Functional enrichment 
analysis of genes upregulated in SCC FAK-wt cells (grey bar in a). Overrepresented biological 
processes are displayed as a heat map (log10-transformed color scale) (top panel); asterisks 
indicate presence of cytokine-related genes. Overrepresented gene families are displayed as a 
bar chart (bottom panel); dashed line indicates P = 0.001. Displayed terms satisfy P < 0.05 
(Benjamini–Hochberg-corrected hypergeometric tests). Figure courtesy of Dr Adam Byron. 
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To further establish which chemokines and cytokines were regulated by FAK, and to 
confirm the results from the microarray analysis, we used a focussed chemokine / 
cytokine qRT-PCR array to compare transcript expression between SCC FAK-wt 
and SCC FAK-/- cells (Figure 8.2a). We identified a subset of chemokines and 
cytokines that were upregulated more than two-fold in the SCC FAK-wt cells, of 
which a number have been reported to play a role in Treg induction, expansion395  
(TGFβ2; Figure 8.2a red arrow) and recruitment396 (CCL5, CxCL10, CCL1 and 
a b 
c 























Figure 8.2 I FAK regulates transcription of chemokines and cytokines implicated 
in Treg recruitment and expansion. a qRT-PCR array analysis of cytokine and chemokine 
expression in SCC FAK-wt and SCC FAK-/- cells. Cytokine and chemokine gene names within 
cluster upregulated in SCC FAK-wt cells are listed. Green arrows indicate reported roles in Treg 
recruitment; red arrow indicates reported role in peripheral Treg induction. b qRT-PCR analysis 
of selected cytokine and chemokine gene expression in SCC cells. c qRT-PCR array analysis of 
chemokine receptor expression in tumor- and thymus-derived Tregs. Grey bar indicates cluster 
of genes upregulated in tumor-derived Tregs; receptor gene names are listed. ****P < 0.0001 
(Sidak-corrected one-way ANOVA). Data are represented as mean ± s.e.m. Figures courtesy of 




CCL7; Figure 8.2a green arrows).   
Having identified CCL5, CxCL10 and TGFβ as being upregulated in SCC FAK-wt 
cells compared to SCC FAK-/- cells, we next wanted to determine the relative 
quantity of these three chemokines and cytokines in SCC FAK-kd cells.  qRT-PCR 
analysis of SCC FAK-wt, SCC FAK-/- and SCC FAK-kd cells showed that CCL5 
was down-regulated 10-fold in SCC FAK-/- cells and 4-fold in SCC FAK-kd cells 
compared to SCC FAK-wt (p value = <0.0001; Figure 8.2b). CxCL10 was down-
regulated 10-fold in SCC FAK-/- cells and approximately 2-fold in SCC FAK-kd 
cells compared to SCC FAK-wt (p value = <0.0001) and TGFβ2 was down-regulated 
5-fold in SCC FAK-/- and 2-fold in SCC FAK-kd cells compared to SCC FAK-wt (p 
value = <0.0001; Figure 8.2b). We conclude that the FAK kinase activity is required 
for the transcriptional upregulation of CCL5, CxCL10 and TGFβ2. FAK has been 
shown previously to regulate the transcriptional levels TGFβ in other cell 
models397,398, validating our findings.  Further, it is possible that the differences 
observed between SCC FAK-/- and SCC FAK-kd cells were due to the fact that SCC 
FAK-kd cells are ‘kinase deficient’ not kinase-dead, and therefore retain some 
residual kinase activity.  
To compliment this analysis, and to identify whether there was a relationship 
between FAK-dependent chemokine expression and Treg chemokine receptor 
profile, we isolated both intra-tumoural Tregs and thymic derived Tregs and 
compared their chemokine receptor expression using qRT-PCR (Figure 8.2c). 
Analysis of this data identified a subset of chemokine receptors that were greater 
than two-fold upregulated on intra-tumoural Tregs when compared to thymic derived 
Tregs, indicating a switch from lymphoid homing receptors, including CCR7399 and 
CxCR4400, towards expression of memory / effector-type chemokine receptors 
involved in recruitment to non-lymphoid tissues and sites of inflammation, including 
CCR2, CCR5, CCR8, and CxCR6401.  
Network analysis identified a FAK-driven paracrine-signaling axis between cancer 
cells and intra-tumoural Tregs based on chemokine ligand-receptor interactions. 
Indeed, 5 of the chemokine receptors upregulated on intra-tumoural Tregs were the 
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cognate receptors for the chemokine ligands upregulated in response to FAK 
expression in SCC cells (Figure 8.3).  
 
  
Figure 8.3 I Upregulation of chemokine ligands in SCC FAK-wt cells correlate 
with the upregulation of cognate receptors on SCC FAK-wt intra-tumoural Tregs. 
Interaction network analysis of chemokine ligand gene expression detected in SCC cells (circles; 
left) and corresponding receptor gene expression detected in intra-tumoural Tregs (squares; 
right). Genes are ordered vertically by fold change. Light gray lines connect receptor–ligand 
pairs; green lines indicate pairs upregulated at least two-fold in SCC FAK-wt cells and tumor-
derived Tregs. Figure courtesy of Dr Adam Byron. 
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8.3.2 SCC FAK-wt tumour survival and growth requires TGFβ2 and 
CCL5, associated with an increase in intra-tumoural Tregs. 
 
Following identification of a subset of chemokine and cytokine ligands upregulated 
in response to FAK expression, I sought to prioritise a small number for further 
testing. TGFβ2 and CCL5 have been previously reported to be important for Treg 
induction and recruitment to non-lymphoid tissues respectively137,138,243,402. Indeed, 
disruption of the CCL5 / CCR5 axis has been reported to result in reduced intra-
tumoural Tregs and slowed tumour growth implying that FAK-dependent regulation 
of this paracrine signaling axis may be important137.  I therefore used shRNA to 
knockdown TGFβ2 and CCL5 in SCC FAK-wt cells, and tested the impact of this on 
tumour growth and intra-tumoural Treg levels. 
TGFβ2 knockdown was validated using qRT-PCR, and a single clone was chosen 
with reduced expression levels of TGFβ2 (Figure 8.4a). 1 x 106 TGFβ2 shRNA 
expressing SCC FAK-wt cells (SCC FAK-wt shRNA-TGFβ2) were implanted in to 
the flanks of FVB/N mice (n=3) by bilateral subcutaneous injection, along side SCC 
FAK-wt pLKO vector only controls and SCC FAK-/- cells for comparison. Tumour 
growth was measured twice weekly. SCC FAK-wt pLKO and SCC FAK-/- tumours 
grew as expected (Figure 8.4b). SCC FAK-wt shRNA-TGFβ tumour growth 
appeared to split into two groups (Figure 8.4b). Tumours which were observed to 
have initial increase in tumour growth compared to the SCC FAK-wt pLKO control, 
subsequently ulcerated prematurely (Figure 8.4b blue dash). Tumours that did not 
have this initially increase in growth did not ulcerate, and these tumours were cleared 
after 27 days (Figure 8.4b red dash). TGFβ signalling has been shown to have 
pleiotropic effects on tumour growth138,243,403,404 and this could account for high 
variability in tumour growth observed. I concluded that, as a subset of SCC FAK-wt 
TGFβ2 shRNA expressing tumours were cleared, which was not seen in the SCC 




SCC FAK-wt shRNA-CCL5 cells were generated from two independent shRNAs 
and knockdown validated using qRT-PCR (Figure 8.5a). Clones were chosen with 
reduced expression levels similar to that of SCC FAK-/- cells  (SCC FAK-wt 
shRNA-CCL5 1 and 2). 1 x 106 of both CCL5 shRNA-expressing cells 
(SCC FAK-wt shRNA-CCL5 1 and 2) were implanted in to the flanks of FVB/N 
mice (n=3) by bilateral subcutaneous injection, alongside SCC FAK-wt pLKO vector 
only controls and SCC FAK-/- cells for comparison and tumour growth was 
measured twice weekly. SCC FAK-wt pLKO and SCC FAK-/- tumours grew as 
expected (Figure 8.5b). Both SCC FAK-wt shRNA-CCL5 1 and 2 tumours grew in a 
manner akin to SCC FAK-/- cells (Figure 8.5b); tumours grew until day 7, at which 
point tumour growth stalled, until complete tumour regression a day 27 
(SCC FAK-wt shRNA-CCL5 1) and day 23 (SCC FAK-wt shRNA-CCL5 2).  
These data show that SCC FAK-wt tumour growth is dependant on TGFβ2 and 
CCL5 expression. Therefore I next wanted to determine whether knockdown of 


















































SCC FAK-wt shRNA-TGFβ2 
SCC FAK-/-
SCC FAK-wt shRNA-TGFβ2 (ulcerated)
SCC FAK-wt shRNA-TGFβ2 (non-ulcerated)
b a 
Figure 8.4 I FAK regulates transcription of TGFβ2 that is required for Treg 
expansion and tumour growth. a qRT-PCR analysis of TGFβ2 gene expression 
knockdown in SCC cells. b SCC FAK-wt shRNA-TGFβ2 tumour growth in FVB/N mice. Green 
solid line indicates the mean growth of all SCC FAK-wt shRNA-TGFβ2 tumours until signs of 
ulceration were observed. Tumour growth was determined by the implantation of 1 x 10
6 
SCC 
FAK-wt or SCC FAK-/- cells in to both flanks of FVB/N mice by bilateral subcutaneous injection. 
Tumour diameter was measured twice weekly and tumour volume was determined by 4/3πr
3
. 
Statistical significance was calculated by one-way Anova with Tukey’s multiple comparisons. 
Bar height = mean, Error bars = s.e.m. P-value = Not significant >0.05,  * <0.05, ** <0.01, *** 




analysis. SCC FAK-wt shRNA TGFβ2 and SCC FAK-wt CCL5 1 cells, and SCC 
FAK-wt and SCC FAK-/- controls, were implanted in to both flanks of FVB/N mice 
by bilateral subcutaneous injection. Tumours were disaggregated and stained with 
Stain 4 (Table 7.1) Samples were then analysed by FACS as described in Figure 7.6.  
Comparison between SCC FAK-wt pLKO, SCC FAK-/- and SCC FAK-wt shRNA-
CCL5 tumours showed a statically significant decrease between the SCC FAK-/- and 
SCC FAK-wt shRNA-CCL5, and the SCC FAK-wt tumour (p value = <0.01 and 
<0.05 respectively; Figure 8.6a).  
FACS analysis of TGFβ2 shRNA-expressing SCC FAK-wt cells showed a 
significant decrease in Tregs between SCC FAK-wt shRNA-TGFβ2 and 
SCC FAK-/- tumours, compared to SCC FAK-wt tumours (p value = <0.0001; 
Figure 8.6b). From this data I concluded that TGFβ2 and CCL5 were required for 
SCC FAK-wt tumour survival and this was associated with an increase in intra-
tumoural Tregs. 
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Figure 8.5 I FAK regulates transcription of CCL5 required for Treg recruitment, 
retention and tumour growth. a qRT-PCR analysis of CCL5 gene expression knockdown in 
SCC cells. b SCC FAK-wt shRNA-CCL5 tumour growth in FVB/N mice. Tumour growth was 
determined by the implantation of 1 x 10
6 
SCC FAK-wt or SCC FAK-/- cells in to both flanks of 
FVB/N mice by subcutaneous injection. Tumour diameter was measured twice weekly and 
tumour volume was determined by 4/3πr
3.
 Statistical significance was calculated by one-way 
Anova with Tukey’s multiple comparisons. Bar height = mean, Error bars = s.e.m. P-value = Not 






We have identified a novel paracrine-signalling axis between FAK expressing SCC 
tumour cells and intra-tumoural Tregs. Chemokines and cytokines regulated by FAK, 
including TGFβ2 and CCL5, are associated with an increase in intra-tumoural Tregs 
and sustained SCC FAK-wt tumour growth. Further, I show that transcription of 
TGFβ2 and CCL5 is dependent on FAK kinase activity, suggesting that they may be 
modulated by FAK kinase inhibitors to result in a similar outcome. Clinically these 
observations are important, as they suggest that FAK kinase inhibition may alter the 
chemokine and cytokine profile being secreted by tumour cells, with a resultant 
impact on the composition of the tumour immune infiltrate. Further work will focus 
on whether these phenotypes could be replicated by treatment of a FAK kinase 
inhibitor. 
The regulation of chemokines and cytokines by FAK kinase activity was identified 















































































Figure 8.6 I TGFβ2 and CCL5 are required for Treg expansion and tumour 
growth in SCC FAK-wt tumours. a FACS analysis of the absolute number of Tregs / mg 
of tumour in SCC FAK-wt CCL5-shRNA tumours. b FACS analysis of intra-tumoural SCC 
FAK-wt TGFβ2-shRNA Tregs and a percentage of CD4
+
 cell. Tumours were taken 7 days 
post implantation, disaggregated and stained for FACS with Stain 4 (Table 7.1). FACS 
analysis was gated as described in Figure 7.6. Statistical significance was calculated by one-
way Anova with Tukey’s multiple comparisons. Bar height = mean, Error bars = s.e.m. P-




chemokine and cytokine qRT-PCR arrays. Steady-state transcriptomic approaches 
such as these give excellent coverage of transcripts (30000 targets in the GeneChip 
Mouse genome arrays) and include some alternative probes for select targets, thus 
allowing for the identification of some non-specific amplification. However, 
steady-state transcriptomic approaches suffer from a static view of transcription, and 
thus give no detail into transcriptional kinetics and downstream processing (i.e. the 
rate of transcription vs. the rate of transcript turnover, the rate of translation, and 
whether the rates of transcription and translation change over time). Other genetic 
tools, such as gene reporter constructs, would allow for more dynamic analysis of the 
transcription of a select number of chemokines and cytokines, and could be utilized 
to determine whether the rate of transcription of these factors modulate over time.  
Further proteomic approaches are also required to determine whether the levels of 
functional chemokines and cytokines are produced in a FAK kinase-dependent 
manner. This offers a challenge as the secretion of chemokines and cytokines by 
tumour cells in culture can often be minimal, and thus can be difficult to detect above 
the high levels of background found when culturing cells in FBS. Our SCC model 
strictly requires FBS to be maintained in culture for periods longer than 24 hours, 
making analysis into chemokine and cytokine secretion difficult. Determination of 
chemokine and cytokine levels can be achieved however following the treatment of 
cultured cells with Ionomycin, which activates chemokine and cytokine production, 
and Brefeldin A, which blocks chemokine and cytokine secretion thus causing their 
intracellular retention. Treatment with these compounds allow for the quantification 
of chemokine and cytokine proteins without the inherent high levels of background 
following secretion into FBS containing media.  
This transcriptomic approach however, identified a subset of genes upregulated in 
SCC FAK-wt cells, known to be involved in Treg biology, including TGFβ2 and 
CCL5 (2.1.2.2 and 2.1.3.2). Although SCC FAK-kd cells were omitted from the 
initial transcriptomic data set, qRT-PCR data supports the array results and identifies 
the dependence of FAK kinase activity in the upregulation of TGFβ2 and CCL5. 
SCC FAK-kd cells display an intermediate phenotype in this regard, potentially due 
to the small amount of residual FAK kinase activity seen in these kinase deficient 
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cells in 2D culture conditions, but which is absent in cells grown in 3D culture 
conditions and most importantly, is insufficient to induce SCC FAK-kd tumour 
tolerance in vivo (see 276). Although a true kinase dead FAK mutant or in vitro 3D 
culture conditions would help in part to answer this question, the immune-mediated 
clearance of SCC FAK-kd cells highlights the necessary requirement for full 
FAK-kinase activity.  
Subsequent stable RNAi knockdown of CCL5 and TGFβ2 shows that both these 
factors are required for FAK-expressing tumour tolerance compared to vector-only 
transfected SCC FAK-wt pLKO cells. SCC FAK-wt pLKO cells are transfected with 
the vector-backbone (pLKO) in which both CCL5 and TGFβ2 shRNAs are 
expressed. These controls were used in lieu of the more commonly used scrambled 
RNAi controls, as off-target scrambled RNAi mediated depletion of other 
chemokines and cytokines were observed after the transfection of scrambled RNAi 
control (data not shown). A vector-only control is effectively a sham-transfection 
which allows you to determine whether changes observed in experimental 
parameters, in this case tumour tolerance, are due to the exposure of cells to the 
transfection agent, retrovirus or other aspects of the transfection protocol (4.1.15 and 
4.2.11) without any RNAi-mediated effects. A scrambled control also validates these 
effects, but also determines the probability that any changes in experimental 
parameters are due to the RNAi-mediated knockdown of a specific target, and not 
due to off-target depletion by non-targeting RNAi. Although the vector-only controls 
did not exhibit any observed changes in phenotype, they are not sufficient in 
determining the specificity of either the CCL5 or TGFβ2 shRNA for their respective 
targets. The induction of tumour clearance after the RNAi mediated-knockdown of 
either CCL5 or TGFβ2 could be due to off-target depletion of other non-specific 
targets. A scrambled control would, in part, help to clarify this. Although the use of 
multiple shRNAs for both CCL5 and TGFβ2 knockdown reduces the possibility SCC 
FAK-wt tumour clearance was mediated by off-target effects, it should still be taken 
into consideration that loss of tumour tolerance could be due to non-target effects of 
CCL5 or TGFβ2 shRNAs, and a different scrambled control should used used, one 
which does not effect other chemokines and cytokines to clarify this further.    
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Knockdown of TGFβ2 resulted in a split phenotype, with some tumours undergoing 
premature ulceration and others continuing to complete regression. The pleiotropic 
effects of TGFβ on tumour growth are well characterised. TGFβ signalling has 
cytostatic effects on epithelial, endothelial and immune cells, specifically T cells, and 
is critically important in the maintenance of tissue homeostasis and the prevention of 
hyperproliferative disorders such as cancer405,406. TGFβ acts to induce the expression 
of cyclin-dependant kinase inhibitors CDKN2B407, CDKN1A408 and p27/Kip1409, 
resulting in the arrest of  G1 to S phase transition410, and also by the repression of the 
proliferation-inducing transcription factor c-Myc411. The loss of controlled 
proliferation by TGFβ has been observed in a number of different human cancers due 
to mutations in various components of the TGFβ signalling pathway.  Loss of 
function or truncating mutations in Smad2 and Smad4 as well as TGFβRI and 
TGFβRII have been detected in colorectal, pancreatic, gastric and prostate 
cancers406,412-419. Futhermore, TGFβ is well recognized to enhance the proliferation 
of CAFs, mediated indirectly by the secretion of TGFβ-induced connective tissue 
growth factor (CTGF), which stimulates fibroblast proliferation and ECM 
generation406,420. This increase in ECM generation, specifically the deposition of 
collagen I and II fibrils, promotes cellular adhesions, and thus increase mechanical 
forces within the tumour,  enhancing the mechanosensory conversion of fibroblasts 
to differentiated myofibroblasts421,422. Therefore inhibiting the cytostatic functions of 
TGFβ by RNAi may act a pro-tumorigenic and enhance the proliferation of both 
tumour cells and pro-tumorigenic stromal populations. To counter these 
pro-tumorigenic functions, and as stated previously (2.2.1.2 and 2.2.1.3) TGFβ acts 
to suppress of CD8+ T cell proliferation and acts to differentiae CD4+ T cells into 
immunosuppressive Tregs. It is therefore not unsurprising that the RNAi-mediated 
knockdown of TGFβ2 results in a split phenotype. However, considering that a 
reduction in Tregs was observed after TGFβ2 knockdown, and that neither SCC 
FAK-wt pLKO or SCC FAK-wt tumours are seen to regress, I concluded that TGFβ2 
was in fact crucial to the survival of SCC FAK-wt cell, despite the pleotropic 









Small molecule FAK kinase inhibitors are currently being tested in a number of 
clinical trails, and it will be imperative to identify their potential utility and prioritise 
combinations for further testing. FAK is upregulated in a number of cancers 
including breast423,424, pancreatic425, colorectal426, melanoma427 and squamous cell 
carcinoma264 where FAK inhibition has been shown to prevent cell motility, 
invasion, cancer progression and survival264. I wanted to investigate whether 
treatment with FAK kinase inhibitor VS-4718, which is currently in clinical 
development, recapitulated our previous results that highlighted the 




• To determine how treatment with a FAK inhibitor compares with our genetic 
model  
• To investigate the response to FAK inhibition in multiple syngeneic cancer 
models 









9.3.1 FAK kinase inhibitor VS-4718 induced SCC FAK-wt tumour 
regression associated with a reduction in intra-tumoural Tregs. 
 
To complement our data establishing a kinase-defective mutation in FAK (SCC 
FAK-kd) driving immune mediated tumour clearance, studies were preformed with 
FAK inhibitor VS-4718, which is currently in clinical development (Figure 9.1). 
FVB/N mice (n=5) were treated with 75mg/kg VS-4718 for 24 hours prior to 
bilateral subcutaneous injection of 1 x 106 SCC FAK-wt and SCC FAK-/- cells in 
both flanks, and twice daily thereafter. VS-4718 treated SCC FAK-wt and SCC 
FAK-/- tumours grew in manor akin to the SCC FAK-/- vehicle treated control 
(Figure 9.2); a significant delay in tumour growth was seen until day 10 (compared 
to SCC FAK-wt vehicle treated control; p value = <0.0001) where growth stalled, 
resulting in tumour clearance by day 24. Moreover, following cessation of VS-4718 
treatment, no tumour regrowth was observed (data not shown).  Although SCC FAK-
/- tumour growth and subsequent clearance was largely unaffected by VS-4718 
treatment, implying that anti-tumour effects of VS-4718 treatment were due to FAK 
inhibition in tumour cells, a growth delay was observed between both drug treated  



































* p< 0.025,  
two-tailed t-test 
Figure 9.1 Analysis of FAK pY397 phosphorylation in tumors following treatment 
with VS-4718. a Structure of VS-4718. Figure taken from Merlin Deficiency Predicts FAK 
Inhibitor Sensitivity: A Synthetic Lethal Relationship. Shapiro et al. Sci Transl Med, 2014. b 
Phosphorylation of FAK on Y397 was measured in protein lysates isolated from tumors following 
treatment with VS-4718 using ELISA. Tumors were removed within 30 minutes of treatment. N = 





tumours and the SCC FAK-/- vehicle controls at day 7 (Figure 9.2). Although this 
did not reach significance, it may be a consequence of targeting FAK in the stromal 
compartments prior to an established anti-tumour immune response, or alternatively 
it may represent a small off-target effect of VS-4718.    
To determine whether the mechanism of action of VS-4718 complimented our 
previous results, FVB/N mice were treated with 75mg/kg VS-4718 for 24 hours prior 
to bilateral subcutaneous injection of 1 x 106 SCC FAK-wt and SCC FAK-/- cells in 
both flanks, and twice daily thereafter. Tumours were removed, disaggregated and 
stained with Stain 2 (Table 6.3) and Stain 4 (Table 7.1). Samples were analysed as 
described in Figure 6.5 and Figure 7.1 respectively. Regression of VS-4718 treated 
tumours was not attributed to decreased cell viability, shown by Cell viability marker 
eFluor® 506 conjugated fixable viability dye (Figure 9.3). In both SCC FAK-wt 
tumours, treatment with VS-4718 increased cell viability, but this increase did not 
reach significance (p value = >0.05; Figure 9.3). 














SCC FAK-wt Vehicle Treated
SCC FAK-wt VS-4718 Treated
SCC FAK-/-  Vehicle Treated
SCC FAK-/- VS-4718 Treated
**** 
**** 
Figure 9.2 I The FAK kinase inhibitor VS-4718 leads clearance of SCC FAK-wt 
tumours. SCC FAK-wt and SCC FAK-/- tumour growth in animals treated with either vehicle 
or with 75 mg/kg VS-4718, BID by oral gavage. Treatment started 24 hours pre-tumour cell 
inoculation and continued for the duration of the experiment. 1 x 10
6
 SCC FAK-wt or SCC 
FAK-/- cells were implanted by bilateral subcutaneous injection into each flank of FVB/N mice. 
Tumour diameter was measured twice weekly and tumour volume was calculated using the 
formula 4/3πr
3
. Statistical significance determined by matched, two-way Anova with Tukey’s 
multiple comparisons Data are represented as mean ± s.e.m. P-value = Not significant >0.05,  




Regarding T-cells, a statistically significant increase in CD8+ T-cells was evident in 
SCC FAK-wt VS-4718-treated tumours (mean ± s.e.m. = FAK-wt vehicle, 3.94% ± 
0.20; FAK-wt VS-4718 = 7.32% ± 0.65; FAK-/- vehicle = 6.34% ± 0.56; FAK-/- 
VS-4718 = 3.20% ± 0.85; Figure 9.4a), but no change was observed in effector 
CD8+ T-cells (mean ± s.e.m. = FAK-wt vehicle = 43.25% ± 2.11; FAK-wt VS-4718 
= 44.93% ± 1.69; FAK-/- vehicle = 40.66% ± 5.04; FAK-/- VS-4718 = 40.68% ± 
3.19; Figure 9.4b). Decreases were observed in total CD4+ T-cells between SCC 
FAK-wt VS-4718 treated tumours (mean ± s.e.m. = FAK-wt vehicle, 15.47% ± 0.53; 
FAK-wt VS-4718, 23% ± 0.74; FAK-/- vehicle, 21.62% ± 2.07; FAK-/- VS-4718, 
21.87% ± 1.73; Figure 9.4c) and effector CD4+ T-cells (mean ± s.e.m. = FAK-wt 
vehicle = 52.37% ± 1.58; FAK-wt VS-4718 = 74.03% ± 1.46; FAK-/- vehicle= 
65.37% ± 4.53; FAK-/- VS-4718 = 61.54% ± 4.16; Figure 9.4d). 
Crucially, there was a significant reduction in CD4+CD25+FoxP3+ Treg cells in 
VS-4718-treated SCC FAK-wt tumours (mean ± s.e.m. = FAK-wt vehicle, 24.71% ± 
0.50; FAK-wt VS-4718, 13.64% ± 2.32; p value = <0.0001; Figure 9.5), which was 
similar to that observed in vehicle (mean ± s.e.m. = 14.17% ± 0.59; p value = 

























SCC FAK-wt SCC FAK-/-
n/s n/s 
Figure 9.3 I FAK kinase inhibitor VS-4718 did not effect tumour viability in early 
SCC FAK-wt and SCC FAK-/- tumours. FVB/N mice treated with either vehicle or with 75 
mg/kg VS-4718, B.I.D by oral gavage. Treatment started 24 hours before cell inoculation and 
continued for the duration of the experiment. 1.0 x 10
6
 SCC FAK-wt and SCC FAK-/- cells were 
implanted into both flanks of FVB/N mice by bilateral subcutaneous injection. Tumours were 
disaggregated at day 7, stained with fixable viability dye eFluor® 506 and analyzed by FACS (n = 
5). Statistical significance was determined by one-way Anova with Tukey’s multiple comparisons. 
Data are represented as mean ± s.e.m. P-value = Not significant >0.05,  * <0.05, ** <0.01, *** 




p value = <0.001; Figure 9.5).  Thus, VS-4718 promoted robust anti-tumour activity, 
by decreasing levels of intra-tumoural Tregs. 
I have shown that CD8+ T-cells were responsible for the immune mediated clearance 
of SCC FAK-/- tumours (Figure 4.9b). Thus, if the anti-tumour effects of VS-4718 
were indeed mediated through the immune response, I hypothesised that CD8+ 
T-cells were required for the clearance of SCC FAK-wt tumours treated with 
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Figure 9.4 I VS-4718 treatment modulates intra-tumoural T-cell populations. a 
FACS analysis of tumor infiltrating CD8
+
 T-cells from vehicle or VS-4718 treated tumours. b 















 (grey bar). c FACS analysis of tumor infiltrating CD4
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 SCC FAK-wt and SCC FAK-/- cells were implanted into both flanks of FVB/N mice 
by bilateral subcutaneous injection. Tumours were disaggregated at day 7, and stained with 
Stain 2 (Table 5.3). FACS analysis was gated as described in Figure 5.5. Data are represented 





VS-4718 and CD8 depleting antibodies, as described in Figure 9.6. Animals treated 
with CD8 depleting antibodies or isotype control in combination with vehicle grew 
as expected; SCC FAK-wt CD8+ depletion with vehicle treatment (Figure 9.7 solid 
red line) showed a significant increase in tumour growth compared to the control 
treated tumours (SCC FAK-wt isotype and vehicle treated; Figure 9.7 solid black 
line).  In mice treated with VS-4718 in combination with isotype control, SCC 
FAK-wt tumours were cleared by day 21 (Figure 9.7 dashed black line), as shown 
previously with VS-4718 treatment alone (Figure 9.2). However in animals treated 
with both VS-4718 and CD8 depleting antibody (Figure 9.7 dashed red line), 
tumours grew in a manner similar to VS-4718 in combination with isotype control 
until day 10, at which point tumour growth significantly increased until day 21 at 
which point animals had to sacrificed due to signs of ulceration. The final tumour 
volume reached a similar size to SCC FAK-wt CD8+ depletion with vehicle treated 
tumours.  I concluded that VS-4718 required CD8+ T-cells to clear SCC FAK-wt 
tumours.  
To determine if VS-4718 showed similar anti-tumour effects in a clinically relevant 






















SCC FAK-wt SCC FAK-/-
**** *** ***
Figure 9.5 I VS-4718 treatment reduces reduces Tregs in SCC FAK-wt tumours. 
FACS analysis of intra-tumoural Tregs expressed as a percentage of tumour infiltrating CD4
+
 T-
cells. 1.0 x 10
6
 SCC FAK-wt and SCC FAK-/- cells were implanted into both flanks of FVB/N 
mice by bilateral subcutaneous injection. Tumours were disaggregated at day 7, and stained with 
Stain 4 (Table 7.1). FACS analysis was gated as described in Figure 7.6. Statistical significance 
was determined by one-way Anova with Tukey’s multiple comparisons. Data are represented as 




of FVB/N (n = 5) by bilateral subcutaneous injection. At day 5, mice were treated 
with 75mg/kg of VS-4718 or vehicle twice daily, when a palpable tumour of 
approximately 50 mm3 was present (Figure 9.8). SCC FAK-wt tumours treated with 
VS-4718 grew until day 10, at which point tumour growth slowed and subsequent 
complete regression was observed by day 21. Vehicle treated SCC FAK-wt tumours 
grew as expected and SCC FAK-/- tumour growth remained unaffected by VS-4718 
treatment. Thus, VS-4718 appeared to have the same anti-tumour activity against 
pre-established FAK expressing tumours as shown with mice pre-treated with VS-
4718 prior to tumour cell implantation. 
From these data, I concluded that the effects of VS-4718 treatment correlated with 
modulation of FAK expression and FAK kinase activity in tumour cells alone; both 
VS-4718 treatment and SCC FAK-kd tumours underwent immune-mediated 
regression by CD8+ T-cells, which was associated with a decrease in intra-tumoural 
Drug or Vehicle 
only control group 
SC injection 
of SCCs 
monitor tumour volume 
Day 1 Day 2 Day 3 
2-day rest 
period 
150 μg IP of antibody 
Day 6 
monitor tumour volume 
Every 3 Days 
150 μg IP of antibody 
Day 5 
Day 5 
VS-4718 or  
Vehicle treatment  
Day 6 
2 x Daily VS-4718 or 
Vehicle Treatment 
2 x Daily VS-4718 or 
Vehicle Treatment 
Figure 9.6 | Schematic describing treatment regime for combined antibody-
mediated  T-cell depletion and VS-4718 treatment. FVB/N mice were treated daily for 3 
consecutive days with 150 μg of CD8
+
 depleting antibody or isotype control antibody by IP injection. 
Antibody treatment then ceased for 2 days. VS-4718 treatment began 24 hours before tumour cell 
inoculation. Mice were treated with 75 mg/kg VS-4718 or vehicle control BID by oral gavage. 1 x 
10
6
 SCC FAK-wt or SCC FAK-/- cells were implanted by bilateral subcutaneous injection into each 





T-cell depletion was maintained by 150 μg IP injection of antibody every 3 days, 
and VS-4718 BID treatment continued until the end of the experiment. SC = bilateral subcutaneous 





Tregs. Thus the anti-tumour effects of VS-4718 are likely due to the tumour-specific 
inhibition of FAK. 
  


















SCC FAK-wt CD8+ Vehicle
SCC FAK-wt Isotype Ctrl + Vehicle
SCC FAK-wt Isotype Ctrl +VS-4718
SCC FAK-wt CD8+ VS-4718
Figure 9.7 I VS-4718 induced SCC FAK-wt regression is dependent on CD8
+
 T-
cells. Tumour growth of SCC FAK-wt  treated with either CD8 depleting antibodies or isotype 
control, in combination with VS-4718 or vehicle treatment. FVB/N animals were treated as 
described in Figure 9.6 (n = 5). Tumour diameter was measured twice weekly and tumour 
volume calculated using the formula 4/3πr
3
. Data are represented as mean ± s.e.m. 
  














SCC FAK-wt Vehicle Treated
SCC FAK-/-  Vehicle Treated
SCC FAK-wt VS-4718 Treated











Figure 9.8 I VS-4718 treatment results in regression of established SCC FAK-wt 
tumours. SCC FAK-wt and SCC FAK-/- tumour growth in FVB/N mice (n = 5) treated with either 
vehicle or VS-4718. Treatment started 5 days post-inoculation with 1 x 10
6
 tumour cells and 
continued for the duration of the experiment. Tumour diameter was measured twice weekly and 
tumour volume calculated using the formula 4/3πr
3
. Data are represented as mean ± s.e.m. 
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9.3.2 VS-4718 treatment of a panel of syngeneic mouse models of 
cancer 
 
Thus far, the work described has focussed on a single model system. Therefore, it 
was important to investigate the broad relevance of these findings across multiple 
syngeneic models of cancer harbouring different genetic driver mutations, different 
tissues of origin, and different mouse strains of origin. Therefore, so I set out to 
investigate the effects of VS-4718 on a number of syngeneic mouse models of 
cancer. A panel of different syngeneic cancer models were selected covering a 
number of different host-strains, cancer types, genetic drivers and pathological 
grades (Table 9.1; Mel31428, Panc043, Panc047 and Panc117 were generously 
donated by the Samson Lab, The Beatson Institute for Cancer Research, Glasgow; 
Met01 were generously donated by Bin-Zhi Qian, Centre for Reproductive Health, 
University of Edinburgh, Edinburgh). These included breast, skin and pancreatic 
cancer models, from BALB/c, FVB/N and c57BL/6 mouse strains, and a number of 
genetic drivers including MMTV-PyMT (mouse mammary tumour virus LTR driven 
polyoma middle T antigen), CDK4 and KPC (KrasLSL.G12D/+; p53R172H/+; 
PdxCretg/+). I included the parental heterogeneous SCC population (SCC 7.1) from 
which our SCC model was derived, and an additional independently derived 
heterogenous SCC cell model, SCC 6.2 (Table 9.1). For each model, mice (n = 3) 
were treated with 75 mg/kg VS-4718 for 24 hours prior to bilateral subcutaneous 
injection of 1 x 106 cells in both flanks, and twice daily thereafter. Tumour diameter 
was measured twice weekly and tumour volume calculated using the formula 4/3πr3.   
All tumour models were observed to respond to VS-4718, albeit to varying extents. 
Models were grouped into those in which a significant growth delay was observed 
between VS-4718 treated and vehicle treated controls (moderate response; Figure 
9.9) and those in which VS-4718 resulted in disease stabilization or tumour 





















































































































































































































































































































































































































































































































































































Five models showed a moderate response to VS-4718 treatment (Figure 9.9a-e). 
Panc041, Panc043, and Panc117 tumours grew until day 7, where growth stalled, 
resulting in a statistically significant growth delay by day 14 (p value = <0.0001;  
Figure 9.9a-c). Tumours continued to grow until day 17, at which point animals had 
to be sacrificed due to the onset of ulceration.  Control-treated animals showed signs 
of ulceration by day 14, and had to be sacrificed in accordance with home office 
guidelines.  VS-4718 treated Mel31 tumour growth stalled at day 7, resulting in a 
significant growth delay by day 14 (p value = <0.001; Figure 9.9d). Both VS-4718 
and control treated tumours continued to grow until day 17, and a significant growth 
delay observed in VS-4718 treated tumours (p value = <0.0001), but by day 17 
tumours showed signs of ulceration and animals were sacrificed. Finally, 4T1 tumour 
growth was complicated by the highly metastatic nature of this model.  VS-4718 
treated 4T1 tumours showed a significant growth delay by day 10 compared to 
vehicle treated control (p value = <0.001; Figure 9.9e), but animals became 
increasing ill and showed signs of advanced metastatic disease by days 14 and 10 
respectively, and therefore mice had to be sacrificed in accordance with home-office 
guidelines. Following sacrifice, multi-organ metastasis was observed in both cohorts 
of mice. 
SCC 7.1 and Met01 tumours responded better to VS-4718 treatment (Figure 9.10). 
VS-4718 treated SCC 7.1 tumours grew until day 7, at which point tumour growth 
stalled and regressed until day 24 (Figure 9.10a). At this point some SCC 7.1 
tumours appeared to rebound while still receiving VS-4718, and grew rapidly 
thereafter even in the presence of VS-4718. Analysis of individual tumour growth 
determined that most tumours regressed by day 18, but two tumours (from different 
mice) escaped tumour regression at day 24 (Figure 9.10b). Tumour growth increased 
in both tumours until day 38, at which point animals were sacrificed and tumours 
were removed, so that cell lines could be derived from them (Figure 9.10b). VS-
4718 treated Met01 tumour growth stalled at day 7, after which tumour growth 
stabilized (Figure 9.10c). Tumour growth did not regress after 28 days but continued 


















































































































Figure 9.9 I Syngeneic mouse models with moderate response to VS-4718. 1 x 106 
cells were implanted into both flanks of mice (n = 5) by bilateral subcutaneous injection. a 
Panc041, b Panc047, c Panc117 and d Mel31 cells were implanted into c57Bl/6 mice. e SCC 
6.2 cells were implanted into FVB/N mice and f 4t1 cells were implanted in BALB/c mice (Table 
9.1). Mice were treated with either vehicle or with 75 mg/kg VS-4718, BID by oral gavage. 
Treatment started 24 hours before cell inoculation and continued for the duration of the 
experiment. Tumour diameter was measured twice weekly and tumour volume calculated using 
the formula 4/3πr
3
. Statistical significance was determined by matched, two-way Anova with 
Tukey’s multiple. Data are represented as mean ± s.e.m. P-value = Not significant >0.05,  * 
<0.05, ** <0.01, *** <0.001, **** <0.0001. 
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A number of preliminary conclusions can be drawn from these data. Firstly, all 
syngeneic cell models responded to VS-4718 treatment, albeit to different extents. 
Despite this variation, all responses were observed to result in a significant growth 
delay. Secondly, the point at which VS-4781 treated tumours deviated from their 
controls, was consistently 7 days post-implantation, correlating with the average time 
thought to be required to mount an adaptive immune response (2.1). And finally, 
with regards to the parental SCC 7.1 model, although this most tumours regressed in 
this model, this model also contained cells with the capacity to escape clearance 
suggesting potential mechanisms of resistance. These observations led us to consider 
the possibility that additional mechanisms of immune evasion, independent of those 
regulated by FAK, may influence tumour response to FAK inhibitor monotherapy. 
Such potential mechanisms include tumour cell surface expression of co-inhibitory 




































































Figure 9.10 I SCC 7.1 and Met01 models exhibit a good response to VS-4718. a 
Average Tumour growth of SCC 7.1 cells and b the growth of each individual tumour. c Tumour 
growth of Met01 cells. 1 x 10
6
 cells were implanted into both flanks of FVB/N mice (n = 5) by 
bilateral subcutaneous injection (Table 9.1). Mice were treated with either vehicle or with 75 
mg/kg VS-4718, BID by oral gavage. Treatment started 24 hours before cell inoculation and 
continued for the duration of the experiment. Tumour diameter was measured twice weekly and 
tumour volume calculated using the formula 4/3πr
3
. Statistical significance was determined by 
matched, two-way Anova with Tukey’s multiple comparisons. Data are represented as mean ± 




9.3.3 PD-L1/PD-L2 and CD80 expression correlated with response to 
VS-4718 treatment.  
 
Tumour cells may regulate the adaptive immune response through a number of 
mechanisms. These include tumour cell expression of PD-1 ligands PDL-1 and 
PD-L2, which after engagement with T-cell expressed PD-1, induce T-cell anergy 
and exhaustion (2.4). A second mechanism is through the upregulation of co-
stimulatory molecules such as CD80, which can induce T-cell activation and lead to 
increased Tregs or T-cell anergy exhaustion (2.4). Therefore, I set out to determine 
whether any of our syngeneic tumour models expressed PD-L1, PD-L2 or CD80, and 
whether levels of expression correlated with response to VS-4718. 1 x 106 
cultered-4T1, Met01, Mel31, Panc041, Panc043, Panc117, SCC 6.1, SCC FAK-wt 
and SCC 7.1 cells were stained with PD-L1, PD-L2 and CD80 fluorescently labelled 
antibodies and analysed by FACS (Figure 9.11).  4T1, Met01, Mel31, Panc041, 
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Figure 9.11 I Levels of PD-L1, PD-L2 and CD80 expression on a panel of
syngeneic mouse tumour cell lines. FACS analysis of a panel of cell lines from
syngeneic models of breast cancer, melanoma, pancreatic cancer and SCC (see Table 9.1).
Each FACS blot representative of 5 x 105 cells. Grey populations = negative
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SCC 7.1 did not express PD-L1 or PD-L2 (Figure 9.11a). 4T1, Met01, SCC FAK-wt 
and SCC 7.1 were found to express CD80, whereas Mel31, Panc041, Panc043, 
Panc117 and SCC 6.1 did not (Figure 9.11b).   
Both SCC FAK-wt and SCC 7.1 cells showed the greatest response to VS-4718 
treatment, and were the only models to show complete tumour regression following 
treatment. Both SCC FAK-wt and SCC 7.1 cells expressed CD80 and did not express 
PD-L1 and PD-L2. Met01 tumours showed a good response to VS-4718 treatment, 
and were found to express CD80. Met01 also expressed PD-L1 and PD-L2, which 
may explain why tumour regression was not seen in this model. Mel31, Panc041, 
Panc043, Panc117 and SCC 6.1 all responded modestly to VS-4718 treatment, and 
were all negative for CD80 and positive for PD-L1 and PD-L2. This small dataset 
highlighted a potential link between CD80, PD-L1 and PD-L2 expression and 
response to VS-4718. However, a much larger data set is required to make any 




Here I have shown that the small molecule FAK kinase inhibitor VS-4718 shows 
preclinical potential as an anti-cancer immunotherapy agent. VS-4718 treatment of 
SCC FAK-wt tumours resulted in tumour clearance associated with a reduction in 
intra-tumoural Tregs. Across a panel of syngeneic tumour models VS-4718 treatment 
resulted in a significant growth delay in all cases, with a tentative correlation 
between increased CD80 expression and response to monotherapy. Further work is 
required to determine whether immune-modulation is a general phenomenon in these 
models when treated with a FAK kinase inhibitor, or when FAK expression in cancer 
cells is down regulated, especially in models that continue to grow in the presence of 
FAK inhibitor treatment.  These models may represent good candidates for testing 
combination therapies, such anti-PD-1 or anti-CTLA-4, with the aim of unlocking 
the potential anti-tumour activity of FAK kinase inhibitors. 
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VS-4718 was administered twice-daily (BID) by oral gavage as per the protocol 
submitted by the manufacturer, Verastem. Although details regarding the work 
undertaken to set up the clinical protocol for VS-4718 are protected under licence, 
Phase I clinical trials with VS-4718 are currently being undertaken 
(ClinicalTrials.gov Identifier: NCT02651727), with the clinical protocol for these 
stating oral administration of VS-4718 BID. The timings of drug dosage are typically 
determined by the pharmacodynamics of the therapeutic in question, and consider the 
biological half-life of the drug (t1/2). t1/2 refers to the time taken for a substance to 
lose half its its pharmacologic and biologic activity, typically associated with the 
renal clearance of the drug, and may be measured as the time taken for blood plasma 
concentrations of a therapeutic to halve if biological activity is not possible to 
determine. Substances with shorter half-lives require more frequent dosage, or are 
administered at an increased dosage if well tolerated. Although the BID dosing 
schedule in both humans and mice alludes to the short half-life of VS-4718 in vivo, 
this raises the question as to the rationale behind the differences in administration 
route between clinical patients and mouse models.  
Enteral administration protocols such as oral gavage, therapeutics admixed into food 
stuffs or water, or by nasogastric gavage have the benefits of being economical, 
convenient, reliable and relatively safe429,430 compared to other routes such as 
intraperitoneal (IP)431 or intravenous (IV)432 administration. Furthermore, the Home 
Office procedural standards surrounding experiments with animals and their welfare, 
regards the severity of oral gavage to be less than other administration routes due to 
animals becoming accustomed to the procedure over time, not seen in IP or IV 
administrations433,434. Although admixing drugs into food stuffs or water is by far the 
least invasive/stressful enteral admiration route435, it suffers from the lack of accurate 
and consistent dosage. Cohorts of caged mice will eat varying amounts of food, 
requiring food to be weight before and after administrations, but also mice within 
each cohort will ingest significantly different levels of food436. This depends of 
factors such as social and physical dominance within caged cohorts, and with effects 
on appetite by therapeutic agents or by the onset/implantation of tumours, factors that 
will  will vary between each treated mouse and across different genetic 
backgrounds429. Therefore, even though the voluntary oral consumption of VS-4718 
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in mice would reflect more accurately the clinical protocol in humans, oral gavage 
allows the drug to be administered with the same dosing schedule as with humans, 
but in a more reliable, effective and controlled manner. 
Oral administration in this way also allows for the evaluation of possible 
pharmacologically inactivation following gastric ingestion of VS-4718. Although in 
majority of cases, metabolism of therapeutics occurs in the liver by oxidation, 
reduction, hydrolysis, hydration, conjugation, condensation, or isomerization, in 
some cases metabolism/inactivation can occur in the stomach, rendering them 
inert437. In consideration of this and other factors involved in pharmacodynamics, 
and to validate the effective delivery of VS-4718 to the tumour, collaborators at 
Verastem undertook an in vivo FAK pY397 Eliza (Figure 9.1). Crucially, the 
inhibition of FAK pY397 as shown here, indicates that the route of administration, 
dosing schedule and pharmacodynamics of VS-4781 in our mouse studies results in 
effective inhibition of FAK kinase activity.  
The mouse models of cancer used in this chapter only include subcutaneously 
implanted models. This raises the question as to whether a more diverse range of 
mouse models should have been used to address the clinical potential of FAK 
activity inhibition with VS-4718. Transgenic mouse model allow tumours to develop 
in a more clinically relevant setting, but which take significantly longer than 
implantation models. The extended time frame however, subjects the tumour to a 
number of significant developmental changes within the tumour itself and within the 
tumour microenvironment, the most pertinent in this case being the development of 
T-cell exhaustion and anergy143,144. This decrease in the effective cytotoxic activity 
of CD8+ T-cells could reduce the clinical efficacy of VS-4718, but invites the 
possibility of combinations of VS-4718 and checkpoint inhibitors targeting PD-1 
such as nivolumab or pembrolizumab, discussed in further detail below (10). 
Therefor the treatment of transgenic models with VS-4718 may give further insight 
into the potentially clinical efficacy of FAK kinase inhibition. 
As metastatic disease is the primary cause of death in cancer patients, and as FAK 
has been a target previously for the reduction of metastatic progression, it may been 
appropriate to determine the roles of FAK within a metastatic mouse model. Previous 
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work focused on the roles of FAK in cell migration and adhesion collectively 
concluded that FAK inhibition reduces metastatic development and 
progression4,265,302,438-447. None of these studies consider changes in the immune 
compartment to contribute to metastasis but focus on FAK as an adhesion molecule 
and regulator of cell migration. The work presented here regarding FAK kinase 
activity modulating the tumour microenvironment, highlights the need to re-address 
the role of FAK in the metastatic cascade as a number of immune compartments 
modulated by FAK activity contribute to metastatic progression31,54,55,73. Use of 
metastatic mouse models will help not only to address these points but to also in part, 
help to consider the multifaceted potential activity of FAK inhibition in clinical 
setting, to not only modulate the tumour immune response but to also inhibit 
metastasis.  
CD80 is a high affinity ligand for the receptor CTLA-4 which is constitutively 
expressed on Tregs, and ligand-receptor interaction has been shown to enhance Treg 
suppressive capacity448. Profiling of CD80 expression on the surface of our 
syngeneic panel of cell lines revealed high surface expression on the SCC FAK-wt, 
SCC 7.1, Met01, and 4T1 cell lines.  Thus, three of the four models that respond 
robustly to VS-4718 treatment express high surface levels of CD80.  While small 
sample numbers preclude the conclusion that high CD80 surface expression may 
represent a biomarker for sensitivity to FAK kinase inhibitor monotherapy, it is 
tempting to speculate that CD80 expression may drive increased Treg dependence 
rendering these tumours more susceptible to FAK inhibition. 
One potential issue with the DMBA/TPA chemically induced model was with the 
restriction of neoantigens by the isolation of SCC FAK-/- clone by single cell cloning 
(see 5.4). This would have generated an atypically immunogenic SCC FAK-wt cell 
line, which in turn would increase the immunomodulation, and consequently the 
efficacy of VS-4718 treatment. The good response observed with the treatment of 
SCC 7.1 with VS-4718 indicates that the clone selected is indicative of the 
heterogeneous population. Regarding the escape of a small number of tumours, one 
potential hypothesis is that these tumours are capable of evading the immune 
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modulation of VS-4718 treatment, and this could present new information regarding 






10 Discussion and Concluding Remarks 
 
Using an SCC tumour cell model in which FAK has been genetically deleted 
(SCC FAK-/-), I have shown that loss of FAK results in complete SCC tumour 
regression when grown in immune-competent mice (the FVB/N strain from which 
the cell model was derived). Re-expression of a kinase-defective mutant into 
SCC FAK-/- cells was not sufficient to rescue tumour growth, implying that 
FAK-dependent immune escape required FAK catalytic activity. Treatment with the 
FAK kinase inhibitor VS-4718, which is currently in Phase 1 clinical trials, resulted 
in complete regression of SCC FAK-wt tumours irrespective of whether treatment 
was initiated prior to tumour cell inoculation, or after tumours had reached 
approximately 50 mm3. CD8+ T-cell depletion was sufficient to rescue both 
SCC FAK-/- tumour growth, and VS-4718 mediated SCC FAK-wt clearance. Thus, 
for the first time I show that loss of FAK expression or catalytic activity is sufficient 
to release the anti-tumour effects of antigen-primed CD8+ T-cells and drive tumour 
regression. This response is suppressed in SCC FAK-wt tumours as a consequence of 
FAK-dependent recruitment of immuno-suppressive Tregs into the tumour niche, the 
requirement for these cells being confirmed by both anti-CD25+ and anti-CD4+ T-
cell depletion. Mechanistically, we identify a new role for FAK in the transcriptional 
regulation of chemokines and cytokines in SCC cells, and show that FAK-driven 
expression of both CCL5 and TGFβ2 is required for elevated intra-tumoural Treg 
levels and sustained SCC FAK-wt tumour growth. Furthermore, analysis of 
chemokine receptor expression on intra-tumoural Tregs revealed a paracrine 
signalling axis between FAK-expressing SCC cells and intra-tumoural Tregs based 
on chemokine ligand-receptor interaction, that likely plays a role in driving Treg 
recruitment and retention in the tumour bed. Our data implies that FAK may 
contribute to the development of malignancy in vivo by increasing the recruitment 
and retention of intra-tumoural Tregs, leading to a change in the balance between 
CD8+ T-cells and Tregs resulting in tumour tolerance. This proposed mechanism is 
summarized in Figure 9.1. 
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The secretion of chemokines and cytokines into the tumour environment represents 
an important mode of communication between cell types, and drives recruitment of 
immune cells into tumours19,44,52. Identification that FAK expression results in the 
transcriptional upregulation of a number of these molecules, suggests that FAK may 
play a role in governing this type of communication between tumour cells and 
tumour infiltrating immune cells. Indeed our observation that both FAK-dependent 
expression of CCL5 and TGFβ2 was required for elevated intra-tumoural Tregs, and 
that CCL5 represents part of a paracrine signalling axis between tumour cells and 
Tregs, supports this notion and implies a critical role for FAK-dependent chemokine 
regulation in the development and progression of SCC tumours. In our model, a clear 
outcome of this signalling was to alter the CD8+ T-cell to Treg ratio within the 
tumour, a parameter that is a prognostic indicator in ovarian449, breast450, 
pancreatic182,451, colorectal452, oesophageal and gastric cancers453. Furthermore, 
inhibition of FAK kinase activity through expression of a kinase-deficient FAK 
protein (FAK-kd) resulted in reduced CCL5 and TGFβ2 expression that was 
associated with a reduction in Tregs and SCC tumour regression. Similar 
observations were made following VS-4718 treatment. Thus, FAK regulates the 
tumour immune environment through promoting expression of chemokines and 
cytokines that favour tumour tolerance. FAK has been reported to regulate secreted 
factors in other cell models, including IL-6454, VEGF455 and TGFβ398, suggesting that 
our observations are not unique to our tumour cell model.  
The SCC cell model used in this study was derived using the DMBA / TPA model of 
skin chemical carcinogenesis, and FAK expression has been identified to increase 
with malignant progression in this model.  Furthermore, deletion of FAK in this 
model prevents benign papilloma formation and progression to malignant 
carcinoma456, implying that FAK is required to support tumour development. In 
support of our findings, genetic ablation of CD4+ T-cells has been shown to reduce 
the number of tumours formed after DMBA/TPA treatment, while ablation of CD8+ 
T-cells resulted in enhanced tumour formation457. Thus, it is possible that at least one 
outcome of elevated FAK expression in this model is to modulate the tumour 
immune environment and promote tumour growth and progression. FAK has also 
been reported to be required for tumour development and progression in a number of 
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other pre-clinical mouse models of cancer, including breast, prostate, and colon 
cancer279,458-462 and it will be interesting to identify whether targeting FAK in these 
models, or transplantable cell lines derived from similar models, also results in 
underlying immune-modulation.  
I have demonstrated that treatment of a number of syngeneic mouse models covering 
breast, pancreatic, melanoma, and skin cancer with VS-4718 either results in a 
growth delay, disease stabilisation, or disease regression. The effects of FAK 
inhibition in these models does not become apparent until 7 days post tumour cell 
implantation and treatment initiation, a timeline that would correlate with the 
development of an adaptive immune response. It is perhaps not surprising that the 
SCC 7.1 tumours exhibited a similar sensitivity to VS-4718 when compared with the 
SCC FAK-wt tumours, given that the SCC FAK-wt cells are essentially a subclone 
from this parental heterogeneous population. However, the rebound of some SCC 7.1 
tumours following an extended period of disease stabilisation while on VS-4718 was 
surprising, and suggests either the development of intrinsic tumour cell resistance or 
the emergence of environmental changes that negate the anti-tumour properties of 
VS-4718 treatment. This characteristic was not observed when using the SCC FAK-
wt tumours. Further investigation is warranted in order to understand the mechanistic 
basis of this resistance.  
Comparison of VS-4718 sensitivity between the SCC 7.1 and SCC 6.2 tumours also 
provides further interesting insights. Both cell types were derived from late-stage 
carcinomas albeit from different mice. Both have a mesenchymal morphology, and 
both were derived using DMBA/TPA treatment and thus likely have a similar 
mutagenic burden. Therefore it seems reasonable to hypothesise that high mutagenic 
burden as a consequence of exposure to carcinogens does not dictate sensitivity to 
VS-4718. While it is difficult to stratify such conclusions from small sample 
numbers, this theory is supported by our observations when using the Met01 model. 
This transplantable cell line was derived from the MMTV-PyMT model of breast 
cancer, and when treated with VS-4718 shows durable disease stabilization. This 
oncogene driven model is likely to have a very low mutagenic burden, yet responds 
robustly to VS-4718 treatment. Interestingly, studies by the Rudensky Lab have 
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shown that in the MMTV-PyMT FoxP3DTR knockin mouse, Treg ablation following 
treatment with diphtheria toxin (DT) results in tumour regression and a reduction in 
metastatic progression393. Combination of Treg ablation with the immune checkpoint 
inhibitors anti-PD-1 and anti-CTLA-4 did not increase therapeutic efficacy over that 
of Treg ablation alone393, suggesting that this model is highly dependent on the 
immuno-suppressive capabilities of Tregs to support tumour growth and progression. 
These observations parallel with those observed using our SCC FAK-wt tumour 
model, and suggest that the observed Met01 response to VS-4718 may be due to 
FAK-dependent regulation of intra-tumoural Treg levels. Further work will be 
required to determine if this is indeed the case.  
A number of models tested exhibited a growth delay (but not disease stabilisation or 
regression) when treated with VS-4718, suggesting that other mechanisms of 
immune-suppression, independent of FAK, are likely involved in supporting tumour 
growth. For example, the three cell models derived form the KPC Kras P53 model of 
pancreatic cancer463, namely the Panc043, Panc047, and Panc117, all showed 
sensitivity to VS-4718 that manifested at day 7 but was overcome only a few days 
later. Profiling of surface ligand expression on these cells revealed that all expressed 
high levels of PD-L1 and PD-L2, but little to no CD80. Thus, it is tempting to 
speculate that engagement of the PD-1 pathway may circumvent the anti-tumour 
activity of VS-4718 in these models by helping to overcome the impact of 
modulating intra-tumoural Tregs, and that combination of these two therapies may 
prove efficacious in this instance. In support of this hypothesis targeting intra-
tumoural Tregs with a p110δ inhibitor was reported to result in a small survival 
benefit in mice from the KPC pancreatic model464. However, targeting Tregs alone 
was not sufficient to gain long-term tumour control and drive tumour regression. 
Similar observations have been reported for strategies targeting the CXCR4 axis463, 
and tumour infiltrating macrophages87. However, when these strategies were 
combined with anti-PD-1 treatment, tumour control and regression was observed87. 
FAK kinase inhibitors have been reported to block CAF recruitment into tumours by 
virtue of FAK’s role in regulating their migration302, with similar observations 
reported for macrophage recruitment following FAK inhibitor treatment. Thus, the 
immuno-modulatory outcome of treatment with FAK kinase inhibitors may extend 
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beyond that identified here to encompass multiple immune and stromal cell types 
that contribute to promoting tumour growth through suppressing CD8+ T-cell 
activity. Therefore FAK inhibitors may represent a therapeutic strategy for broad 
targeting of tumour promoting immune and stromal cell types, providing rational for 
their testing in combination with immune-checkpoint inhibitors including anti-PD1. 
Treatment of human tumours with immune-checkpoint therapies has proven highly 
efficacious in some tumour types. For example, a clinical study combining agents 
targeting cytotoxic-T-Lymphocyte-associated Antigen-4 (CTLA-4), which is thought 
to influence Treg function104,169,170,465-467, and Programmed Death Receptor-1 (PD-1), 
which blocks signals that inhibit T-cell function147,468,469, has reported impressive 
responses in patients with advanced melanoma, with 53% of patients having an 
objective response resulting in greater than 80% reduction in tumour 
burden232,470(2.3). However, this combination of checkpoint blockade antibodies was 
also reported to elicit substantial side-effects (clinical grade 3-4) in greater than 50% 
of patients, highlighting the need to find alternative combinations with improved 
tolerability profiles (2.3). A number of FAK inhibitors are in early Phase I / II 
clinical trials, and initial reports on one of these, GSK2256098 (Clinical trial 
identifier: NCT01938443), suggests a favorable tolerability profile (clinical toxicity 
grades 1-2) with some activity as a monotherapy471. No autoimmune side effects 
were reported. Alternative methods for targeting immune populations, including anti-
CD25 monoclonal antibodies472, and anti-CSF1-receptor antagonists473, are in 
clinical trials. However, this approach of targeting immune populations directly is 
hampered by immune-based toxicity due to the homeostatic roles of their target 
populations148,149,469,470,474,475. It is interesting to consider why FAK kinase inhibitors 
do not appear to exhibit immune-related toxicity given the role I have established for 
FAK in controlling Treg levels. It is possible that the role I have identified is limited 
to a minority of tumour models, or alternatively that the immune-modulatory 
function of FAK is specific to malignant cancer cells. Since finishing the work for 
my PhD, my colleagues in the Frame Laboratory have identified that the immuno-
modulatory function of FAK in the SCC tumour model is dependent of FAK nuclear 
translocation, and that this only occurs in malignant cancer cells. These recent 
findings support the conclusion that FAKs immuno-modulatory function is specific 
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to cancer cells, and that in normal cells FAK does not translocate to the nucleus and 
excerpt regulatory control over chemokine and cytokine expression. Such 
observations may underlie the lack of autoimmune side effects in clinic when 
treating with FAK kinase inhibitors. 
Taken collectively our data suggest that targeting the pleiotropic cellular functions of 
FAK, both nuclear and adhesion-related, using small molecule inhibitors may have a 
broad impact on the immunosuppressive tumour microenvironment, differentiating 
these agents from many of the therapeutic approaches currently being tested in the 
clinic which target single immune cell populations. Our findings provide good 
rationale for pre-clinical and clinical testing of FAK kinase inhibitors alongside 
agents that stimulate CD8+ T-cell activity, such as the checkpoint blockade therapies 
that target CTLA-4 and PD-1104, and have prompted a clinical trial combining 
VS-6063 (A FAK kinase inhibitor closely related to VS-4718 which has shown 





11 Future Work 
 
Future work will focus on investigating the immuno-modulatory effects of FAK in 
multiple models of cancer, including those in Table 9.1. This will include both 
inhibiting FAK kinase activity (FAKi) with VS-4718 and the genetic deletion of 
FAK, using clustered regularly interspaced short palindromic repeats (CRISPR)/ Cas 
technology. This will include phenotyping T-cells, Tregs, macrophages, MDSCs and 
CAFs using FACS analysis. The key objectives here will be to identify the 
underlying immune changes that result from FAK deletion and VS-4718 treatment.   
Furthermore, SCC cells will be derived from c57BL/6 K14CreER FAKflox/flox mice 
by the two-stage DMBA/TPA chemical carcinogenesis protocol, and this work is 
currently underway. By re-deriving the SCC model onto a c58BL/6 background, will 
allow access to a number of c57BL/6 transgenic mouse models that will help 
investigate the immuno-modulatory roles of FAK. These include mice harboring 
human diphtheria toxin receptor (DTR) expressed under a variety of leukocytes-
specific promoters, in which the chronic administration of diphtheria toxin (DT) 
leads to conditional, targeted cell ablation. The aim will be to use the DTR/DT 
system to deplete immune populations such as Tregs with greater specificity than 
using antibody-mediated depletion. 
These results will help guide further work into the translational aspects of the 
FAKi/anti-PD-1 Combinations Alliance clinical trial, which is proposed to start 
within the next year in Edinburgh and four other centers across the UK. Together 
with Dr Stefan Symeonides (Edinburgh Cancer Center), further work will investigate 
pre-clinical dosing and scheduling studies in order to interrogate and optimize the 
commination of VS-4718 and anti-PD-1 inhibitors. Other inhibitors of co-inhibitory 
receptors, such as anti-CTLA4 treatment in multiple syngeneic mouse models of 
cancer will also be assessed. Utilization of c57BL/6 PD-1 knockout mice for work 
involving pancreatic and melanoma models initially (generated on c57BL/6 
backgrounds) and further work will focus on the re-derived c57BL/6 SCC model. 
Associated with this, markers of T-cell exhaustion will be investigated across our 
panel of cancer models to determine to what extent CD8+ T-cells are exhausted, how 
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this contributes to tumour tolerance and investigate whether FAKi modulates these 
factors. This includes further characterization of exhausted T-cells identified in 
SCC FAK-wt tumours. This will be done using FACS analysis of PD-1, LAG-3 and 
Tim-3 alongside secreted chemokine and cytokine arrays and functional studies.   
One potential caveat with the proposal for the clinical trial is how will the success of 
FAKi/anti-PD-1 therapy in modulating immune populations be determined. Access 
to tissue will be very limited and will be either frozen or embedded in paraffin blocks 
for histology, making FACS analysis not plausible. By identifying and characterizing 
the cell populations most frequently altered by FAKi, these may in turn, be used to 
predict rational choices as biomarkers of response. Histology could be used as a 
clinical read out, specifically fluorescent histology using fluorophore-conjugated 
antibodies that has been optimized in the lab previously, which will allow us to 
identify a number of cell populations and their activation statuses simultaneously.  
Collaborators on this trial (Prof. Christian Ottensmeier, Faculty of Medicine, 
University of Southampton) will be using RNA sequencing to determine and 
quantify leukocyte-specific gene signatures present within tissue samples, and I hope 
that our histology approach will complement these analyses. 
VS-4718 treatment of the cell models in Table 9.1 raised several questions that 
require further investigation. Firstly, long-term analysis of Met01 tumour growth 
with VS-4718 treatment is required to determine the outcome of VS-4718 treatment 
in this model. Furthermore to understand whether VS-4718’s control of the Met01 
tumour growth is immune mediated, and if ‘rebound’ or resistance can occur upon 
prolonged drug treatment, further work will include immune phenotyping Met01 
tumours, comparing tumours at both early and later time points. This would also 
include T-cell depletion studies. Secondly, I have derived cells from SCC 7.1 
tumours that appear to ‘rebound’ following VS-4718 treatment. Further 
characterization of these cells will identify whether re-occurrence of tumour growth 
was as a consequence of acquired resistance to VS-4718 treatment or whether other 
mechanisms within the tumour microenvironment, independent of FAK, were 
responsible. These mechanisms could include the upregulation of PD-1 and other co-
inhibitory molecules, and through FACS analysis this hypothesis will be tested.  
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Finally, further investigation will take place into chemokine and cytokine regulation, 
using our unique forward phase protein arrays, currently under development and 
generated using our Aushon BioSystems’ 2470 array printing platform. Current 
commercially available arrays typically include only a select few chemokines and 
cytokines, may only be used to analyze one sample per array and do not contain 
controls for the validation of analyte binding. The Aushon BioSystems’ 2470 array 
printing platform has the capacity to generate forward phase protein microarrays that 
cover a much more extensive range of chemokines, cytokines and growth factors and 
that contain dilution series of each printed anybody for the validation and 
quantification of analyte binding. Using this microarray-printing platform in 
combination with a ArrayIt Innoscan 710 high-resolution microarray scanner, 
miniaturization of current available arrays occurs to such an extent that the levels of 
chemokines, cytokines and growth factors can be determined in multiple samples on 
each array simultaneously. When completed, these arrays will be able to monitor the 
status of chemokines and cytokine for both lab-based studies, with the ultimate goal 
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SUMMARY
Focal adhesion kinase (FAK) promotes anti-tumor
immune evasion. Specifically, the kinase activity of
nuclear-targeted FAK in squamous cell carcinoma
(SCC) cells drives exhaustion of CD8+ T cells and
recruitment of regulatory T cells (Tregs) in the tumor
microenvironment by regulating chemokine/cytokine
and ligand-receptor networks, including via tran-
scription of Ccl5, which is crucial. These changes
inhibit antigen-primed cytotoxic CD8+ T cell activity,
permitting growth of FAK-expressing tumors. Mech-
anistically, nuclear FAK is associated with chromatin
and exists in complex with transcription factors and
their upstream regulators that control Ccl5 expres-
sion. Furthermore, FAK’s immuno-modulatory nu-
clear activities may be specific to cancerous squa-
mous epithelial cells, as normal keratinocytes do
not have nuclear FAK. Finally, we show that a
small-molecule FAK kinase inhibitor, VS-4718, which
is currently in clinical development, also drives
depletion of Tregs and promotes a CD8+ T cell-medi-
ated anti-tumor response. Therefore, FAK inhibitors
may trigger immune-mediated tumor regression,
providing previously unrecognized therapeutic
opportunities.
INTRODUCTION
First described more than a decade ago (Onizuka et al., 1999;
Shimizu et al., 1999), regulatory T cells (Tregs) have become
recognized as a core component of the immuno-suppressive ar-
mory utilized by many tumors to keep the anti-tumor activity of
antigen-primed CD8+ T cells at bay. Increased Treg numbers
has been associated with poorer survival in ovarian (Curiel
et al., 2004), gastrointestinal (Sasada et al., 2003), and esopha-
geal (Kono et al., 2006) cancer. Indeed, the ratio of CD8+
T cells/Tregs correlates with poor prognosis, shifting the balance
from anti-tumor immunity toward tumor tolerance (Quezada
et al., 2006; Sato et al., 2005; Shah et al., 2011). Through
secreting a range of chemokines and cytokines, cancer cells
can promote the recruitment of Tregs into tumors and can also
facilitate their peripheral expansion and retention (Darrasse-
Jèze and Podsypanina, 2013; Ondondo et al., 2013). Thus, Tregs
can act as a barrier to effective immune-based therapy aimed at
activation of a CD8+ T cell anti-tumor immune response. How-
ever, the specific signals within tumor cells that stimulate
elevated intra-tumoral Tregs, giving rise to tumor tolerance,
remain elusive.
FAK is a tyrosine kinase that regulates diverse cellular func-
tions, including adhesion, migration, invasion, polarity, prolifera-
tion, and survival (Frame et al., 2010). Using targeted gene dele-
tion in mouse skin, we have previously shown a requirement for
fak in tumor initiation and progression to malignant disease
(McLean et al., 2004). FAK is also required for mammary tumor
progression, intestinal tumorigenesis, and the androgen-inde-
pendent formation of neuroendocrine carcinoma in a mouse
model of prostate cancer (Ashton et al., 2010; Lahlou et al.,
2007; Luo et al., 2009a; Provenzano et al., 2008; Pylayeva
et al., 2009; Slack-Davis et al., 2009). Expression of FAK is
elevated in a number of tumor types (reviewed in McLean
et al., 2005), and FAK inhibitors are being developed as potential
cancer therapeutics (Roberts et al., 2008; Shapiro et al., 2014).
Many of FAK’s functions in cancer are via its role in signaling
downstream of integrins and growth factor receptors at the
plasma membrane. FAK also contains putative nuclear localiza-
tion sequences (NLS) within the F2 lobe of its FERM domain and
can localize to the nucleus upon receipt of cellular stress, where
it binds to p53 (Lim et al., 2008). However, the extent of FAK’s nu-
clear functions remains largely unknown. Here, we report a func-
tion for nuclear FAK in regulating transcription of inflammatory
cytokines and chemokines, in turn promoting an immuno-sup-
pressive, pro-tumorigenic microenvironment. This is mediated
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by recruitment and expansion of Tregs via FAK-regulated che-
mokine/cytokine networks, and we have found an important
role for Ccl5 and TGFb2. Therefore, FAK controls the tumor envi-
ronment, and suppressing FAK activity, including via a clinically
relevant FAK inhibitor, may be therapeutically beneficial by trig-
gering immune-mediated tumor regression.
RESULTS
FAK-Deficient SCC Tumors Undergo Regression in
an Immune-Competent Host
We used a syngeneic model of SCC in which the fak gene had
been deleted by Cre-lox recombination (McLean et al., 2004;
Serrels et al., 2012) and mutant tumor cell lines generated. We
monitored tumor growth following injection of 13 106 FAK-defi-
cient cells (FAK!/!) or FAK-deficient cells that re-expressed
wild-type FAK (FAK-WT) at comparable levels to endogenous
FAK in both CD-1 nude and FVB (syngeneic) host mouse strains.
In CD-1 nude mice, SCC FAK!/! tumor growth was character-
ized by amodest growth delay (Figure 1A) as reported previously
(Serrels et al., 2012). By contrast, in FVB mice, SCC FAK!/! tu-
mor growthwas characterized by an initial period of growth in the
first 7 days followed by complete regression by day 21 (Fig-
ure 1B). Thus, FAK expression is required for the survival and
Figure 1. Loss of FAK or FAK Kinase Activ-
ity Results in CD8+ T Cell-Dependent SCC
Tumor Clearance
(A and B) SCC FAK-WT and SCC FAK!/! subcu-
taneous tumor growth in immune-deficient CD-1
nude mice (A) and immune-competent FVB
mice (B).
(C and D) SCC FAK!/! (C) and SCC FAK-WT (D)
tumor growth in FVB mice treated with T-cell-
depleting antibodies.
(E)Secondary tumor re-challengewithSCCFAK!/!
(top) and SCC FAK-WT (middle) cells following a
pre-challenge with SCC FAK!/! cells and a 7-day
tumor-free period. Subcutaneous growth of SCC
FAK-WT and SCC FAK!/! tumors injected at day
28 without pre-challenge (bottom).
(F) Tumor growth in FVB mice following subcu-
taneous injection of SCC FAK-WT, SCC FAK!/!,
and SCC FAK-KD cells.
*p < 0.05, **p or ++p < 0.01, ****p < 0.0001; Sidak-
corrected two-way ANOVA (A and B) or Tukey-
corrected two-wayANOVA (C,versusSCCFAK!/!;
D, versus SCC FAK-WT; F, *, versus SCC FAK!/!
and +, versus SCC FAK-KD). Data are represented
as mean ± SEM; n = 5–6 tumors.
growth of SCC tumors in FVB mice with
a functional adaptive immune system.
SCC FAK!/! Tumor Regression Is
Dependent on CD8+ T Cells
To characterize the role of adaptive im-
munity in FAK!/! SCC tumor regression,
we used antibody-mediated T cell deple-
tion in animals bearing FAK!/! tumors
(Figures 1C and S1). Depletion of CD4+ T cells had no effect on
tumor growth. In contrast, depletion of CD8+ T cells, either alone
or in combination with CD4+ T cells, restored SCC FAK!/! tumor
growth. This implies that cytotoxic CD8+ T cells were respon-
sible for regression of FAK!/! tumors (Figure 1C) but does not
exclude an accessory role for CD4+ T cells. T cell depletion in
mice bearing SCC FAK-WT tumors (Figure 1D) revealed that:
(1) depletion of CD8+ T cells, either alone or in combination
with CD4+ T cells, caused a significant increase in tumor growth
when compared to isotype-treated controls at day 14, and
(2) depletion of CD4+ T cells alone caused regression of FAK-
WT SCC tumors by day 21. This implied that FAK-expressing
tumors were also under negative pressure from the immune sys-
tem and that cells from the CD4+ T cell compartment play a role
in protecting FAK-WT tumors from immune-mediated regression
(reason discussed later; Figure 3).
Next, we re-challenged mice with 1 3 106 SCC FAK-WT cells
after regression of primary FAK!/! SCC tumors, following 7 days
of tumor-free survival after the tumors had regressed (Figure 1E,
top andmiddle graphs). Neither FAK-deficient nor FAK-express-
ing SCC cells were able to grow after the mice had been pre-
challenged with SCC FAK!/! cells. As controls, SCC FAK-WT
and FAK!/! cells were injected at day 28 into mice with no
pre-challenge, and these grew as expected (Figure 1E, bottom).
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This implies that, following FAK!/! SCC tumor regression, host
mice remain immunized against further tumor challenge
because immunological memory had been established. It is
possible that either broad immunization against SCCs may
have occurred or, more likely, that the FAK!/! and FAK-WT
SCCs shared common antigen(s) that are expressed irrespec-
tive of FAK status. We conclude that FAK enables SCC cancer
cells to suppress an adaptive immune response rather than to
circumvent it through evading recognition per se. SCC FAK!/!
cells in which a FAK kinase-deficient mutant was re-expressed
(SCC FAK-KD) initially grew and then regressed with kinetics
that were only modestly delayed when compared to FAK!/!
cells, indicating that immune suppression depends on FAK ki-
nase activity (Figure 1F).
We next investigated the nature of the T cell response within
tumors derived from all three SCC cell lines using FACS analysis
on disaggregated tumor tissue taken at day 7. We did not
observe a significant change in the percentage of total CD4+
T cells (Figures 2A and S2 and Table S2) or the percentage of
CD4+ T cells that expressed the activation marker CD69 (Fig-
ure 2B). In contrast, we did observe a significant increase in
the proportion of effector CD4+CD44hiCD62Llow T cells in SCC
FAK!/! and FAK-KD tumors when compared to FAK-WT tumors
(Figures 2C and S2 and Table S2). Analysis of tumor-infiltrating
CD8+ T cells revealed a significant increase in SCC FAK!/!
and SCC FAK-KD tumors when compared to SCC FAK-WT tu-
mors (Figures 2D and S2 and Table S2), indicative of a height-
ened cytotoxic anti-tumor immune response. Staining with the
activation marker CD69 identified the presence of CD8+CD69+
T cells in all tumors (Figure 2E). Further analysis revealed an in-
crease in percentage of effector CD8+CD44hiCD62Llow T cells
in SCC FAK!/! and SCC FAK-KD tumors when compared to
SCC FAK-WT tumors (Figures 2F and S2 and Table S2), espe-
cially when effector CD8+ T cell numbers were normalized to
account for the observed changes in total CD8+ T cells and pre-
sented as a ‘‘fold change’’ (Figure 2G). However, while SCC
FAK!/! and SCC FAK-KD tumors had increased effector CD8+
T cells, there were activated CD8+ T cells present in all of the
SCC tumors, raising the question of why SCC FAK-WT tumors
do not succumb to the cytotoxic CD8+ T cell response.
It is now established that not only the quantity of tumor-infil-
trating CD8+ T cells is important, but also their ‘‘quality.’’
Tumor-induced T cell exhaustion has been reported in a number
of tumor types, including melanoma (Fourcade et al., 2010) and
ovarian cancer (Matsuzaki et al., 2010), and is characterized by
expression of co-inhibitory surface receptors, including pro-
grammed death receptor 1 (PD-1), lymphocyte-activation gene
3 (LAG-3), and T cell immunoglobulin mucin-3 (Tim-3), either
alone or in combination (Fourcade et al., 2010; Sakuishi et al.,
2010; Wherry, 2011). Analysis of these markers on antigen-
primed CD8+CD44hi T cells infiltrating SCC FAK-WT, FAK!/!,
and FAK-KD tumors revealed increased surface expression of
PD-1, LAG-3, and Tim-3 in CD8+CD44hi T cells present in SCC
FAK-WT tumors (Figures 2H–2J). Together, our data imply that
antigen-primed CD8+CD44hi T cells infiltrating SCC FAK-WT tu-
mors exhibit a heightened state of exhaustion indicative of a
dysfunctional T cell response. Linked to their exhausted state,
there was also evidence of decreased proliferation of CD8+
T cells isolated from SCC FAK-WT tumors (judged by Ki-67
staining in Figure 2K).
Histological staining of tumor sections taken at day 7 revealed
that: (1) CD8+ T cells are present throughout all tumors, and
(2) while CD8+ T cells infiltrating SCC FAK-WT tumors appear
predominantly as individual cells, CD8+ T cells infiltrating SCC
FAK!/! and FAK-KD tumors are clustered (Figure 2L). Thus,
the ability of SCC FAK-WT tumors to evade the anti-tumor im-
mune response is not due to limited CD8+ T cell penetration
into these tumors.
FAK Expression Drives Establishment
of an Immuno-Suppressive Environment
Macrophages, myeloid-derived suppressor cells (MDSC), and
Tregs with intrinsic immuno-suppressive capabilities can pro-
mote tumor development by inhibiting cytotoxic CD8+ T cell ac-
tivity in mouse and humans (Beyer and Schultze, 2006; Biragyn
and Longo, 2012; Marigo et al., 2008). Flow cytometric analysis
revealed no differences in macrophage or MDSC populations
that correlated with tumor regression (Figures 3A, 3B, S3, and
S4 and Table S2), although this does not rule out an accessory
role for these cells in eventual tumor clearance. However, we
did find a significantly greater number of CD4+FoxP3+CD25+
Tregs in SCC FAK-WT tumors (Figures 3C and S4 and Table
S2) when compared with FAK!/! and FAK-KD tumors (Fig-
ure 3C). Tregs have been associated with the development of
CD8+ T cell exhaustion (Sakuishi et al., 2013) and may therefore
be linked to the CD8+ T cell exhaustion that we observed in SCC
FAK-WT tumors (Figures 2H–2J). We next calculated the ratio of
CD8+ T cells to Tregs (Figure 3D), as this has been reported to
correlate with poor prognosis in a number of tumor types (Sato
et al., 2005; Shah et al., 2011). We found a substantially lower
CD8+ T cell to Treg ratio in SCC FAK-WT tumors when compared
to SCC FAK!/! and SCC FAK-KD tumors, which correlated with
outcome in terms of tumor tolerance versus immune-mediated
tumor regression.
Tregs Protect FAK-WT Tumors from Immune-Mediated
Regression
We next examined SCC FAK-WT tumor growth in animals
treated with an anti-CD25 antibody to deplete Tregs (Figure 3E).
Depletion of CD25+ cells led to regression of SCC FAK-WT
tumors. Therefore, FAK-dependent Tregs are required for the
growth of FAK-WT-expressing tumors by creating an im-
muno-suppressive environment that impairs cytotoxic CD8+
T cell activity. This role of CD4+ Tregs is the likely reason for ef-
fects of the CD4-depleting antibody in promoting regression of
SCC FAK-WT tumors (Figure 1D). We note that high Treg levels
have been reported in a number of solid tumor types (Beyer
and Schultze, 2006) and that elevated Tregs are linked to
poor clinical outcome (Beyer and Schultze, 2006; Sato et al.,
2005).
We demonstrated that Tregs derived from SCC FAK-WT tu-
mors expressed the transcription factor (TF) Helios (Figure S5A),
indicative of thymic origin (Thornton et al., 2010). Thus, we hy-
pothesized that FAK may drive the recruitment and expansion
of the intra-tumoral Tregs by influencing the availability of
secreted factors.
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FAK Regulates the Transcription of Chemokines and
Cytokines to Control Tregs
To address how FAK activity in SCC cancer cells promotes
elevated intra-tumoral Tregs, we next analyzed global transcrip-
tional profiles of SCC FAK-WT and SCC FAK!/! cells using Affy-
metrix GeneChip microarrays (Figure 4A). FAK expression re-
sulted in the upregulation of 498 genes and the downregulation
of 598 genes (p < 0.01). The upregulated transcript set in SCC
Figure 2. FAK-Depleted Tumors Exhibit a Heightened CD8+ T Cell Response
(A) FACS quantification of total intra-tumoral CD4+ T cells.
(B) FACS quantification of CD69+ cells as a percentage of CD4+ T cells.
(C) FACS quantification of CD4+CD44hiCD62Llow, CD4+CD44hiCD62Lhi, CD4+CD44lowCD62Llow T cell subpopulations.
(D) FACS quantification of total intra-tumoral CD8+ T cells.
(E) FACS quantification of CD69+ cells as a percentage of CD8+ T cells.
(F) Quantification of CD8+CD44hiCD62Llow, CD8+CD44hiCD62Lhi, CD8+CD44lowCD62Llow T cell subpopulations.
(G) Changes in effector (CD8+CD44hiCD62Llow) CD8+ T cells normalized to total CD8+ T cell proportions.
(H) FACS quantification of PD-1+LAG-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 6 tumors.
(I) FACS quantification of PD-1+Tim-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 3 tumors.
(J) FACS quantification of PD-1+Tim-3+LAG-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 3 tumors.
(K) FACS quantification of Ki-67+ cells as a percentage of tumor-infiltrating CD8+ T cells. n = 3 tumors.
(L) Representative histological staining of CD8 in frozen sections from SCC FAK-WT, SCC FAK!/!, and SCC FAK-KD tumors. Dashed white lines demark tumor
boundary.
Scale bars, 500 mm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (C and F, CD44hiCD62Llow only). Data
are represented as mean ± SEM; n = 5 tumors unless stated.
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FAK-WT cells was associated with a number of processes,
including cell migration, receptor binding, secretion, wounding,
and ovulation (Figure 4B, top). Analysis of this gene set revealed
the chemokine ligand group of genes to be significantly overrep-
resented (Figure 4B, bottom), which is interesting given that a
number of these chemokines and cytokines mediate both Treg
recruitment to tumors and induction of peripheral Tregs within
tumors (Goldstein et al., 2013; Ondondo et al., 2013).
To establish which chemokines and cytokines were regulated
by FAK and to address whether the FAK-dependent transcrip-
tional profile was linked to chemokine receptor expression on tu-
mor-infiltrating Tregs, we performed quantitative (q)RT-PCR
array analysis. Comparison of chemokine/cytokine transcript
levels between SCC FAK-WT and SCC FAK!/! cells revealed a
subset of ligands increased >2-fold in SCC FAK-WT cells (Fig-
ure 4C). Several of these (Ccl1, Ccl5, Ccl7, Cxcl10) have roles
in Treg recruitment (Ondondo et al., 2013) (green arrowheads,
Figure 4C), while one (Tgfb2) has a reported role in peripheral in-
duction and expansion of Tregs (Goldstein et al., 2013) (red
arrowhead, Figure 4C). To complement this, comparison of
Tregs isolated from the thymus of normal FVB mice with those
isolated directly from SCC FAK-WT tumors revealed a chemo-
kine receptor switch (Figure 4D). We found increased expression
of the cognate receptors for five of the six chemokine ligands up-
regulated in SCC FAK-WT cells (Figure 4C). These receptor
changes may represent a switch from lymphoid homing recep-
tors, including Ccr7 and Cxcr4, toward expression of memory/
effector-type chemokine receptors, including Ccr2, Ccr5, Ccr8,
and Cxcr6, involved in recruitment to non-lymphoid tissues
and sites of inflammation. Network analysis of the relationship
between FAK-dependent chemokine ligand expression in SCC
cells and tumor-infiltrating Treg chemokine receptor expression
revealed the existence of a FAK-dependent paracrine signaling
axis between cancer cells and intra-tumoral Tregs based on che-
mokine ligand-receptor interactions (Figure 4E). Furthermore, (q)
RT-PCR analysis of Ccl5, Cxcl10, and Tgfb2 demonstrated that
their expression was dependent on FAK kinase activity (Fig-
ure 4F). We note that disruption of the Ccl5/Ccr5 axis in a model
of pancreatic adenocarcinoma results in reduced intra-tumoral
Tregs and slows tumor growth (Tan et al., 2009), implying that
FAK-dependent regulation of this paracrine signaling axis may
be more generally important. Thus, FAK activity regulates the
expression of a subset of chemokines that can specifically
mediate crosstalk between tumor cells and tumor-infiltrating
Tregs. This likely has importance in recruitment and retention
of CD4+FoxP3+CD25+ Tregs into SCC FAK-WT tumors.
Nuclear FAK Regulates the Transcription of Ccl5
and TGFb2 to Increase Tregs
The finding that the Tregs enriched in SCC FAK-WT tumors
were likely recruited into SCC FAK-WT tumors led us to
consider a potential role for Ccl5 that has been implicated in
the recruitment and expansion of CD4+FoxP3+CD25+ Tregs
(Tan et al., 2009), via the paracrine signaling axis that we iden-
tified. We found that efficient knockdown of Ccl5 using two
independent shRNA hairpins (P1 and P2, Figure 5A) resulted
in SCC FAK-WT shRNA-Ccl5 tumor regression by days 21–27
(Figure 5B). We measured the absolute number of Tregs in
SCC FAK-WT shRNA-Ccl5 tumors at day 7 and found that there
was a substantial reduction in both Ccl5-depleted tumors when
compared with empty vector control SCC FAK-WT pLKO tu-
mors (Figure 5C).
Expanding on these findings, shRNA-mediated knockdown of
Tgfb2 expression in SCC FAK-WT cells also influenced tumor
growth (Figures S5B and S5C). Partial knockdown of TGFb2
had complex effects, which resulted in one of two outcomes.
One group (Figure S5C, dashed blue line), grew more rapidly
and ulcerated, leading to removal from study at day 14. In the
Figure 3. FAK Regulates the Immuno-Sup-
pressive Microenvironment
(A) FACS quantification of Ly6Chi and Ly6Clow
macrophage populations expressed as a per-
centage of tumor-infiltrating CD45+ leukocytes.
(B) FACS quantification of Ly6ChiGr1low (M-MDSC)
and Ly6CintGr1hi (G-MDSC) populations ex-
pressed as a percentage of tumor-infiltrating
CD45+ leukocytes.
(C) Quantification of CD4+CD25+FoxP3+ Tregs
expressed as a percentage of tumor-infiltrating
CD4+ T cells.
(D) CD8+ T cell-to-Treg ratio calculated using
mean values from Figures 2D and 3C.
(E) SCC FAK-WT tumor growth in FVB mice
treated with anti-CD25 depleting antibody.
n = 6 tumors. * or +p < 0.05, ++p < 0.01, ***p <
0.001, **** or ++++p < 0.0001; Tukey-corrected
one-way ANOVA (A, *, Ly6Chi; +, Ly6Clow). Data are
represented as mean ± SEM; n = 5 tumors unless
stated.
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Figure 4. FAK Regulates Transcription of Cytokines Implicated in Treg Recruitment and Expansion
(A) Transcriptomic profiling of SCC FAK-WT and SCC FAK!/! cells.
(B) Functional enrichment analysis of genes upregulated in SCC FAK-WT cells (bottom gray bar in A). Overrepresented biological processes are displayed as a
heatmap (log10-transformed color scale) (top); asterisks indicate presence of cytokine-related genes. Overrepresented gene families are displayed as a bar chart
(bottom). p < 0.05; Benjamini–Hochberg-corrected hypergeometric tests.
(C) qRT-PCR array analysis of cytokine and chemokine expression in SCCFAK-WT andSCC FAK!/! cells. Gray bar indicates cluster of genes upregulated in SCC
FAK-WT cells; cytokine and chemokine gene names are listed. Green arrowheads indicate reported roles in Treg recruitment; red arrowhead indicates reported
role in peripheral Treg induction.
(D) qRT-PCR array analysis of chemokine and receptor expression in tumor- and thymus-derived Tregs. Gray bar indicates cluster of genes upregulated in tumor-
derived Tregs; receptor gene names are listed.
(E) Interaction network analysis of chemokine ligand gene expression detected in SCC cells (circles, left) and corresponding receptor gene expression detected in
Tregs (squares, right). Genes are ordered vertically by fold change. Light gray lines connect receptor-ligand pairs; green lines indicate pairs upregulated at least
2-fold in SCC FAK-WT cells and tumor-derived Tregs.
(F) qRT-PCR analysis of selected cytokine and chemokine gene expression in SCC cells. ***p < 0.001, ****p < 0.0001; Tukey-corrected one-way ANOVA. Data are
represented as mean ± SEM.
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other group that did not display such frank ulceration, we
observed tumor regression by day 27 (Figure S5C, dashed red
line). Analysis of Treg levels in SCC FAK-WT shRNA-TGFb2 tu-
mors at day 7 (regardless of initial growth characteristics) re-
vealed that TGFb2 knockdown was also associated with a
reduction in CD4+FoxP3+CD25+ Tregs (Figure S5D). Therefore,
while the effects of reducing TGFb2 expression aremore compli-
cated than for Ccl5, FAK-dependent TGFb2 expression does
contribute to elevated CD4+FoxP3+CD25+ Tregs in SCC FAK-
WT tumors; and in the subset of mice bearing tumors that
were able to complete the study, TGFb2 knockdown also caused
tumor regression.
Figure 5. Nuclear FAK Regulates Transcription of Ccl5, which Is Required for Treg Recruitment and Tumor Growth
(A) qRT-PCR analysis of Ccl5 gene expression knockdown in SCC FAK-WT cells stably expressing two independent shRNA constructs targeting Ccl5 (P1
and P2).
(B) SCC FAK-WT shRNA-Ccl5 tumor growth in FVB mice. n = 6 tumors.
(C) FACS quantitation of tumor-infiltrating Treg numbers from SCC FAK-WT shRNA-Ccl5 tumors. Data represent a single value from six pooled tumors.
(D) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC FAK!/!, and SCC FAK-NLS cells.
(E) qRT-PCR analysis of Ccl5 gene expression in SCC FAK-NLS cells.
(F) Tumor growth of SCC FAK-NLS cells in FVB mice.
(G) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC FAK!/!, and SCC FAK-KD cells.
(H) Western blotting of whole-cell (WC) and nuclear (Nuc) protein fractions from SCC FAK-WT cells and primary skin keratinocytes. 60 s exposure time is shown
for all samples; additional 10 min exposure time is shown for FAK in keratinocyte samples. GAPDH, cytoplasmic; PARP, nuclear.
***p < 0.001, ****p < 0.0001; Tukey-corrected one-way ANOVA. Data are represented as mean ± SEM unless stated.
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Our findings that FAK regulated the transcription of cytokines
and chemokines (including Ccl5 and TGFb2) that were associ-
ated with elevated intra-tumoral Tregs and tumor tolerance led
us to consider a possible role for nuclear FAK in regulating the
transcription of these genes. Based on previous reports (Lim
et al., 2008), which identified putative NLSs within the FERM
domain of FAK, we constructed an optimally nuclear targeting-
impaired mutant FAK by replacing two arginines (positions 177
and 178) and four lysines (positions 190, 191, 216, and 218)
with alanines (termed FAK-NLS). Western blotting of cyto-
plasmic and nuclear fractions confirmed that the FAK-NLS
mutant was indeed defective in nuclear localization (Figure 5D).
Subsequent (q)RT-PCR analysis of Ccl5 and Tgfb2 expression
in SCC cells expressing only FAK-NLS revealed that FAK nuclear
localization was required for transcription of these genes (Fig-
ures 5E and S5E, respectively). Thus, nuclear FAK drives the
transcription of Ccl5 and TGFb2, which are required for recruit-
ment and expansion of immuno-suppressive Tregs into SCC tu-
mors, altering the balance between CD8+ T cells and Tregs in
favor of tumor tolerance. In support of this, growth of SCC
FAK-NLS tumor cells was similar to that of SCC FAK!/!, with ul-
timate tumor regression (Figure 5F). This confirmed that it was
nuclear FAK that afforded protection from the anti-tumor im-
mune response. Western blotting of cytoplasmic and nuclear
fractions from SCC FAK-KD showed that the kinase-deficient
mutant was able to localize to the nucleus, so we conclude
that the immune modulatory effects of FAK are dependent on
FAK kinase activity in the nucleus (Figure 5G).
We next examined nuclear FAK levels in primary skin keratino-
cytes, the normal cellular counterparts of the SCC cells used
here, and did not find detectable nuclear FAK (Figure 5H).
Thus, abundant nuclear localization, and therefore the capacity
to exert regulatory control over chemokine and cytokine expres-
sion, is likely a feature of oncogenic transformation in skin kera-
tinocytes. This suggests that the nuclear functions of FAK that
we have identified—namely, regulating transcription of chemo-
kine/cytokine networks—may be associated with the cancerous
state when FAK is highly expressed.
Nuclear FAK Interacts with a Network of Ccl5
Transcriptional Regulators
Having established an important role for the nuclear FAK-
dependent transcription of Ccl5 in mediating recruitment and
expansion of intra-tumoral Tregs, we wanted to determine
how nuclear FAK could exert control over Ccl5 transcription.
Using sucrose gradients, we fractionated the nuclei of SCC
FAK-WT cells and demonstrated that nuclear FAK was present
in the chromatin-containing fraction (Figure 6A). Transcriptional
regulation of Ccl5 is mediated predominantly through six short
regulatory elements contained within a region of the Ccl5 pro-
moter spanning "300 base pairs (Fessele et al., 2002). These
regulatory elements contain binding sites for a number of
TFs, including AP-1, C/EBP, IRF-1, NF-kB, and TATA box-bind-
ing protein (TBP), which is part of the transcription factor IID
complex (TFIID). Using FAK immunoprecipitation and quantita-
tive label-free mass spectrometry, we identified FAK binding
partners in purified nuclear extracts and contextualized these
by mapping onto a network of proteins associated with pre-
dicted Ccl5 TFs (constructed in silico; Figure 6B). This integra-
tive approach identified a subset of Ccl5 TFs and regulators of
these that interact with FAK in SCC cell nuclei (Figures 6C, S6
and Table S1). Interaction network analysis of this protein sub-
set revealed nuclear FAK binding partners with roles in multiple
transcriptional pathways, including regulators of AP-1, C/EBP,
IRF-1/-7, NF-kB/Rel, and TFIID. Thus, we identified nuclear
FAK binding partners that can interact, directly or indirectly,
with five of the six main regulatory elements reported to control
transcription of Ccl5 in multiple cell types (Fessele et al., 2002).
Given that our interaction network was somewhat dominated
by proteins associated with the TFIID pathway, including three
TBP-associated factors (TAFs) (Figures 6C and S6), we used
co-immunoprecipitation to confirm the interaction of nuclear
FAK with one of these, TAF9, a core component of the TFIID
complex (D’Alessio et al., 2009) (Figure 6D). Our data show
that FAK binds to core components of the transcriptional ma-
chinery, many of which are known to be located on the pro-
moter of genes undergoing active transcription and that are
known or predicted to regulate Ccl5. Therefore, in SCC cells,
nuclear FAK associates with chromatin and is physically linked
to a network of TFs and their regulators known to modulate
Ccl5 expression.
Small-Molecule FAK Kinase Inhibitor Promotes
Immune-Mediated Tumor Clearance
Therapeutic targeting of FAK kinase activity using small-mole-
cule inhibitors will inhibit FAK signaling not only in tumor cells,
but also potentially in multiple host cell types. To complement
expression of the FAK-KD mutant protein in the cancer cells
and investigate whether a FAK inhibitor could induce immune-
mediated regression of SCC tumors, we used the FAK/Pyk2 ki-
nase inhibitor VS-4718 (Shapiro et al., 2014), which is currently
in clinical development. Mice were treated with VS-4718 at
75 mg/kg for 24 hr prior to injection of 1 3 106 FAK-WT or
FAK!/! SCC tumor cells and twice daily thereafter. This resulted
in VS-4718-induced regression of SCC FAK-WT tumors by day
24 (Figure 7A). Following cessation of VS-4718 treatment, no
tumor regrowth was observed (data not shown). SCC FAK!/! tu-
mor growth and clearance was not greatly affected by VS-4718
treatment, suggesting that the anti-tumor effects of VS-4718 can
be explained by FAK inhibition in tumor cells. Activity of VS-4718
was confirmed using an ELISA to measure FAK autophosphory-
lation on tyrosine-397 in tumor lysates from mice treated with
75 mg/kg VS-4718 (Figure S7). Regression of VS-4718-treated
SCC tumors was not accompanied by loss of cell viability at
day 7, as measured by FACS using a viability stain following tu-
mor disaggregation (Figure 7B). There was a significant but small
increase in leukocytes in VS-4718-treated SCC FAK-WT tumors
(Figure 7C) and a significant increase in total CD4+ T cells (Fig-
ures 7D andS2 and Table S2) and effector CD4+CD44hiCD62Llow
T cells (Figures 7E and S2 and Table S2). A significant increase in
CD8+ T cells was also evident in SCC FAK-WT VS-4718-treated
tumors (Figures 7F and S2 and Table S2), although there was no
change in effector CD8+CD44hiCD62Llow T cells (Figures 7G and
S2 and Table S2). Crucially, there was a significant reduction in
CD4+CD25+FoxP3+ Treg cells in VS-4718-treated SCC FAK-
WT tumors, which was similar to that observed in vehicle and
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VS-4718-treated SCC FAK!/! tumors (Figures 7H and S4 and
Table S2).
Thus, VS-4718 promoted robust anti-tumor activity, with
similar immune cell changes to that observed upon FAK deletion
or expression of a kinase-deficient form of FAK. Furthermore,
anti-tumor efficacy of VS-4718 was also dependent on CD8+
T cells, and SCC FAK-WT tumors treated with VS-4718 on a
CD8+ T cell-depleted background exhibited a growth delay but
did not undergo tumor regression (Figure 7I). We conclude that
the FAK kinase inhibitor targets mechanisms of immune
suppression andmay therefore represent a form of effective ‘‘im-
muno-modulatory’’ therapy that reduces Tregs in the tumor envi-
ronment. Importantly, the FAK kinase inhibitor does not affect
the cytotoxic function of antigen-primed CD8+ T cells. We also
found that VS-4718 treatment that was initiated 5 days post-
inoculation of 1 3 106 SCC FAK-WT cells, when these had
Figure 6. Nuclear FAK Interacts with Regulators of Ccl5 Transcription
(A) Sucrose fractionation of soluble chromatin prepared from SCC FAK-WT cell nuclei. Protein preparations recovered from each fraction were analyzed by
western blotting (top). DNA recovered from each fraction was analyzed by agarose gel electrophoresis (bottom, 1 kilobase [kb] and 100 base pair [bp] ladders
shown). Fraction 7 (black arrowhead) represents the chromatin-containing fraction.
(B) Schematic detailing the workflow used for proteomic analysis of the nuclear FAK interactome in the context of Ccl5 transcription factors (TFs).
(C) Interaction network analysis of proteins that bind FAK in the nucleus of SCC cells. PredictedCcl5 TFs (squares, bottom) and respective TF binders (circles, top)
enriched by at least 4-fold in nuclear FAK immunoprecipitations (SCC FAK-WT over SCC FAK!/! controls; p < 0.05) are shown (stringent network). Ccl5 TFs not
detected (ND) are shown as gray squares. TF complexes or groups are indicated; proteins are labeledwith gene names for clarity. TF binders are aligned above TF
groups with which there are the greatest number of reported interactions. For full network, see Figure S6; for protein interaction list, see Table S1.
(D) Isolation of the TFIID component TAF9 by FAK immunoprecipitation (IP) from SCC FAK-WT cell nuclear extracts.
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Figure 7. The FAK Kinase Inhibitor VS-4718 Leads to Immune-Mediated SCC Clearance
(A) SCC FAK-WT and SCC FAK!/! tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 24 hr pre-tumor cell inoculation and
continued for the duration of the experiment.
(B) FACS analysis of cell viability from disaggregated tumors treated with either vehicle or VS-4718.
(C) FACS analysis of vehicle- or VS-4718-treated tumor-infiltrating leukocytes expressed as a percentage of viable CD45+ cells relative to the total number of
single cells.
(D) FACS analysis of tumor-infiltrating CD4+ T cells from vehicle- or VS-4718-treated tumors.
(E) FACS sub-categorization of tumor-infiltrating CD4+ T cells into CD45+CD3+CD4+CD8!CD44hiCD62Llow, CD45+CD3+CD4+CD8!CD44hiCD62Lhi, and
CD45+CD3+CD4+CD8!CD44lowCD62Llow populations.
(F) FACS analysis of tumor-infiltrating CD8+ T cells from vehicle- or VS-4718-treated tumors.
(G) FACS sub-categorization of tumor-infiltrating CD8+ T cells into CD45+CD3+CD4!CD8+CD44hiCD62Llow, CD45+CD3+CD4!CD8+CD44hiCD62Lhi, and
CD45+CD3+CD4!CD8+CD44lowCD62Llow populations.
(H) FACS analysis of tumor-infiltrating CD4+CD25+FoxP3+ Tregs expressed as a percentage of tumor-infiltrating CD4+ T cells.
(I) SCC FAK-WT tumor growth in FVB mice treated with either vehicle or VS-4718 and either isotype control or CD8-depleting antibodies.
(J) SCC FAK-WT and SCC FAK!/! tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 5 days post-tumor cell inoculation (gray
dashed line) and continued for the duration of the experiment.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (E and G, CD44hiCD62Llow only). Data are represented as
mean ± SEM; n = 6 tumors.
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already formed palpable tumors of"50mm3, led to complete tu-
mor regression (Figure 7J).
DISCUSSION
We show that nuclear FAK in SCC cancer cells drives the tran-
scription of chemokines and cytokines, including Ccl5 and
TGFb2, which promote the formation of an immuno-suppressive,
pro-tumorigenic microenvironment. This is dependent on FAK
kinase activity, and expression of a catalytically inactive mutant
FAK protein (FAK-KD) or treatment with a small-molecule inhib-
itor causes tumor regression. This is effective even when tumors
are already established, raising the exciting possibility that tar-
geting of FAK kinase activity may have immune-mediated anti-
tumor efficacy in patients. We established that nuclear FAK is
associated with chromatin and interacts with a number of TFs
and transcriptional regulators, including components of the
TFIID complex, that are linked to regulation of Ccl5 expression.
Our data imply that FAK interacts with core transcriptional
machinery to influence gene transcription and promote tumor
immune escape.
Historically, FAK has been recognized as an adhesion-related
non-receptor protein tyrosine kinase that clusters at focal adhe-
sion (FA) structures and regulates cancer-associated processes,
including adhesion, migration, invasion, survival, and prolifera-
tion (reviewed in Frame et al., 2010). FAK was also found to
translocate to the nucleus (Lim et al., 2008; Luo et al., 2009b),
leading to the idea of nuclear functions for FAK within the nu-
cleus. Our data show that, at least in cancer cells, FAK regulates
inflammatory transcriptional programs associated with genera-
tion and maintenance of a pro-tumorigenic and immuno-sup-
pressive microenvironment. FAK associates with chromatin,
and in the context of Ccl5 expression, it interacts with a number
of TFs, and regulators of TFs, that bind regulatory elements in the
Ccl5 promoter (Fessele et al., 2002). Our data imply that FAK ex-
ists in complexes with a number of TAF proteins, including TAF9
and TAF12, key components of the core promoter complex
TFIID that serves to initiate transcription by driving recruitment
of chromatin remodeling complexes, coactivators, and RNA po-
lymerase II to the promoter (D’Alessio et al., 2009). Therefore,
FAK interacts with components of the core transcriptional
machinery in order to drive transcription of chemokines and cy-
tokines that contribute to recruitment of Tregs into the tumor
environment, promoting immunological tolerance and permitting
tumor growth.
Recently, nuclear accumulation of active FAK (phosphory-
lated on Tyr-397) within tumor cells of patients with colorectal
cancer was reported to correlate with poor prognosis (Albasri
et al., 2014), highlighting the need to understand the nature of
FAK’s role within the nucleus. Studies using endothelial cells,
muscle cells, and fibroblasts have previously reported low
steady-state levels of nuclear FAK that are substantially
increased in response to cellular stress (Lim, 2013; Lim et al.,
2008; Luo et al., 2009b). Our work implies that oncogenic stress
is another route to inducing high levels of nuclear FAK and that
this, in turn, can influence transcriptional programs, such as the
chemokine and cytokine networks that control the tumor
microenvironment.
A number of therapeutic strategies targeting components of
the immuno-suppressive tumor microenvironment are currently
being tested, with the aim of restoring anti-tumor immunity by
releasing the break on CD8+ T cell cytotoxic activity. In pre-clin-
ical models of cancer, targeting Tregs (Ali et al., 2014; Bos et al.,
2013) has shown anti-tumor efficacy, either alone or when used
in combination with agents that enhance CD8+ T cell activation.
A clinical study combining agents targeting cytotoxic-T-lympho-
cyte-associated antigen 4 (CTLA-4), which is thought to influ-
ence Treg function (Peggs et al., 2009; Quezada et al., 2006;
Simpson et al., 2013; Wing et al., 2008), and PD-1, which blocks
signals that inhibit T cell function, has reported impressive re-
sponses in patients with advanced melanoma (Wolchok et al.,
2013). However, this combination of checkpoint blockade anti-
bodies elicits substantial side effects in >50% of patients, high-
lighting the need to find alternative combinations with improved
tolerability. We have shown that targeting FAK kinase activity has
the potential to modulate intra-tumoral Treg levels, resulting in
robust CD8+ T cell anti-tumor immunity, while others have re-
ported previously that FAK kinase inhibitors block monocyte/
macrophage and cancer-associated fibroblast recruitment into
tumors by virtue of FAK’s role in regulating their migration
(Stokes et al., 2011). Taken together, these findings suggest
that targeting the pleiotropic cellular functions of FAK may
have a broad impact on the immuno-suppressive tumor micro-
environment, differentiating these agents frommany therapeutic
approaches that target single immune cell populations.
Targeting a molecular pathway that is upregulated in cancer
cells may provide tumor specificity and help to overcome
some of the potential issues with severe autoimmunity when
modulating immune cell populations. FAK inhibitors, such as
VS-4718, are in clinical development. VS-4718 is currently in a
phase I dose escalation clinical trial in patients with solid tumors
(www.clinicaltrials.gov NCT01849744). Our findings provide
good rationale for pre-clinical and clinical testing of FAK kinase
inhibitors alongside agents that stimulate CD8+ T cell activity,
such as the checkpoint blockade therapies that target PD-1
and CTLA-4, which are both in clinical development (Pardoll,
2012).
EXPERIMENTAL PROCEDURES
Experiments involving animals were carried out in accordance with the
UKCCCR guidelines by approved protocol (HO PL 60/4248). Brief experi-
mental procedures are listed here. For details, please see the Supplemental
Experimental Procedures.
Generation of FAK Nuclear Localization Mutant
Mutations were introduced into FAK-WT at R177A, R178A, K190A, K191A,
K216A, and K218A using PCR-based site-directed mutagenesis.
Cell Lines
Isolation and generation of the FAKSCC cell model is described in Serrels et al.
(2012). Keratinocyte cultureswere prepared as detailed inMcLean et al. (2004).
Western Blot Analysis
To prepare whole-cell lysates, cells were washed in cold PBS and lysed in
RIPA buffer. Cytoplasmic and nuclear extracts were prepared as described
in Lim et al. (2008). Lysates were resolved by gel electrophoresis, transferred
to nitrocellulose, and probed with respective antibodies.
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Subcutaneous Tumor Growth
Cells were injected into both flanks of either CD-1 nude mice or FVB mice and
tumor growth measured twice-weekly. Animals were sacrificed when tumors
reached maximum allowed size or when signs of ulceration were evident.
For treatment with VS-4718, drug was prepared in 0.5% carboxymethyl cellu-
lose + 0.1% Tween 80 and mice treated at 75 mg/kg BID by gavage. No signs
of toxicity were observed.
Tumor Growth following Re-Challenge
SCC FAK!/! cells were injected into the left flank of FVBmice. Following tumor
regression, mice were left for 7 days before being challenged with SCC FAK-
WT or FAK!/! cells injected into the right flank. Tumor growth was measured
twice-weekly. Control groups were injected into both flanks at day 28 using
mice that had not been pre-challenged with SCC FAK!/! cells.
CD4+, CD8+, and CD25+ T Cell Depletion
T cell depletion was achieved following IP injection of 150 mg of depleting anti-
body into female age-matched FVB mice for 3 consecutive days and was
maintained by further IP injection at 3 day intervals until the study was termi-
nated. SCC FAK-WT or FAK!/! cells were injected into both flanks 6 days after
initial antibody treatment and tumor growth measured. The extent of T cell
depletion was determined at the end of the study using FACS (Figure S1).
FACS Analysis of Immune Cell Populations
Tumors established following injection of SCC cells into both flanks of an FVB
mouse were removed at day 7. Tumor tissue was processed to obtain single
cell suspension for staining and subsequent FACS analysis (antibodies listed
in Table S2).
Gene Expression Profiling
RNA was analyzed using the GeneChip Mouse Genome 430 2.0 Array.
Normalized data for differentially expressed genes were median centered
and clustered using Cluster 3.0 and Java TreeView. Functional enrichment
analysis was performed using ToppGene.
Quantitative RT2-PCR Array Analysis of Cytokine, Chemokine,
and Chemokine Receptor Expression
RNA prepared from SCC cells was analyzed using the mouse cytokine and
chemokine RT2 Profiler PCR Array and that from isolated Tregs was analyzed
using the mouse chemokine and receptor array. Relative gene expression
(2!DCt) values were log transformed, median centered, and subjected to hier-
archical clustering as for microarray analysis. An interactome of chemokine
ligands and receptors was constructed using the IUPHAR/BPS Guide to Phar-
macology database and curated from the literature, onto which expression
data for detected genes were mapped and visualized using Cytoscape.
Expression of selected cytokine and chemokine genes was assessed by stan-
dard quantitative RT-PCR.
shRNA-Mediated TGFb2 and Ccl5 Knockdown
Cells were subject to two rounds of lentiviral infection prior to selection with
puromycin. shRNA constructs used were part of the pLKO lentiviral TRC
library.
Preparation and Fractionation of Nuclei and Chromatin
Nuclei were prepared as described (Gilbert et al., 2003) but with a reduced
concentration (0.05%) of NP-40 in nuclei buffer B. Soluble chromatin was pre-
pared as described (Gilbert et al., 2004) and fractionated on a sucrose step
gradient to separate soluble and chromatin-associated nuclear proteins.
DNA was recovered from fractions and subjected to agarose gel electropho-
resis. Protein was purified using TCA precipitation. Samples were analyzed
by SDS-PAGE and blotted using anti FAK, HP1a, and histone H3 antibodies.
Proteomic Analysis of Nuclear FAK Protein Complexes
FAK nuclear protein complexes were subjected to on-bead proteolytic diges-
tion, desalting, and liquid chromatography-tandem mass spectrometry, as
described (Turriziani et al., 2014). For interaction network analysis, Ccl5 tran-
scription factors were extracted from the DECODE database and used to seed
a network of 1,000 transcription factor-related proteins using the GeneMANIA
plugin in Cytoscape. Proteins specifically isolated in nuclear FAK protein com-
plexes were mapped onto the interactome, and those with physical or pre-
dicted direct or indirect interactions with Ccl5 transcription factors were
analyzed using the NetworkAnalyzer plugin in Cytoscape.
CD8 T Cell Fluorescent Immunohistochemistry
Tumors were removed 7 days post-implantation and frozen by submersing in
liquid nitrogen. Tumor sections were cut, processed and stained. They were
imaged using an Olympus FV1000 confocal microscope.
ACCESSION NUMBERS
The microarray data discussed in this manuscript has been deposited in
NCBI’s Gene Expression Omnibus and is accessible through GEO series
accession number GEO: GSE71662.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.09.001.
AUTHOR CONTRIBUTIONS
A.S. andM.C.F. devised and oversaw the project. A.S., T.L., B.S., A.B., S.M.A.,
R.J.B.N., and M.C.F. designed the experiments with contributions from E.M.,
J.A.P., V.G.B., and N.G. A.S., T.L., B.S., A.B., R.C.M., and A.v.K. performed
experiments with contributions from L.G.-C., M.C., M.M., and J.E.R. A.S.,
T.L., B.S., A.B., R.C.M., A.v.K., and A.H.S. analyzed the data. A.B. and
A.H.S. performed bioinformatic analysis. A.S. and M.C.F. wrote the manu-
script with contributions from T.L., B.S., and A.B.; all authors commented on
and approved the final version. We consider that A.S. and T.L. made equal
contributions and that B.S. and A.B. made equal contributions.
ACKNOWLEDGMENTS
This work was supported by Cancer Research UK (Grant no. C157/A15703 to
M.C.F.), European Research Council (Grant no. 29440 Cancer Innovation to
M.C.F.) and Medical Research Council (Grant no. G1100084 to S.M.A.). We
thank Frederic Li Mow Chee for help with transcriptomic analysis, Amaya Gar-
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Goldstein, J.D., Pérol, L., Zaragoza, B., Baeyens, A., Marodon, G., and Piag-
gio, E. (2013). Role of cytokines in thymus- versus peripherally derived-regula-
tory T cell differentiation and function. Front. Immunol. 4, 155.
Kono, K., Kawaida, H., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N.,
Omata, H., and Fujii, H. (2006). CD4(+)CD25high regulatory T cells increase
with tumor stage in patients with gastric and esophageal cancers. Cancer Im-
munol. Immunother. 55, 1064–1071.
Lahlou, H., Sanguin-Gendreau, V., Zuo, D., Cardiff, R.D., McLean, G.W.,
Frame, M.C., and Muller, W.J. (2007). Mammary epithelial-specific disruption
of the focal adhesion kinase blocks mammary tumor progression. Proc. Natl.
Acad. Sci. USA 104, 20302–20307.
Lim, S.T. (2013). Nuclear FAK: a newmode of gene regulation from cellular ad-
hesions. Mol. Cells 36, 1–6.
Lim, S.T., Chen, X.L., Lim, Y., Hanson, D.A., Vo, T.T., Howerton, K., Larocque,
N., Fisher, S.J., Schlaepfer, D.D., and Ilic, D. (2008). Nuclear FAK promotes cell
proliferation and survival through FERM-enhanced p53 degradation. Mol. Cell
29, 9–22.
Luo, M., Fan, H., Nagy, T., Wei, H., Wang, C., Liu, S., Wicha, M.S., and Guan,
J.L. (2009a). Mammary epithelial-specific ablation of the focal adhesion kinase
suppressesmammary tumorigenesis by affectingmammary cancer stem/pro-
genitor cells. Cancer Res. 69, 466–474.
Luo, S.W., Zhang, C., Zhang, B., Kim, C.H., Qiu, Y.Z., Du, Q.S., Mei, L., and
Xiong, W.C. (2009b). Regulation of heterochromatin remodelling and myoge-
nin expression during muscle differentiation by FAK interaction with MBD2.
EMBO J. 28, 2568–2582.
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008). Tumor-
induced tolerance and immune suppression by myeloid derived suppressor
cells. Immunol. Rev. 222, 162–179.
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T.,
Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010). Tumor-infiltrating NY-
ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in
human ovarian cancer. Proc. Natl. Acad. Sci. USA 107, 7875–7880.
McLean, G.W., Komiyama, N.H., Serrels, B., Asano, H., Reynolds, L., Conti, F.,
Hodivala-Dilke, K., Metzger, D., Chambon, P., Grant, S.G., and Frame, M.C.
(2004). Specific deletion of focal adhesion kinase suppresses tumor formation
and blocks malignant progression. Genes Dev. 18, 2998–3003.
McLean, G.W., Carragher, N.O., Avizienyte, E., Evans, J., Brunton, V.G., and
Frame, M.C. (2005). The role of focal-adhesion kinase in cancer - a new ther-
apeutic opportunity. Nat. Rev. Cancer 5, 505–515.
Ondondo, B., Jones, E., Godkin, A., and Gallimore, A. (2013). Home sweet
home: the tumor microenvironment as a haven for regulatory T cells. Front. Im-
munol. 4, 197.
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., andNakayama, E.
(1999). Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 re-
ceptor alpha) monoclonal antibody. Cancer Res. 59, 3128–3133.
Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immuno-
therapy. Nat. Rev. Cancer 12, 252–264.
Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., and Allison, J.P.
(2009). Blockade of CTLA-4 on both effector and regulatory T cell compart-
ments contributes to the antitumor activity of anti-CTLA-4 antibodies.
J. Exp. Med. 206, 1717–1725.
Provenzano, P.P., Inman, D.R., Eliceiri, K.W., Beggs, H.E., and Keely, P.J.
(2008). Mammary epithelial-specific disruption of focal adhesion kinase re-
tards tumor formation and metastasis in a transgenic mouse model of human
breast cancer. Am. J. Pathol. 173, 1551–1565.
Pylayeva, Y., Gillen, K.M., Gerald, W., Beggs, H.E., Reichardt, L.F., and Gian-
cotti, F.G. (2009). Ras- and PI3K-dependent breast tumorigenesis in mice and
humans requires focal adhesion kinase signaling. J. Clin. Invest. 119, 252–266.
Quezada, S.A., Peggs, K.S., Curran, M.A., and Allison, J.P. (2006). CTLA4
blockade and GM-CSF combination immunotherapy alters the intratumor bal-
ance of effector and regulatory T cells. J. Clin. Invest. 116, 1935–1945.
Roberts, W.G., Ung, E., Whalen, P., Cooper, B., Hulford, C., Autry, C., Richter,
D., Emerson, E., Lin, J., Kath, J., et al. (2008). Antitumor activity and pharma-
cology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res.
68, 1935–1944.
Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., and Ander-
son, A.C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaus-
tion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194.
Sakuishi, K., Ngiow, S.F., Sullivan, J.M., Teng, M.W., Kuchroo, V.K., Smyth,
M.J., and Anderson, A.C. (2013). TIM3(+)FOXP3(+) regulatory T cells are tis-
sue-specific promoters of T-cell dysfunction in cancer. OncoImmunology 2,
e23849.
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., and Takabayashi, A. (2003).
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:
possible involvement of regulatory T cells in disease progression. Cancer
98, 1089–1099.
Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth,
A.A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005). Intraepithelial
CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio
are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad.
Sci. USA 102, 18538–18543.
Serrels, A., McLeod, K., Canel, M., Kinnaird, A., Graham, K., Frame, M.C., and
Brunton, V.G. (2012). The role of focal adhesion kinase catalytic activity on the
proliferation and migration of squamous cell carcinoma cells. Int. J. Cancer
131, 287–297.
Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., andWang, Y. (2011). A reversed
CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of
CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical
outcome in squamous cell carcinoma of the cervix. Cell. Mol. Immunol. 8,
59–66.
Shapiro, I.M., Kolev, V.N., Vidal, C.M., Kadariya, Y., Ring, J.E., Wright, Q.,
Weaver, D.T., Menges, C., Padval, M., McClatchey, A.I., et al. (2014). Merlin
deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Sci. Transl. Med. 6, 237ra68.
Shimizu, J., Yamazaki, S., and Sakaguchi, S. (1999). Induction of tumor immu-
nity by removing CD25+CD4+ T cells: a common basis between tumor immu-
nity and autoimmunity. J. Immunol. 163, 5211–5218.
172 Cell 163, 160–173, September 24, 2015 ª2015 The Authors
Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K.,
Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. (2013). Fc-
dependent depletion of tumor-infiltrating regulatory T cells co-defines the effi-
cacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710.
Slack-Davis, J.K., Hershey, E.D., Theodorescu, D., Frierson, H.F., and Par-
sons, J.T. (2009). Differential requirement for focal adhesion kinase signaling
in cancer progression in the transgenic adenocarcinoma of mouse prostate
model. Mol. Cancer Ther. 8, 2470–2477.
Stokes, J.B., Adair, S.J., Slack-Davis, J.K., Walters, D.M., Tilghman, R.W.,
Hershey, E.D., Lowrey, B., Thomas, K.S., Bouton, A.H., Hwang, R.F., et al.
(2011). Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth
and metastasis of pancreatic cancer concomitant with altering the tumor
microenvironment. Mol. Cancer Ther. 10, 2135–2145.
Tan, M.C., Goedegebuure, P.S., Belt, B.A., Flaherty, B., Sankpal, N., Gil-
landers, W.E., Eberlein, T.J., Hsieh, C.S., and Linehan, D.C. (2009). Disruption
of CCR5-dependent homing of regulatory T cells inhibits tumor growth in amu-
rine model of pancreatic cancer. J. Immunol. 182, 1746–1755.
Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid,
Y., and Shevach, E.M. (2010). Expression of Helios, an Ikaros transcription fac-
tor family member, differentiates thymic-derived from peripherally induced
Foxp3+ T regulatory cells. J. Immunol. 184, 3433–3441.
Turriziani, B., Garcia-Munoz, A., Pilkington, R., Raso, C., Kolch, W., and von
Kriegsheim, A. (2014). On-beads digestion in conjunctionwith data-dependent
mass spectrometry: a shortcut to quantitative and dynamic interaction prote-
omics. Biology (Basel) 3, 320–332.
Wherry, E.J. (2011). T cell exhaustion. Nat. Immunol. 12, 492–499.
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z.,
Nomura, T., and Sakaguchi, S. (2008). CTLA-4 control over Foxp3+ regulatory
T cell function. Science 322, 271–275.
Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin,
A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. (2013). Nivolu-
mab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133.
Cell 163, 160–173, September 24, 2015 ª2015 The Authors 173
Supplemental Figures
Figure S1. T Cell FACS Analysis Post Antibody-Mediated T Cell Depletion, Related to Figure 1
(A) FACS analysis of spleen and thymus tissue from non-tumor-bearing animals 6 days after commencing antibody treatment. (B) FACS analysis of T cell
populations from spleen and thymus tissue from tumor-bearing animals at the end of T cell depletion studies in Figures 1C and 1D.
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Figure S2. T Cell FACS Gating Strategy, Related to Figures 2 and 7
(A) FACS gating strategy applied for identification of T cell sub-populations. E = effector, CM = central memory, and N = naive. (B) FMO (full antibody set minus
one) control samples used to determine correct gating for T cell sub-population identification.
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Figure S3. Macrophage FACS Gating Strategy, Related to Figure 3
(A) FACS gating strategy applied for identification of macrophage sub-populations. (B) FMO control samples used to determine correct gating for macrophage
sub-population identification.
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Figure S4. MDSC and Treg FACS Gating Strategy, Related to Figures 3 and 7
(A) FACS gating strategy applied for identification of MDSC sub-populations. M-MDSC – Monocytic Myeloid Derived Suppressor Cell; G-MDSC – Granulocytic
Myeloid Derived Suppressor Cell. (B) FMO control samples used to determine correct gating for MDSC sub-population identification. (C) FACS gating strategy
applied for identification of regulatory T cells (Treg).
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Figure S5. Tregs Infiltrating SCC FAK-WT Tumors Express the ThymicMarker Helios; Nuclear FAK Regulates Transcription of TGFb2, which
Contributes to Treg Expansion and Tumor Growth, Related to Figures 3 and 5
(A) FACS analysis of Helios expression in CD4+CD25+FOXP3+ SCC FAK-WT tumor-infiltrating Tregs and Tregs isolated from the thymus of tumor-bearing mice.
Control represents background signal from a sample stained with CD4, CD25, and FoxP3 conjugated antibodies but not Helios. Representative replicates are
shown in different colors for thymus and SCC FAK-WT samples. (B) qRT-PCR analysis of Tgfb2 gene expression knockdown in SCC cells. ****p < 0.0001 (Tukey-
corrected one-way ANOVA). (C) SCC FAK-WT shRNA-TGFb2 tumor growth in FVB mice. Blue dashed line indicates growth of SCC FAK-WT shRNA-TGFb2
tumors that had to be sacrificed due to ulceration at day 14. Red dashed line indicates growth of SCC FAK-WT shRNA-TGFb2 tumors that showed no ulceration.
Green solid line indicates the mean growth of all SCC FAK-WT shRNA-TGFb2 tumors up until cohort numbers were reduced due to ulceration. n = 6 tumors /
group. (D) FACS analysis of SCC FAK-WT shRNA-TGFb2 tumor infiltrating Tregs. ****p < 0.0001 (Tukey-corrected one-way ANOVA) (E) qRT-PCR analysis of
Tgfb2 gene expression in SCC FAK-NLS mutant cells. ***p < 0.001, ****p < 0.0001 (Tukey-corrected one-way ANOVA). Data are represented as mean ± SEM.
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Figure S6. Nuclear FAK Interactome in the Context of Ccl5 Transcription Factors, Related to Figure 6 and Table S1
(A) Interaction network analysis of proteins that bind FAK in the nucleus of SCC cells. Predicted Ccl5 transcription factors (TFs) (squares; bottom) and respective
TF binders (circles; top) enriched by at least two-fold in nuclear FAK immunoprecipitations (SCC FAK-WT over SCC FAK!/! controls; p < 0.05) are shown. Ccl5
TFs not detected (ND) are shown as gray squares. TF complexes or groups are indicated; proteins are labeled with gene names for clarity. TF binders are aligned
above TF groups with which there are the greatest number of reported interactions. Overrepresented molecular functions determined by functional enrichment
analysis are displayed as a heat map (log10-transformed color scale) (inset). Displayed terms satisfy p < 0.01 (Benjamini–Hochberg-corrected hypergeometric
test) with > 5 proteins assigned per term. (B) Topological analysis of Ccl5 TF–associated proteins identified in the nuclear FAK interactome. Ccl5 TF binders were
clustered using the yFiles Organic algorithm implemented in Cytoscape. Topological parameters were computed using NetworkAnalyzer, excluding self-in-
teractions. Protein node size is proportional to the number of interaction partners in the network (degree); node color indicates betweenness centrality
(normalized number of shortest paths between proteins; a measure of the control a protein exerts over the interactions of other proteins in the network). Box-and-
whisker plots (inset) show the distributions of degree and betweenness centrality for Ccl5 TF–associated proteins that bind nuclear FAK compared to those that
were not enriched in nuclear FAK immunoprecipitations, indicating that FAK binders tend to havemore interactions and bemore central in the interaction network
than undetected Ccl5 TF–associated proteins. Plots display the median (line), interquartile range (box) and 1.5 3 interquartile range (whiskers) (n = 169 and 761
Ccl5 TF–associated proteins detected and not detected, respectively, with degree R 1 based on physical or predicted interactions). ****p < 0.0001 (two-tailed
Mann–Whitney test).
See also Table S1.
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Figure S7. Analysis of FAK pY397 Phosphorylation in Tumors following Treatment with VS-4718, Related to Figure 7
Phosphorylation of FAK on Y397 was measured in protein lysates isolated from tumors following treatment with VS-4718 using ELISA. Tumors were removed
within 30 min of treatment. n = 5. Data are represented as mean ± SEM.
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